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Abstract 
Novel Markers for the Diagnosis of Pancreatic Ductal Adenocarcinoma: The 
Proteomic Approach. Joseph Man Fung Tang 
Background: Pancreatic ductal adenocarcinoma (PDAC) is a disease of late 
presentation where the majority of patients present with non-specific symptoms and 
advanced disease. Current guidelines recommend that patients presenting with 
symptoms of suggestive of PDAC should be investigated by Contrast-Enhanced 
Computed Tomography (CE-CT). However, the radiographic features are often 
similar to benign diseases such as chronic pancreatitis (CP). Evidently, there is a 
need for a novel diagnostic biomarker, which can accurately identify patients with 
PDAC thereby reducing the number of otherwise unnecessary invasive procedures.  
Aim: The current thesis aimed to determine the potential of a number of serum 
proteins as diagnostic markers of PDAC. 
Method: Two approaches for the discovery and validation of diagnostic markers of 
PDAC were employed. In Chapter 2, the serum expression of three iTRAQ- Mass 
Spectrometry identified proteins (vitamin d-binding protein [VDBP], retinol-binding 
protein 4 [RBP-4], and fibronectin [FINC]) were validated by western blotting in a 
three-phased study consisting of 20, 60, and 120 serum samples. Their diagnostic 
potentials as individual and combined markers were assessed statistically. In Chapter 
3, the serum concentrations of 27 cytokines, chemokines, and growth factors 
(CCGFs) in 90 PDAC and 90 controls were quantified using the multiplex cytokines 
assay and the potential of individual CCGFs for the diagnosis of PDACs were 
assessed. One-hundred and twenty serum samples were randomly allocated to 
discovery where stepwise regression was used to select independent CCGF markers 
of PDAC. These were then combined into a single marker and the diagnostic 
accuracy for PDAC assessed. Finally, validation utilised the remaining sixty samples 
to investigate the accuracy of the combined CCGF marker for the diagnosis of PDAC. 
Results: Results from Chapter 2 showed that the serum concentrations of VDBP, 
RBP-4, and FINC were significant decreased in PDAC with ROC-AUCs of >0.74 
against CP and healthy volunteers (HC). However, their diagnostic accuracies were 
decreased (ROC-AUC <0.63) in the presence of individuals with biliary obstruction 
(disease controls, DC). Combining all three markers increase the diagnostic accuracy 
for PDAC against HC and CP (ROC-AUC, 0.91) but not against DC (ROC-AUC, 
0.74). Further validation using pre-diagnostic serum samples showed that a small 
subset of patients exhibited a gradual decline in the serum concentration of VDBP 
and RBP-4 closer to diagnosis. 
Results from Chapter 3 showed that fourteen CCGFs were differentially expressed in 
PDAC compared to controls, of which, IFN-was the most significant individual 
marker of PDAC with comparable accuracy to CA19-9. Discovery analysis identified 
four independent markers of PDAC: IL-4, IL-17, G-CSF, and IP-10. When combined, 
an ROC-AUC of 0.99 was achieved. Validation of the combined CCGF marker in 
yielded encouraging results of ROC-AUC >0.95.  
Conclusion: Results indicate that combined VDBP, RBP-4, FINC, as well as IL-4, 
IL-17, G-CSF, and IP-10 are accurate markers of PDAC. It is possible that their use 
will improve the current diagnostic process.  
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Chapter 1 
General Introduction:  
Pancreas and Pancreatic Cancer 
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1.1 Anatomy of the pancreas 
The pancreas is a retroperitoneal organ, which can be anatomically divided into the 
head, neck, body, and tail (Figure 1.1
1
)
2-4
. The head of the pancreas lies within the 
curvature of the duodenum and overlies the body of the second lumbar vertebra and 
the aorta
3
. The neck represents a constriction, which connects the head to the body of 
the pancreas
3
. It can be identified by the superior mesenteric vessels, which pass over 
the uncinate process and then posteriorly behind the neck of the pancreas
4
. The tail of 
the pancreas extends towards the spleen and connects with the splenic flexure of the 
colon
4
. The pancreas receives its blood supply from the lineal and the 
pancreaticoduodenal branches of the hepatic and superior mesenteric arteries and it is 
drained by the lineal and superior mesenteric veins
2-4
.  
Figure 1.1-Anatomy of the pancreas
1
. By courtesy of Encyclopaedia Britannica, Inc., 
copyright 2003; used with permission. The pancreas is a retroperitoneal organ that is situated 
in front of the third lumbar vertebrae and is in close proximity to a number of important 
organs and vessels including the liver, stomach, small intestines, spleen, bile duct, aorta, vena 
cava, and superior mesenteric artery and vein. 
 
This text box is where the unabridged thesis included the following third party 
copyrighted material: 
 
Encyclopaedia Britannica. Anatomy of the Pancreas. [Image]  [2nd July, 2010]. 
Available at: http://www.britannica.com/EBchecked/topic/440971/pancreas. 
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Structurally, the pancreas is composed of lobules connected by areola tissue
3-4
. Each 
lobule consists of multiple acini each receiving one of the ultimate ramifications of 
the main pancreatic duct (Figure 1.1
1
). Histologically, two broad types of cells can 
be found in the pancreas parenchyma: exocrine and endocrine cells. Pancreatic 
exocrine cells are responsible for secreting digestive enzymes into the lumen of the 
acini, which in turn drains into the main pancreatic duct and ultimately into the 
duodenum
2-4
. Endocrine cells of the pancreas form clusters (islets of langerhans), 
which are embedded within the exocrine tissue and are responsible for secreting 
hormones such as insulin and glucagon into the systemic circulation
2-4
. 
 
1.2 Introduction to Pancreatic Cancer  
1.2.1 Epidemiology of Pancreatic Cancer 
Pancreatic cancer is the eleventh most commonly diagnosed cancer in the United 
Kingdom and it has an incidence rate of over 7,500 new cases per annum
5
. 
Furthermore, it is the sixth leading cause of cancer mortality in 2007 with a reported 
5-year overall survival rate of less than 5%
6
. The lifetime risk of developing 
pancreatic cancer for both men and women is 1/86 with the majority of cases 
occurring in patients over 65 years of age. Interestingly, studies have observed that 
pancreatic cancer is more frequent in the black population compared to the 
Caucasian and Asian populations
7
. Whilst the reasons for this difference remain 
unclear, studies have identified a higher prevalence of risk factors such as smoking, 
diabetes, obesity, and vitamin D insufficiency in the black population, which may 
explain this observation
7-8
.  
In addition to demographical risk factors, a number of medical, genetic, and 
environmental factors have also been linked to an increased risk of pancreatic cancer 
(Box 1.1)
7
. Indeed several studies have associated benign medical conditions such as 
chronic pancreatitis, obesity, and diabetes with an increased risk of developing 
pancreatic cancer. Chronic pancreatitis is one of the most frequently reported risk 
factors for the development of pancreatic cancer
9-11
 with various studies reporting a 
10-fold increased risk of pancreatic cancer in individuals with chronic pancreatitis 
compared to healthy controls 
10, 12
.  
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Another frequently identified disease-related risk factor is obesity. Despite various 
studies reporting an increased risk of pancreatic cancer in obese individuals, the 
exact role of obesity in the development of pancreatic cancer remains unclear
13-15
. 
However, some studies have suggested that obesity may be indirectly linked to 
cancer via inflammatory responses
16
. 
The role of diabetes mellitus in pancreatic cancer is somewhat difficult to evaluate 
because although some studies demonstrated that patients with >10-year history of 
type 2 diabetes are 1.5 times more likely to develop pancreatic cancer
17-19
, other 
studies indicated that new onset diabetes is an early symptom in up to a third of all 
pancreatic cancer patients
20
.  
Genetic predisposition plays an important role in the development of pancreatic 
cancer. Studies have reported that the relative risk of pancreatic cancer is increased 
by as much as 57-fold in families with four or more affected members
21
. Furthermore, 
a number of studies have reported that various germline diseases such as familial 
Peutz-Jeghers syndrome and hereditary pancreatitis are associated with a very high 
risk of pancreatic cancer development
7, 22
. Indeed, Giardiello et al. reported that 
individuals with familial Peutz-Jeghers syndrome are 132 times more likely to 
develop pancreatic cancer
23
.  
There are several environmental factors, which may increase the risk pancreatic 
cancer development. In particular, the association between pancreatic cancer and 
cigarette smoking has been frequently reported
7-8, 19, 21, 24
. Results from a study by 
Iodice et al.
8
 indicated that the relative risk of pancreatic cancer in current smokers is 
approximately 1.7 times greater than non-smokers and this risk remains elevated for 
at least 10 years after cessation.  
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Box 1.1- Summary of Factors Associated with Pancreatic Cancer
7 
 Pancreatic cancer typically occur in patients >65 years of age. 
 The black population has an increased risk of pancreatic cancer compared to 
Caucasians and Asians. 
 20-25% of pancreatic cancers are attributable to cigarette smoking, which is the 
most frequent but also the most preventable risk factor for pancreatic cancer. 
 Benign pancreatic diseases such as chronic pancreatitis and type II diabetes mellitus 
are independent risk factors for developing pancreatic cancer 
 5-10% of pancreatic cancers are associated with a germline disease 
 Non-O blood type has been associated with an increased risk of pancreatic cancer25. 
 Several hallmark genetic mutations have been identified in pancreatic cancer 
including the KRAS2 oncogene, which is present in 90-95% of all pancreatic 
cancers
26
. 
 
1.2.2 Pathogenesis of Pancreatic Cancer 
The majority of pancreatic cancers are ductal adenocarcinomas (PDACs)
27
. 
Microscopically, this type of cancer is characterised by a glandular structure with a 
ductal appearance and varying degrees of cellular atypia and differentiation
27
. Whilst 
the development of PDAC is generally regarded as sporadic, some studies have 
proposed that PDAC may arise from precursor lesions, which are cells with an 
atypical but non-cancerous cellular morphology that are frequently observed in 
association with PDAC
27-28
. Three types of PDAC precursor lesions have been 
proposed: pancreatic intraepithelial neoplasm (PanIN), mucinous cystic neoplasm 
(MCN), and intra-ductal papillary mucinous neoplasm (IPMN) 
28-30
. 
PanINs are a relatively common finding in the elderly population
27
. This type of 
precursor lesion was initially associated with PDAC by post-mortem studies, which 
showed an increased incidence of PanINs in patients with PDAC
31
. The relationship 
between PanINs and PDAC was later reinforced by molecular profiling studies 
showing an increasing number of common genetic alterations between higher grade 
PanINs and invasive PDAC
29
. PanINs can be graded from stage I to III according to 
the degree of dysplastic growth (Box 1.2)
32-33
. The transformation of high-grade 
PanINs into PDAC is marked by the invasion of intra ductal carcinoma beyond the 
basement membrane
32-33
. 
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Box 1.2- Grading of Pancreatic Intraepithelial Neoplasms32-33 
PanIN Grade  Description 
PanIN-1A Flat mucinous epithelium without cellular atypia 
PanIN-1B Papillary mucinous epithelium without cellular atypia 
PanIN-2 increasing signs of cellular atypia and a prevalence of papillary architecture 
PanIN-3 Carcinoma in situ/ intra-ductal carcinoma 
 
 
MCNs are large mucin-producing epithelial cystic lesions that have a distinctive 
ovarian-type stroma with a variable degree of epithelial dysplasia and focal regions 
of invasion
27, 30, 34-39
. The majority of MCNs arise from the body and tail of the 
pancreas and do not communicate with the pancreatic ductal system except in the 
presence of erosions or fistulous tracts
27, 30, 34
. The association between MCN and 
PDAC is based on observational studies demonstrating the presence of invasive 
tubular/ductal adenocarcinoma in approximately one-third of all resected MCNs and 
on studies showing several common genetic mutations between MCN and PDAC 
(including the KRAS-2 oncogene, TP53, and SMAD4)
28
. However, it should be noted 
that there are some controversies regarding the role of MCNs as precursors of 
pancreatic cancer due to the lack of direct evidence demonstrating the progression of 
MCNs to PDAC. This together with the fact that individuals with invasive ductal 
adenocarcinoma from resected MCNs have a much better prognosis (5-year survival, 
~60%) compared to the reported prognosis for sporadic PDACs (5-year survival, 
<25%), suggest that pancreatic cancer associated with MCNs should be regarded as a 
separate entity compared to sporadic PDAC
35
. 
IPMNs account for 3-5% of all pancreatic masses and are the most common type of 
pancreatic cystic lesions 
27, 40
 and they are defined by the presence of mucin-filled 
cystic lesions ≥1cm in the main pancreatic duct and/or its secondary branches27. 
Histologically, IPMNs are characterised by tall, columnar mucin-secreting epithelial 
cells that form papillae with fibro-vascular core
40
. In addition, IPMNs with intestinal 
or pancreaticobiliary type differentiation often involve the main pancreatic duct and 
show moderate or high-grade dysplasia
27, 40
. Studies have demonstrated that 
approximately 20-50% of IPMNs are associated with the presence of invasive 
adenocarcinomas, which may be of either mucinous type or ductal type 
40-44
. 
Interestingly, studies have shown that whilst adenocarcinoma associated with the 
ductal type of IPMN is morphologically identical and confers a similar prognosis to 
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non-IPMN associated PDACs, the adenocarcinomas associated with the mucinous 
type IPMN is characterised by neoplastic epithelial cells “suspended” in large pools 
of extracellular mucin and is associated with a better prognosis
42-44
. Similar to 
PanINs, the association between IPMNs and PDAC is only based on histological 
observational studies and studies indicating that IPMNs and PDACs share a number 
of genetic mutations (e.g. KRAS2, p16, TP53, and SMAD4)
28
. Therefore, in absence 
of evidence directly demonstrating the progression of IPMNs to PDAC, the role of 
IPMN in the development of PDAC will remain a controversial topic. 
 
1.2.3 Molecular Hallmarks of Pancreatic Cancer 
Pancreatic carcinogenesis is a complex process involving dynamic changes in the 
genome and molecular pathways, which together drive the progression from 
precursor lesions to invasive cancer
45
. Although the exact mechanism underlying 
pancreatic cancer formation is yet to be fully understood, research efforts in the past 
decade has significant improved our understanding of this disease. Recent studies 
have identified several key genetic mutations and signalling pathways, which have 
been found to be essential in pancreatic cancer tumourigenesis
26-27
.  
1.2.3.1 K-Ras signalling pathway 
A number of studies have demonstrated that the mutation of the K-Ras2 oncogene is 
present in 75-90% of all pancreatic cancers
26, 46-47
. The K-RAS gene is the cellular 
homologue of the RAS gene of Kristen murine sarcoma virus. It encodes for a 21-
kDa membrane-bound GTP-binding protein (KRAS protein), which is involved in 
growth factor-mediated signal transduction
48
. The K-RAS signalling pathway plays 
an important role in promoting cell cycle progression, cell proliferation, and 
resistance to apoptosis
26, 47
. Point mutations of the K-RAS gene often result in an 
impaired GTPase activity, which means that the KRAS protein is locked in the GTP-
bound (activated) state and therefore, the permanent activation of downstream 
signalling cascades
26, 47
. In addition, the K-RAS signalling pathway can be activated 
through the over expression or activation of its upstream receptor molecules, such as 
epidermal growth factor receptor (EGFR)
26
. Interestingly, K-RAS mutations are also 
found in patients with chronic pancreatitis and are therefore not exclusive to 
malignant cells of the pancreas
27
. Furthermore, activation of the K-RAS signalling 
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pathway alone is insufficient to cause malignant transformation of pancreatic cells
26-
27, 47
. It has been proposed, therefore, that co-existing aberrations such as epigenetic 
silencing of tumour-suppressors or activation of other oncogenic pathways must also 
be present
26-27, 47
.  
1.2.3.2 Tumour suppressor genes and pathways 
The deletion of the p16 INK4A gene locus in up to 95% of cases and the alteration or 
deletion of the p53 gene locus in 50-75% of cases are the most frequently reported 
mutations observed in pancreatic cancer
27
. Tumour suppression by both of these 
genes is made possible through the inactivation of CDK4/6 and CDK2 thereby 
inhibiting the phosphorylation of the retinoblastoma protein and subsequently 
preventing cell cycle progression through the G1-S checkpoint
26-27
. Furthermore, 
TP53 also contributes to tumour suppression by regulating cell cycle and promoting 
apoptosis in cells when DNA damage is sustained. 
Another common mutation is the deletion of the Smad4 gene, which is found in 55% 
of pancreatic cancers
26-27
. Smad4 is an important downstream mediator for the 
Transforming Growth Factor (TGF- signal pathway (an inhibitory pathway for 
PDAC) and is responsible for the transmission of TGF- signals into the nucleus 
thereby regulating the expression of cancer-associated genes
26-27
. In addition, studies 
have demonstrated that the disruption of TGF- signalling pathway facilitates cancer 
cell growth, differentiation, and migration
26-27
.  
1.2.3.3 Embryonic Signalling pathways 
A number of studies have reported that embryonic signalling pathways such as 
Hedgehog and Notch are reactivated in pancreatic cancer. In particular, over-
expression of the Indian and/or sonic Hedgehog ligands have been associated with 
enhanced tumour progression
26-27, 49
. Moreover, recent studies have demonstrated 
that the expression of the sonic Hedgehog ligand in transgenic mice results in the 
formation of PanIN-like lesions
50
.  
Notch is an embryonic signalling pathway, which controls cellular differentiation, 
proliferation, and apoptosis
51-53
. Although it is not usually active in the pancreas, up-
regulation of Notch target genes has been observed in pre-neoplastic lesions and 
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invasive pancreatic cancer
52
. In addition, Notch signalling has been shown to 
promote neo-vascularisation of tumours
51, 53
. 
 
1.2.4 Symptoms and Signs of Pancreatic Cancer 
For the majority of patients, pancreatic cancer remain undiagnosed until it is at an 
advanced stage and at initial presentation, symptoms are often non-specific (Box 
1.3)
21
. Unlike other cancers, for example prostate and breast cancer, the anatomical 
location of the pancreas means that pancreatic tumours cannot usually be felt on 
physical examination
3
. Therefore, the suspicion of pancreatic malignancy relies 
heavily on systemic symptoms and signs, which are often indications of disparate 
disease
54-55
. 
The majority of symptoms can be explained in terms of compression of anatomical 
structures within or adjacent to the pancreas. In particular, tumours arising from the 
head of the pancreas (approximately 70%) can cause obstruction of the duodenum, 
pancreatic duct, and common bile duct
54-55
. When the main pancreatic duct is 
obstructed, activation of digestive enzymes secreted by the pancreas may lead to 
auto-digestion of the pancreatic parenchyma and subsequently pancreatitis whereas 
bile duct obstruction is likely to result in cholestasis and jaundice
54-55
. Furthermore, 
pancreatic cancer may cause the dysfunction of pancreatic endocrine cells leading to 
dysglycaemia
20, 54-55
. It is therefore important for clinicians to consider pancreatic 
cancer as a differential diagnosis in patients presenting with acute pancreatitis or new 
onset diabetes
20
.  
Clearly, the biggest problem encountered in the diagnosis of pancreatic cancer is that 
all the symptoms associated with pancreatic cancer can also be associated with non-
malignant diseases (Box 1.3)
54
. In particular, jaundice, which is a commonly 
observed symptom in pancreatic cancer, is also frequently reported in benign 
pancreaticobiliary diseases such as biliary obstruction and chronic pancreatitis. 
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Box 1.3
21, 54
- Signs and symptoms of pancreatic cancer and confounding diseases 
Symptom in PDAC Examples of confounding diseases exhibiting the same symptom 
Anorexia 
Bacterial/ viral infections; most cancers, Chronic Pancreatitis; gallstone 
related biliary obstruction  
Weight Loss Most cancers; acute infections; diabetes; Chronic Pancreatitis 
Jaundice Biliary obstruction, acute and chronic pancreatitis; liver failure 
Hepatomegaly Hepatitis, heart failure; liver cirrhosis 
Peripheral lymphadenopathy Heart failure, renal failure; other cancers; medications; malnutrition 
Abdominal Pain 
Chronic Pancreatitis; gallstone related Biliary obstruction; peptic ulcers; 
inflammatory bowel disorders; GI cancers 
Anaemia 
Most cancers; autoimmune diseases; B12 deficiency; malabsorption; GI 
bleeding 
Fatigue Most cancers; diabetes; obesity heart failure; anaemia; depression  
Ascites 
Liver metastasis; most cancers; malnutrition; cirrhosis (liver or biliary); heat 
failure 
Acute pancreatitis 
Alcoholic pancreatitis; acute exacerbation of chronic pancreatitis; cancer of 
biliary tree or duodenum; gallstone-related biliary obstruction 
  
1.2.5 Diagnosis and Staging of Pancreatic Cancer 
In patients with suspected pancreatic cancer, subsequent investigations are designed 
to provide information regarding the presence, location, staging, and resectability of 
the disease
21, 26, 54, 56
. A number of modalities have been developed for the diagnosis 
and staging of pancreatic cancer. The initial investigation may be a simple trans-
abdominal ultrasound scan (USS), which may be able to identify signs of late 
pancreatic cancer such as biliary dilatation and liver metastasis
57-58
. However, USS is 
not useful in the diagnosis of early pancreatic cancer
57
 and therefore, the preferred 
diagnostic investigation is contrast enhanced multi-slice computed tomography (CE-
CT) scan, which is able to assess the location, size and sometimes the type of lesion 
in addition to providing evidence for the staging and resectability of the tumour
57, 59
. 
In general, contrast-enhanced CT scans are 80-90% accurate in predicting surgical 
resectability
59
. Other investigations such as endoscopic ultrasonography (EUS), fine 
needle biopsy (FNB), and Laparoscopy may be useful in confirming the presence of 
smaller or equivocal lesions seen on CT scan
60
. Nevertheless, the final diagnosis of 
PDAC can only be made histologically
21
.  
Pancreatic cancers are staged using the Tumour, Node, and Metastasis (TNM) 
classification system
61
. Each tumour is scored according to three criteria: Tumour 
size/extent (T), Lymph node involvement (N) and the presence of distant metastasis 
(M) (see Box 1.4). In practice, patients with TNM status equal to or less severe than 
T3, N1, and M0 are considered resectable
61
. However, studies have demonstrated 
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that patients with positive lymph node involvement (N1, staged 2B or above) have 
considerably poorer survival compared to patients with N0 status
62-66
.  
 
1.2.6 Management and prognosis of pancreatic cancer 
1.2.6.1 Advanced pancreatic cancer 
Over 75% of pancreatic cancers are inoperable due to localised advanced disease, 
metastases, or performance status
67-68
. The treatment for this group of patients is 
therefore directed at symptom control
57
. Pain is one of the most commonly reported 
symptoms of inoperable pancreatic cancer and it is usually controlled by oral opiate 
preparations
69
. Recent studies have suggested that celiac plexus block may improve 
pain control in selected patients but it has an insignificant effect on the quality of life 
and survival
70-72
. Furthermore, patients with advanced pancreatic cancer invariably 
develop weight loss due to pancreatic exocrine insufficiency, obstruction of the 
common bile duct, or cancer-associated cachexia
26
. Whilst there is no treatment for 
the latter condition, the former two can be effectively treated by pancreatic enzyme 
supplements and stenting of the bile duct
26, 73
.  
Chemotherapy plays an important role in improving the survival and quality of life of 
patients with advanced pancreatic cancer
74-75
. Unlike other cancers, PDACs are 
highly resistant to chemotherapy with a relatively low response rate of 10-25%
74
. 
However, studies have shown that treatment with chemotherapeutic agents such as 5-
Fluorouracil (5-FU) and Gemcitabine can significantly improve the median survival 
of patients with advanced pancreatic cancer
74
. Evidence from a randomised 
Box 1.4- TNM classification system and staging for pancreatic cancer
61
 
TNM Description 
Stage 
with N0 
Stage 
with N1 
Tx Primary tumour cannot be assessed -  
T0 No evidence of primary tumour -  
Tis Carcinoma in situ -  
T1 Tumour limited to pancreas, 2cm or less in greatest dimension 1A 2B 
T2 Tumour limited to pancreas, more than 2cm in greatest dimension 1B 2B 
T3 
Tumour extends beyond pancreas, but without involvement of celiac axis or 
superior mesenteric artery 
2A 2B 
T4 Tumour involves celiac axis or superior mesenteric artery 3 3 
 
Nx Regional lymph nodes cannot be assessed   
N0 No regional lymph node metastasis   
N1 Regional lymph node metastasis   
 
M0 No distant metastasis   
M1 Distant metastasis 4 4 
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controlled trial by Burris et al. 
74
 reported not only that treatment with Gemcitabine 
significantly improves the 1 year survival rate compared to 5-Fluorouracil (18% 
versus 2%, respectively), this trial also observed a milder toxicity and a better 
clinical response (24% versus 5%) with Gemcitabine. This subsequently saw the 
replacement of 5-FU with Gemcitabine as the preferred drug
26
. In addition, a number 
of randomised controlled trials have demonstrated that for patients with advanced 
pancreatic cancer, the combination of Gemcitabine with newer chemotherapeutic 
agents such as Capecitabine (a 5-Fluorouracil pro-drug) and Oxaliplatin is associated 
with a better prognosis
75-80
. In particular, a phase III randomised control trial by 
Cunnigham et al., reported a significant improvement in progression-free survival for 
patients with advanced PDAC treated with Gemcitabine -Capecitabine combined 
chemotherapy compared to Gemcitabine alone (hazard ratio 0.78, p=0.004)
80
.  
1.2.6.2 Resectable pancreatic cancer 
In the remaining 25% of pancreatic cancer patients, where surgical resection with 
intention-to-treat is deemed possible, the aim of surgery is to achieve complete 
clearance of the tumour both macroscopically and microscopically (R0 resection)
81-82
. 
However, in practice, a large proportion of patients have incomplete resection of the 
tumour (R1, microscopically; R2, macroscopically) 
82
. The most commonly 
employed surgical procedure for the removal of pancreatic tumours located in the 
head of the pancreas is pylorus-preserving partial pancreaticoduodenectomy (PP-
PPD) whereas tumours located in the body or tail undergo distal pancreatectomy 
with resection of the spleen and hilar lymph nodes
67
. 
Despite radical resection of the primary tumour, the reported 5-year survival rate 
remains low (approximately 10%), mainly due to cancer recurrence. Furthermore, 
pancreatic cancer patients (resected or otherwise) will invariably develop metastatic 
disease, typically of the liver or lung. Various prognostic markers have been 
identified, of which, lymph node status, tumour size and tumour grade are the most 
important predictors of post-operative survival. Evidence from randomised 
controlled trials by Neoptolemos et al. 
83-85
 and Oettle et al. 
86
 independently reported 
that the use of adjuvant chemotherapy improves the 5-year survival from 9-12% 
(resection alone) to 21-29% (resection with chemotherapy)
87-89
. Further evidence 
from the European Study Group for Pancreatic Cancer 3 (ESPAC-3) trial
90
 supported 
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this finding and, in addition, reported comparable survival rates in patients treated 
with adjuvant 5-FU compared to adjuvant Gemcitabine .  
 
1.3 Biomarkers for pancreatic cancer 
1.3.1 Introduction to biomarkers 
A biomarker is defined by the National Institute of Health
91
 as “a characteristic that 
is objectively measured and evaluated as an indicator of normal biologic process, 
pathogenic process, or pharmacologic responses to a therapeutic intervention”. The 
abundance or scarcity of cancer biomarkers in cancer relative to non-cancer 
conditions (e.g. inflammatory diseases and in health) may be an indication of 
changes to cellular biology in carcinogenesis. Therefore, it is the aim of cancer 
biomarker studies to identify these differentially expressed molecules and to assess 
their clinical usefulness as a screening, diagnostic, and/or prognostic modality for 
cancer. There are many samples, which can be used for the discovery of biomarkers 
including blood derivatives, pancreatic juice, tissue, saliva, and urine
92
. Of these, 
blood plasma or serum is most widely used in biomarker studies because they are 
readily accessible, minimally invasive to collect, generally acceptable to patients, and 
are potentially rich sources for most types of biomarkers
92
.  
 
1.3.1.1 The need for diagnostic biomarkers of pancreatic cancer 
As previously discussed, the differential diagnosis of pancreatic cancer is based 
entirely on non-specific symptoms, signs, and first-line investigation findings that are 
at best suggestive of a disease of pancreaticobiliary origin and/or the presence of 
metastatic disease
54-55
. Moreover, under the current recommendations, patients 
suspected of having pancreatic cancer will undergo a series of relatively invasive 
procedures including CE-CT, EUS, and/or FNB
57
. Clearly, there is a need for novel, 
accurate, and less invasive methods for the diagnosis of pancreatic cancer such as a 
blood-based protein biomarker. Aside from the fact that a blood-based biomarker 
would be less invasive compared to current diagnostic techniques, there are two other 
major advantages: the number of patients undergoing unnecessary invasive 
investigations and the time required to reach a diagnosis of PDAC would be greatly 
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reduced. There is also the possibility that biomarkers can be employed to detect the 
presence of early pancreatic cancer in otherwise asymptomatic individuals. 
Subsequently, this would mean that patients with PDAC are diagnosed earlier 
thereby increasing their chances of having operable disease and therefore improving 
the prognosis. 
 
1.3.2 Current biomarker of pancreatic cancer: CA19-9 
The tumour associated antigen, Carbohydrate Antigen 19-9 (CA19-9), was first 
described in pancreatic cancer by Koprowski et al. in 1981
93
. Approximately 95% of 
the general population are able to synthesise CA19-9 while the remaining 5-10% of 
the population, due to genetic differences, have a Lewis
a-b-
 phenotype meaning that 
they are unable to synthesise CA19-9
94
.  
 
1.3.2.1 CA19-9 in screening and diagnosis of pancreatic cancer 
CA19-9 was initially evaluated as a potential diagnostic marker exclusively for 
pancreatic cancer; however, studies in the past two decades have reported elevated 
levels of CA19-9 in other malignant tumours including gastric, ovarian, 
hepatocellular, and colorectal cancers as well as benign pancreaticobiliary diseases 
such as chronic pancreatitis, cholangitis, and choledocholithiasis
23, 95-99
. Furthermore, 
a recent study by Morris-Stiff et al. demonstrated a direct correlation between serum 
levels of CA 19-9 and bilirubin 
100
. This finding, together with evidence from clinical 
studies demonstrating that CA19-9 is not sufficiently sensitive for the detection of 
early or small-diameter pancreatic cancer, suggest that CA19-9 should not be used 
alone as a screening modality for pancreatic cancer
96, 101-102
.  
Evidence from systematic reviews have suggested that with a median sensitivity of 
79% (70-90%) and a median specificity of 82% (58-91%), CA19-9 is not sufficiently 
accurate as a standalone diagnostic marker of pancreatic cancer
97, 99
. Indeed various 
expert groups including the European Group on Tumour Markers, the National 
Academy of Clinical Biochemistry (NACB), and the National Cancer 
Comprehensive Network have stated that CA19-9 should only be used in conjunction 
with other diagnostic modalities such as CE-CT and EUS
96, 101-102
.  
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1.3.2.2 CA19-9 in prognosis, surveillance, and assessment of chemotherapy  
Mounting evidence shows that serum concentrations of CA19-9 correlate with the 
prognosis of resected pancreatic cancer patients
103-106
. In a retrospective study by 
Ferrone et al., it was reported that a CA19-9 level of <200 kU/l or a decrease in 
CA19-9 levels following surgical resection are independently associated with better 
prognosis
107
. Recently, the NACB guidelines recommend that whilst CA19-9 should 
be considered for risk stratification in patients with pancreatic cancer and that high 
concentrations are indicative of poor outcome, the guidelines emphasised that CA19-
9 is only one of many factors influencing the prognosis and treatment planning of 
pancreatic cancer
102
.  
CA19-9 is also used in postoperative surveillance of pancreatic cancer
96, 108
. Several 
studies have shown that sequential measurements of CA19-9 may be able to detect 
recurrent/metastatic pancreatic cancer before clinical or radiological evidence
95-96, 108
. 
In addition, there is a consensus that a declining CA19-9 level following initiation of 
chemotherapy is associated with a better outcome compared to no decline
96
. Based 
on this evidence, the NACB recommends that serial measurements of CA19-9, along 
with radiological imaging at regular intervals may be used for both post-operative 
surveillance and the monitoring of therapy
102
. 
 
1.3.3 Other markers of pancreatic cancer 
A number of potential diagnostic markers for pancreatic cancer have been proposed 
in the past decade
96, 109
. In 2007, Grote et al.
109
 highlighted 16 novel blood-based 
markers for pancreatic cancer in their review article including Mucin 1 (MUC-1), 
macrophage inhibitory cytokine 1 (MIC-1), inter-alpha-trypsin-inhibitor heavy chain 
4 fragments (ITIH4 fragments), and Apolipoprotein A-II, which have shown 
relatively high sensitivities (range, 0.71-0.90) and specificities (range, 0.92-0.96) for 
pancreatic cancer against chronic pancreatitis and healthy controls compared to 
CA19-9. Similarly, results from a review by Bussom et al.
110
 identified several novel 
biomarkers e.g. PAM4 and carcinoembryonic antigen-related cell adhesion 
molecule-1 (CEACAM-1), which have shown promising results for the detection of 
early-stage pancreatic cancer. Moreover, several studies have demonstrated the 
potential of combining novel markers with CA19-9 to improve the diagnostic 
16 
 
accuracy compared to CA19-9 alone
111-112
. However, considering the relatively small 
sample size in these studies and in view of recent evidence demonstrating the 
confounding effects of biliary obstruction on the diagnostic accuracies of some 
proteomic biomarkers, further validation must be performed before these novel 
markers can replace the role of CA19-9 in pancreatic cancer. 
 
1.3.4 Techniques for biomarker discovery 
There are two main approaches to biomarker discovery: The genomic approach, 
which focuses on identifying genetic mutations or changes in gene expression on 
micro RNA levels and the proteomics approach, which mainly examines the 
difference in protein levels between PDAC and benign conditions. The following 
sections will describe the various techniques used in the discovery of proteomic 
biomarkers including 2D polyacrylamide gel electrophoresis (2D PAGE) and 
isobaric Tag for Relative and Absolute Quantification (iTRAQ) in addition to 
common techniques used in the validation of biomarkers such as western blotting 
and enzyme-linked immunosorbent assay (ELISA). Furthermore, the current section 
will describe the use of a microsphere-based multiplex cytokines assay, for both the 
discovery and validation of biomarkers for pancreatic cancer. 
 
1.3.4.1 2D-PAGE 
The technique of two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) 
was first described by O‟Farrel et al. and Klose in 1975113-116. The original technique 
of 2D-PAGE described by these authors consisted of protein separation by carrier-
ampholyte-generated pH gradients in the first dimension (isoelectric focusing, IEF) 
followed by separation by protein molecular weight in the second dimension (SDS-
PAGE) 
113-116
.  
2D-PAGE has a number of desirable properties and potential applications including 
its ability to separate proteins into their individual polypeptide components, compare 
protein expression profiles of paired samples (e.g. cancer versus control), detect 
global protein behavioural in responses to a change in conditions, and more 
importantly, its potential capacity to simultaneously resolve hundreds to thousands of 
proteins
116-119
. This technique was widely applied throughout the 1980s
118
, however, 
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it was not long before researchers recognised that the original 2D-PAGE method 
suffered from a number of limitations including the lack of reproducibility, low 
resolution, inability to separate very acidic and/or very basic proteins, and limited 
sample loading capacity
116, 118
. In an effort to overcome these limitations, Görg et 
al.
120
 introduced a new gradient for first dimension separation in the 1980s- the 
immobilized pH gradients (IPGs) 
120-122
. The use of IPG enabled an extremely stable 
pH gradient to be generated, which subsequently improved isoelectric focusing and 
the reproducibility of the technique
118
. Later studies further enhanced this technique 
by introducing narrow-overlapping IPGs, which enabled a higher resolution as well 
as permitted the detection of lower abundance proteins and proteins with isoelectric 
points ranging from pH 2.5 to pH 12
123-125
.  
Research on 2D-PAGE and its related technologies in the past decade has been 
focused on improving the solubilisation and separation of hydrophobic proteins, the 
display of low abundance proteins, and achieving more reliable protein quantification 
by either fluorescent dyes or isobaric tags
118
. Indeed, the recent development of the 
difference gel electrophoresis (DIGE) technology has enabled mixed samples to be 
analysed on a single 2-DE gel via differential fluorescent dye labelling
126
.  
1.3.4.2 Mass Spectrometry and iTRAQ 
Isobaric Tag for Relative and Absolute Quantification (iTRAQ) is a chemical 
labelling multiplexing technique, which quantifies the concentration of proteins 
using mass spectrometry
127-129
. iTRAQ coupled with electro-spray ionisation tandem 
mass spectrometry (ESI-MS/MS) is becoming increasingly popular over the past 5 
years in the field of biomarker research due to its ability to identify and quantify 
hundreds of proteins in a single experiment
128
. Indeed, a previous study from the 
Division of Surgery and Oncology, University of Liverpool, have identified over 300 
differentially expressed proteins in the serum of pancreatic cancer patients compared 
to controls
129
. In Chapter 2, the accuracies of three iTRAQ/MS identified proteins as 
diagnostic markers for pancreatic cancer is provided. 
The technique of iTRAQ-MS relies on the fact that proteins can be digested to a 
unique set of different tryptic peptides. The iTRAQ part of the technique consists of 
the digestion of proteins in a sample into their constituent peptides followed by the 
labelling of these peptides by isobaric tags. Each sample group (i.e. HC, CP, and 
18 
 
PDAC) is labelled with a different tag with a unique reporter group of a specific 
mass, which is released during mass spectrometry through collision-induced 
dissociation thus allowing the association of a peptide with a specific sample group. 
The detection part of iTRAQ-MS involves the vaporisation and ionisation of the 
labelled peptides through an electromagnetic field. The resulting trajectory data and 
mass-to-charge ratio data from the MS analysis can then be used to identify the 
protein origins of these peptides. The different tags allow the relative quantification 
of peptides between samples, for example, a given peptide labelled with the disease-
specific tag could be four times more abundant than the same peptide labelled with 
the control specific tag, indicating that the peptide is more abundant in the disease 
than the controls. 
Mass spectrometry based methods such as iTRAQ offers the identification and 
quantification of numerous proteins in a single experiment. This is clearly 
advantageous for biomarker studies, where several potential biomarkers can be 
identified upon data comparison between the disease and control groups. However, 
there are two major drawbacks for this technique: iTRAQ requires a large amount of 
sample and the sample preparation stage may span require weeks to complete 
especially in the case of serum, where abundant protein depletion is necessary. An 
acceptable solution to this problem is the use of pooled samples but this is not 
without its own disadvantages. Although pooled samples present an „average‟ profile 
for the disease group in question, this “average” is very susceptible to skewing by an 
outlier with unusually high or low expression of a particular protein. Therefore, it is 
important to validate the results from pooled samples by other proteomic methods 
such as western blotting or ELISA. 
 
 
1.3.4.3 Western blotting 
Western blotting (also called Protein Immunoblotting) is a laboratory technique used 
to detect the presence of specific proteins in a given sample and it is frequently 
employed to validate the serum expression of proteins identified by iTRAQ. The 
method for western blotting was first described by Burnette in 1981
130
 and 
surprisingly little has changed in the original method over the past 20 years. The 
most prominent changes have been in the development of newer apparatus, specific 
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antibodies, and better labelling/detection methods. Indeed, novel detection methods 
for western blots such as infrared labelling have been of increasing interest to 
researchers. In a recent study comparing tradition chemiluminescence with infrared 
detection
131
, the authors described many potential advantages to infrared detection 
such as the ability to simultaneously detect two proteins and the loss-less 
preservation of signal long periods of time. Due to its higher detection sensitivity 
however, the resulting blot may in practice show more non-specific bands compared 
to traditional chemiluminescence and therefore may not be desirable. 
The technique of western blotting involves two phases: sodium dodecyl sulphate 
(SDS) polyacrylamide gel electrophoresis (PAGE) and immunofluorescence 
detection. The purpose behind SDS-PAGE is to separate uniformly charged, 
denatured proteins according to their molecular weight through the use of an electric 
current. Briefly, denatured proteins are reduced by SDS (i.e. given a uniform charge) 
and are subjected to an electric current. Proteins with a lower molecular weight will 
travel through the polyacrylamide gel at a faster rate compared to heavier proteins, 
therefore, with time, lighter proteins will travel a greater distance compared to 
heavier proteins. The proteins in the polyacrylamide gel are then transferred and 
immobilised on a nitrocellulose membrane in preparation for immuno-detection. In 
the detection phase, a primary antibody is used to bind to the protein of interest and a 
horseradish peroxidase (HRP) secondary antibody is used to bind to the primary 
antibody. This is necessary because the HRP on the secondary antibody allows 
chemiluminescence detection by catalyzing the reaction between two luminescence 
substrates. 
Western blotting remains one of the most favoured techniques in modern proteomic 
research for the validation of the findings in biomarker discovery projects. This is 
largely because of its high sensitivity for detecting the presence of specific proteins 
meaning that it is heavily relied upon in cell-related proteomic analyses. Furthermore, 
in biomarker research where samples are often very precious, western blotting has 
the advantage of being able to detect and quantify proteins using a considerably 
smaller amount of sample compared to other proteomic techniques such as ELISA or 
mass spectrometry. However, there are a number of potential pitfalls in using 
western blotting for the quantification of proteins. Firstly, there is often a variable 
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loss of proteins during the transfer step and therefore direct comparison between 
blots is not recommended unless internal standards are rigorously used. Secondly, the 
primary antibody, which is engineered to recognise a specific amino acid sequence 
unique to the protein of interest, may have a variable ability in recognising the same 
sequence after the protein has been denatured. Finally, the quantification of bands 
from scanned x-ray films must be interpreted with care because the intensities of x-
ray scanned bands follow a sigmoid-like correlation with the actual concentrations of 
the protein of interest in a sample
132
. This means that the difference in band intensity 
is likely to be less distinct when compared to the difference in actual protein 
concentration.   
1.3.4.4 Enzyme-Linked Immunosorbent Assay (ELISA) 
Enzyme-linked immunosorbent assay (ELISA), sometimes referred to as enzyme 
immunoassay (EIA), is another technique frequently employed in the quantification 
of blood-based proteins. Although it is widely used in the research setting, it is also 
frequently employed in clinical settings especially in diagnostic medicine. 
Interestingly, the technique of ELISA is the result of synthesized knowledge from 
studies published by a number of researchers from 1960 to 1971
133-135
. As with 
western blotting, very little has changed in the original method since 1971 other than 
the development of better antibodies and more sophisticated/automated apparatus, 
which play a pivotal role in minimised human error and improving data 
reproducibility. There are a number of variations to the ELISA technique including 
direct, indirect, sandwich, competitive, and multiplex assays however, the principle 
behind the variations remains the same.  
The technique of ELISA is somewhat similar to the chemiluminescence phase of 
western blotting. In a typical sandwich ELISA, the protein of interest (antigen) is 
first immobilised to the surface of the wells by a capture antibody. A primary 
antibody then binds to the antigen, which in turn is bound by an antibody-HRP 
conjugate. The HRP in the secondary antibody catalyses a chromogenic substrate to 
cause a shift in colour that is directly correlated with the concentration of the protein 
of interest. This colour shift is detected by an ELISA plate reader and the resulting 
data can be used to quantify the concentration of the protein of interest.  
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There are many advantages in using ELISA for protein quantification, for example, 
the assay itself is simple and relatively quick to perform, each analysis 
simultaneously quantifies over 40 samples, and the resulting data are readily 
reproducible. However, as with western blotting, one of its basic requirements is the 
availability of an antibody specific to the antigen of interests. In addition, the serum 
sample requirement for a typical ELISA (25 µL) is over 60 times greater than a 
typical western blot analysis (0.4µL) and it is usually more expensive (per sample) to 
perform.  
 
1.3.4.5 Multiplex Assays (LUMINEX) 
Researchers and biomedical companies in the past decade have sought to overcome 
the various disadvantages of conventional ELISAs
136-137
. One of the ways in which 
this is achieved is by combining the ELISA technology with existing biochemical 
techniques such as microspheres, flow cytometry, and laser detection
136-137
. In 
chapter 3 of the current MPhil thesis, I described the use of the LUMINEX multiplex 
assay to analyse 27 different cytokines, chemokines, and growth factors in serum 
samples. A brief description of this technique is given below (see section 3.3.3 for 
detailed protocol). 
The technique for the LUMINEX assay is similar to conventional sandwich ELISA 
in many ways. However, instead of using an antibody-based capture system, the 
LUMINEX assay employs a solid-phase microsphere-based capture system where 
each microsphere population are designed to bind to a specific analyte of interest. 
Furthermore, each microsphere population is internally dyed to emit a unique 
wavelength in the red to infrared spectrum upon laser excitation, which allows the 
identification of its corresponding analyte. As in the case of ELISA, samples are 
incubated with a mixture of microspheres to allow binding of the analyte to its 
corresponding microsphere population. Next, the microsphere-substrate complex is 
allowed to bind to a detection antibody, which facilitates the binding of streptavidin. 
Finally, the LUMINEX system employs a dual laser technology whereby a red laser 
is used to identify the microsphere population, and a green laser is used to detect the 
fluorescence intensity of each microsphere. Data from the assay standards can then 
be used to convert the fluorescence intensities into concentration (pg/ml). 
22 
 
The LUMINEX system is a relatively new technology with the obvious advantage of 
being able to quantify up to 100 analytes in up to 39 samples simultaneously and is 
therefore significantly more sample-efficient than a conventional ELISA. The 
substitution of enzyme-catalysed chromogenic substrate (ELISA) with 
immunofluorescence and laser detection (LUMINEX) meant that a wider range of 
concentrations could be determined. In addition, results from previous studies have 
shown that data obtained from multiplex assays are reproducible and have an 
acceptable accuracy. Furthermore, it is a simple and quick assay to perform with an 
experimental duration of approximately 4 hours. However, as with other 
immunoassays, the integrity of the assay is dependent upon the sensitivity and 
specificity of the primary antibody. Moreover, one major disadvantage is the cost 
incurred by each assay, which can be up to 5 times the cost of an ELISA plate. 
Nevertheless, considering its ability to quantify multiple analytes simultaneously, the 
LUMINEX assay can be considered as sufficiently cost-effective as an alternative 
method for the discovery of potential biomarkers. 
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1.4 Role of CCGFs in inflammation and cancer 
The role of cytokines, chemokines, and growth factors (CCGFs) in pancreatic 
inflammatory diseases (e.g. acute and chronic pancreatitis) has been reported by 
many studies
138-144
. More recently, evidence from experimental and epidemiological 
studies have shown that CCGFs play a pivotal role in mediating cancer-related 
inflammation
144-150
. Indeed, a recent review by Colotta et al. suggested that cancer-
related inflammation may be considered as the seventh hallmark of cancer
150
 and that 
an inflammatory tumour microenvironment contributes to the proliferation, 
angiogenesis, survival and metastasis of certain cancers
143, 151-154
.  
1.4.1 The relationship between inflammation and cancer 
The association between chronic inflammation and cancer was initially proposed by 
Rudolf Virchow over 100 years ago
145
. Later studies have given evidence in support 
of this hypothesis and it was estimated that 20% of all cancers are attributable to 
chronic infection and inflammation
145, 155
. Epidemiological studies have suggested 
that the used of anti-inflammatory agents may reduce the risk and mortality of certain 
cancers
156-159
. More importantly for pancreatic cancer, studies have demonstrated a 
correlation between the activation of certain oncogene signalling pathways (e.g. Ras, 
and TGF-β) and inflammation26, 46, 160. In 2008, Mantovani et al. described two 
pathways linking inflammation and cancer: the intrinsic and extrinsic pathways
155
. 
The intrinsic pathway is activated by the mutation of certain cancer-related genes 
(e.g. activation of oncogenes or inactivation of tumour suppressor genes) thereby 
resulting in the production of inflammatory mediators and ultimately the formation 
of an inflammatory tumour microenvironment. In contrast, the extrinsic pathway 
refers to the promotion of tumour formation in the presence of an underlying 
inflammatory condition (such as chronic pancreatitis)
155
. Both pathways lead to the 
activation of transcription factors such as Nuclear Factor Kappa light-chain-enhancer 
of activated B cells (NF-B), Hypoxia Inducible Factor 1-alpha (HIF-1, and Signal 
Transducer and Activator of Transcription-3 (STAT3), which in turn induce the 
secretion of inflammatory mediators (e.g. cytokines, chemokines, and growth factors) 
by immune cells
145, 161
. 
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1.4.2 Pathways linking inflammation and cancer 
1.4.2.1 NF- 
NF-B is a family of transcription factors consisting of five members including NF-
B1, NF-B2, RelA, RelB, and c-Rel162-163. Members of the NF-B family share a 
300 amino acid region, which gives NF-B the characteristic ability to form dimmers 
and to bind with other NF-B proteins, DNA, and NF-B inhibitors (IB)164. In 
normal eukaryotic cells, NF-B is usually in a quiescence state; however, NF-B can 
be activated by a number of stimuli including cellular stress, inflammatory mediators 
(e.g. TNF- and IL-1), and bacterial/viral antigens162-163. The activation of NF-B 
promotes the transcription of a number of inflammatory mediators including IL-1, 
IL-1, and TNF-, which may in turn stimulate the NF-B pathway in a positive 
feedback loop and may lead to a longer and more severe inflammatory response
162-163
.  
Aberrant activation of the NF-B pathway has been associated with a number of 
cancers
162-163, 165-168
. It has been proposed that the continuous activation of NF-B 
promotes oncogenesis by enhancing the transcription of genes encoding for 
cytokines (e.g. TNF-), chemokines (e.g. IL-8), and growth factors (e.g. Vascular 
Endothelial Growth Factor, VEGF) as well as anti-apoptosis genes
162-163, 166
. 
Furthermore, evidence from a number of in vitro and in vivo studies has 
demonstrated that NF-B can promote tumour metastasis by regulating the 
expression of cell adhesion molecules (e.g. ICAM-1), cell surface proteases (e.g. 
MMP-9), and plasminogen activators (e.g. urokinase-type plasminogen activator).  
 
1.4.2.2 STAT3 
STAT3 is a member of the signal transducer and activator of transcription (STAT) 
family of proteins, which are responsible for the transduction of cytoplasmic signals 
from extracellular stimuli, the regulation of genes involved in tumour proliferation, 
survival, angiogenesis, and metastasis, and the induction of tumour-promoting 
inflammatory mediators especially cytokines (e.g. IL-17) and growth factors (e.g. 
VEGF)
169
. Interestingly, whilst some members of the STAT family (e.g. STAT1) 
exhibit anti-tumour properties, others (e.g. STAT3) induce cancer-promoting 
inflammation
170-174
. Furthermore, studies have shown that STAT3 is commonly 
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activated in malignant cells and it plays a crucial role in regulating the expression of 
genes associated with cancer-related inflammation in the tumour 
microenvironment
169, 175
. STAT3 can be activated via a number of intrinsic and 
extrinsic mechanisms. In particular, STAT3 can be activated by a number of 
upstream receptors including cytokine receptors (e.g. IL-6R, IL-10R) and growth 
factor receptors (e.g. Platelet-derived growth factor (PDGF) receptor and EGFR)
169, 
174
. Indeed, recent studies have demonstrated that IL-6 can activate STAT3 through 
the activation of Janus Kinase (JAK), which ultimately leads to the up-regulation of 
anti-apoptotic genes and tumour cell survival
170, 173, 176-178
. Interestingly, IL-10 has 
been shown to exhibit anti-tumour activity by inhibiting the NF-B pathway179. 
However, recent evidence has also indicated that IL-10 may play a dual role in 
cancer by being an activator of STAT3 thereby indirectly promoting cancer 
proliferation, angiogenesis, survival, and metastasis through promoting the 
transcription of anti-apoptotic genes and growth factors
169, 180
. 
Furthermore, in view of the common role of STAT3 and other cancer-associated 
transcription factors in cancer-associated inflammation, it is somewhat unsurprising 
that the two transcription factor pathways should interact with each other on many 
levels. For example, recent studies have suggested that the activation of NF-B 
promotes the expression of IL-6 gene, which in turn is an activator of STAT3. In 
contrast, the activation of STAT3 prevents RELA of the NF-B family from leaving 
the nucleus thereby contributing to the persistent NF-B activation in cancer181. 
 
1.4.2.3 HIF 1-alpha 
One of the major factors dictating tumour growth, proliferation, and survival is the 
availability of oxygen
182
. Cancer associated hypoxia results when the demand for 
oxygen from the rapidly growing tumour exceeds its vascular supply. Prolong 
hypoxia leads to cellular necrosis, which is often observed in solid tumours. Indeed, 
evidence from computed tomography and intratumoural oxygen tension studies 
indicated that pancreatic cancers are characterised by an avascular appearance and 
that they are unusually hypoxic compared to other solid tumours
183
.  
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HIF are a family of transcription factors consisting of six members (HIF-1, HIF-1, 
HIF-2, HIF-2, HIF-3, and HIF-3), which are responsible for promoting neo-
angiogenesis and wound healing
182
. One of the best-characterized HIFs is the 
heterodimer protein, hypoxia-inducible factor-1. HIF-1 consists of two subunits, 
HIF-1 and HIF-1183-184. Whilst both subunits are expressed in all cells, HIF-1 is 
virtually undetectable in well-oxygenated cells due to its rapid degradation by 
ubiquitination
183-184
. In contrast, during cellular hypoxia, there is an accumulation of 
HIF-1, which undergoes dimerization with HIF-1 and ultimately promoting the 
transcription of various angiogenesis-related proteins including vascular endothelia 
growth factor (VEGF)
183-184
.  
Although the exact role of HIF-1 is not yet fully understood, a number of studies 
have demonstrated that HIF-1 expression is positively correlated to VEGF 
expression, tumour size, and tumour stage (particularly stage III and IV)
183
. 
Furthermore, there is increasing evidence suggesting that HIF-1 may enhance the 
expression of motility factors in pancreatic cancer cells and may therefore play a role 
in promoting metastasis
183
.  
 
1.4.3 Tumour microenvironment, cytokines and cancer 
There are three broad categories of cells within the tumour microenvironment: 
immune cells, cancer cells, and stromal cells
185-186
. The communication within and 
between these cells relies on direct contact or through signalling molecules such as 
cytokines, chemokines, and growth factors (CCGFs), which act in autocrine and 
paracrine manners to control tumour growth, proliferation, migration, and 
metastasis
186-187
. CCGFs and their modulators play a paradoxical role in cancer 
where their expression and abundance within the tumour microenvironment dictate 
the balance between tumour promoting inflammation and anti-tumour immunity
179
. 
When host-mediated anti-tumour immunity is stronger than tumour-induced 
immunosuppression, there is a net elimination of tumour cells
179
. By contrast, in 
established tumours, the balance is shifted towards tumour-associated inflammation 
and there is a net promotion of tumour growth and proliferation
179
. Furthermore, in 
advanced cancer, there is minimal anti-tumour activity and therefore tumour 
regression rarely occurs without therapeutic intervention 
179, 188
. 
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1.4.3.1 Immune cells, cytokines, and cancer 
Tumour-associated macrophages (TAMs) are a major source of inflammatory 
cytokines the tumour microenvironment
189-191
. In contrast to normal macrophages, 
these tumour-recruited phagocytes are unresponsive to their normal regulatory 
mechanisms have been associated with six tumour-promoting extrinsic traits: chronic 
inflammation, matrix remodelling, tumour cell invasion, intravasation (invasion of 
blood vessels), angiogenesis, and distant metastasis
192
. Indeed, studies on the 
transition of carcinoma in-situ to invasive cancer have demonstrated the presence of 
TAMs at points of basement-membrane breakdown
192-193
. This finding, together with 
evidence from multi-photon imagining studies, suggests that tumours can manipulate 
TAMs to facilitate invasion and migration through the surrounding stroma
192, 194
.  
TAMs are also an important producer of VEGF, a key component for 
neoangiogenesis in tumours
179, 193, 195
. It has been proposed that cytokines produced 
by hypoxic cancer cells are responsible for the recruitment of macrophages
193, 196
. 
The induction of hypoxic inducible factor 2 alpha (HIF-2a) in recruited macrophages 
promotes the expression of vascular endothelial growth factor (VEGF) and 
angiogenesis
193, 195
. Furthermore, VEGF also acts as a chemo-attractant for 
macrophages thus creating a positive feedback loop for rapid vascularization in 
tumours
193
.  
In contrast to TAMs, T cells may play a promoting or suppressing role in cancer 
depending on their effector functions
186
. Clinical and experimental evidence 
indicates that the anti-tumour function of T lymphocytes is mediated by both 
cytotoxic mechanisms and cytokines
186
. Correspondingly, studies have demonstrated 
that increased activated cytotoxic T lymphocytes (CTLs) and Type 1 T-helper cells 
(Th1) are associated with better prognosis in pancreatic cancer. However, evidence 
has also suggested that several subsets of T cells (e.g. CD8, IFN-producing Th1 
cells, and Th2 cells) are involved in tumour promotion, progression, or metastasis
186
.  
 
1.4.3.2 Pancreatic stellate cells, CCGFs, pancreatic fibrosis, and cancer 
An important stromal component of pancreatic tumour microenvironment is 
pancreatic stellate cells (PSCs)
185
. PSCs are vitamin A containing spindle-shaped 
cells found in the pancreas that is capable of producing extracellular matrix (ECM) 
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proteins such as collagen, fibronectin, and desmin
186
. In normal pancreas, quiescent 
PCSs produce little ECM proteins and have undetectable levels of cytoplasmic alpha-
smooth muscle actin (-SMA). However, in response to oxidative stress from 
pancreatic injury, PSCs are transformed in to myofibroblast-like cells that express -
SMA
154
. In chronic pancreatitis and pancreatic cancer-associated inflammation, 
cytokines and growth factors released by immune cells stimulate PSC growth (e.g. 
PDGF) and the production of ECM proteins (TGF-, IL-1)140. In addition, activated 
PSCs in turn produce their own inflammatory mediators including MCP-1, IL-8, and 
RANTES, which generate a positive feedback for inflammation
185
. Interestingly, 
PSCs produce both ECM degrading enzymes (e.g.MMPs) and their inhibitors (tissue 
inhibitors of metalloproteinases, TIMPs)
185-186
. Indeed, the suppression of MMP-3 
and MMP-9 by the TGF- pathway and the promotion of MMP-2 expression (causes 
fibre deposition) by IL-6 and TGF-1 have been observed in areas of pancreatic 
fibrosis
186
. Therefore, the regulation of pancreatic fibrosis is dependent on a delicate 
balance between ECM proteins production and degradation. Most importantly, recent 
studies have proposed that ECM remodelling is a key process, which facilitates the 
transition of dormant cancer cells to growth and in addition, angiogenic factors 
released by the remodelled ECM triggers the angiogenic switch thereby resulting in 
tumour growth and metastasis
197-198
. 
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1.5 Statistical Modelling Methods 
1.5.1 Background 
This section is written with the aid of an article titled “Classification of Breast 
Cancer Cells Using JMP” by Dr Marie Gaudard et al. in 2009199. This article was 
later published in Chapter 9 the book Visual Six Sigma: Making Data Analysis Lean. 
However, the original article can still be viewed online at 
http://www.northhavengroup.com/documents/BreastCancer_WhitePaper_Current.pdf.  
In Chapters 2 and 3 of the current thesis, a number of statistical modelling methods 
were employed to select and then combine candidate biomarkers into a single marker 
including stepwise regression model, multinomial logistic regression model, and 
artificial neural network model. 
1.5.2 The Stepwise Regression (SR) Model 
The SR model was used in Chapter 3 to select independent markers of PDAC 
amongst a large number of potential markers, which were statistically significant on 
univariate analysis. The SR model utilises the Wald/Score statistics to select 
independent predictors of outcome. The Wald/Score test in the SR model serves two 
purposes. Firstly, it compares the predictive capabilities of each variable with each 
other and secondly, the predictive capabilities are assessed in consideration of 
variables already entered into the SR mode. Therefore, whilst a variable may be a 
significant predictor of the outcome, it will not be entered into the SR model if 
previously selected variables can already identify the same samples and subsequently, 
this means that only variables with independent predictive abilities are selected by 
the SR model. 
There are three variations of the SR model including Forward, Backward, and 
Combined. In forwards stepwise regression, the variable with the highest 
significance is entered into the SR model at each step providing it has a Wald/Score 
significance within the pre-set parameters (typically <0.05) and this would be 
iterated until no more variables can enter the model. In backwards stepwise 
regression, all variables are entered into the SR model initially and the variable with 
the lowest significances is removed from the SR model at each step if it has a 
Wald/Score statistic outside the pre-set parameters (typically >0.05). In combined 
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stepwise regression (used in Chapter 3), each step consists of a forwards component 
followed by a backwards component. This means that at each step, the variable with 
the highest significance will be entered into the SR model then a backwards step will 
be performed to remove any variables, which then became insignificant.  
1.5.3 The Multinomial Logistic Regression Model 
Logistic (or Binary) regression is a mathematical method used to predict a 
dichotomous outcome e.g. PDAC versus Controls. It is widely employed by 
researches to predict a dependent variable based on a number of continuous and/or 
categorical independent variables.  
In the current thesis, M-LR was used to estimate the probability of PDAC (dependent 
variable) using the serum concentrations of candidate CCGFs selected by the 
stepwise regression model (continuous independent variables). This is achieved 
through the use of the logistic formula: 
                        
 
    
 
Where 
                      
                   
And 
 β0 represents the intercept constant 
 β1, β2, β3, and β4 are regression coefficients for the corresponding CCGF 
 This algorithm will generate, using serum concentrations of candidate CCGFs 
in a given sample, a probability value of PDAC ranging from 0 to 1 
 A probability value of 0 represents a likely control sample where as a 
probability value of 1 represents a likely PDAC sample 
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Figure 1.2- A diagram of the Artificial Neural Network model 
1.5.4 Artificial Neural Network Model 
The neural network model is so named because of its ability to “learn” in a similar 
fashion to neurons in the human body. There are three layers of neurons arranged in 
nets within the NN model: input layer, hidden layer (where processing occurs), and 
output layer. Each layer of neurons can be excited to a range of degrees (i.e. not 
binary). The input layer can be considered as sensory neurons, which react to a 
stimulus (CCGF concentrations) and generates an output signal that reflects the 
intensity of the input stimulus. This signal then enters the hidden layer where a 
predefined number of hidden nodes will again generate a weighted pattern of 
stimulus (i.e. a linear function [the weighted part] of logistic functions generated at 
each node), which is carried to the output layer. Finally, the inputs are summed (i.e. 
the estimated probability of PDAC) and compared to a threshold value (optimal cut-
off) to determine their output (predicted PDAC or Control). Most importantly, 
perhaps the most important feature in NN model is its ability to learn from its 
mistakes. This is achieved by comparing the predicted out-put with the actual 
classification and by propagating the degree of error back through the whole network 
with the incorrectly classified connections down-weighted and correctly classified 
connections strengthened.  
Again, this model will estimate the probability of a sample being PDAC based on the 
serum concentrations of the four CCGFs where a probability of 0 suggests a likely 
control sample whereas a probability of 1 suggests a likely PDAC sample. 
 
  
Input Layer Hidden Layer Output Layer 
PDAC 
Control 
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1.6 Research Project Design  
This research project takes a two-fronted approach to the discovery of proteomic 
biomarkers for pancreatic cancer whereby two independent studies are described in 
Chapter 2 and Chapter 3 of this thesis (see Figure 1.3).  
Chapter 2 aim to determine the diagnostic potential of three serum-based candidate 
markers identified from a previous mass spectrometry experiment are determined by 
western blot analyses using pancreatic cancer and control samples from two database: 
Liverpool Pancreatic Cancer database (LPCD) and UK Collaborative Trial of 
Ovarian Cancer Screening (UKCTOCS) (See section 2.3.2.2). 
Chapter 3 describes the use of multiplex cytokine assays for the discovery of novel 
biomarkers for pancreatic cancer. In this Chapter, the diagnostic potential of 
cytokines is examined as individual and combined markers. The results are validated 
using an independent validation sample set. (See section 3.3.2) 
Figure 1.3- Design of the current MPhil Project. The current thesis consists of two separate 
experimental studies. Each study is described in an individual Chapter and each study consists of 
three phases. The aim of Chapter 2 is to validate the expression of three proteins identified by a 
previous iTRAQ experiment conducted in the department by western blotting: Vitamin D-Binding 
Protein (VDBP), Retinol-Binding Protein (RBP-4), and Fibronectin (FINC). In Chapter 3 the use 
of a multiplex cytokine assay for the quantification of 27 serum cytokines, chemokines, and growth 
factors (CCGFs) is described. In addition, a disease-predicting algorithm was generated in the 
Discovery Phase and then validated by an independent sample set in the validation phase.  
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Chapter 2 
The diagnostic potential of VDBP, RBP-4, 
and FINC for pancreatic cancer 
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2.1 Background and Introduction 
Blood serum is one of the most preferred sources for proteomic biomarker research 
because it offers a rich source of proteins and it is relatively non-invasive to acquire. 
However, despite much effort in the past few decades on the discovery of a novel 
serum diagnostic marker of pancreatic cancer, there has been little success in 
identifying a biomarker that is both sufficiently sensitive and specific to pancreatic 
cancer. Nonetheless, recent developments in proteomic technology such as iTRAQ 
and mass spectrometry have given new hopes to the ongoing search for a diagnostic 
marker or marker panel for use in the detection of pancreatic cancer.  
Previous data from an iTRAQ experiment performed in the Division of Surgery, 
University of Liverpool, by Seonaid Murray and colleagues have identified a number 
of serum-based proteins, which are differentially observed in PDACs compared to 
Controls (chronic pancreatitis [CP] and healthy controls [HC]). Results from this 
experiment identified 254 proteins and quantified 234 proteins with greater than 95% 
confidence. A detailed description of the iTRAQ experimental protocol can be found 
in a previously published article by Tonack et al. 
129
. Of the quantified proteins, 
forty-eight proteins showed a greater than three-fold difference in relative quantities 
between the early-stage pancreatic cancer group (EC) and control groups (CP and 
HC).  
This chapter focuses on the validation of three proteins including Vitamin-D Binding 
Protein (VDBP, >3-fold ↓ in EC), Retinol Binding Protein-4 (RBP-4, >4-fold ↓ in 
EC), and Fibronectin (FINC, >3-fold ↓ in EC), which were found to be down 
regulated in the iTRAQ analysis (Figure 2.1). the serum levels of these proteins in 
individual patient samples were ascertained by western blotting. Furthermore, the 
accuracy of the three proteins for the diagnosis of pancreatic cancer against benign 
pancreaticobiliary disease (chronic pancreatitis and benign biliary obstruction, 
disease control [DC]) and healthy controls is demonstrated. In addition, the 
expression of these proteins was examined in pre-diagnostic serum samples collected 
from patients with PDAC up to 6 years before the confirmed diagnosis of PDAC was 
made.  
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Figure 2.1-  Bar chart showing the relative 
intensities of [A] Fibronectin (FINC), [B] 
Vitamin D-Binding Protein (VDBP), and [C] 
Retinol-Binding Protein 4 (RBP-4)  in pooled 
serum samples from 4 disease groups: 
Chronic Pancreatitis (CP), node-positive 
later-staged pancreatic cancer (LC), node-
negative earlier staged pancreatic cancer 
(EC), and healthy volunteers (HC).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.1 Vitamin D binding protein 
Vitamin D-binding protein is a member of the albumin superfamily and plays a 
number of physiological roles including the transportation of vitamin D and its 
metabolites, the binding of actin, neutrophil chemotaxis, and macrophage activation. 
VDBP was first identified as a group-specific component (Gc) protein by Hirschfeld 
in 1959
200
 but was later given the name DBP after the discovery of its role in the 
transportation of vitamin D analogues
201
. In 1996, Yamamoto et al. 
202
 demonstrated 
in an animal study that VDBP also has a stimulatory effect on macrophage activity 
through its metabolite, which was named DBP-Macrophage Activating Factor (DBP-
MAF). VDBP is a 58kDa glycosylated -globulin consisting of three domains: two 
repeated homologous domains and a shorter domain 
203-205
. It is the unique 
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orientations of these domains and the presence of oxygen-linked carbohydrate chains 
that give VDBP its unique physiological functions
203-205
. 
The plasma concentration of VDBP usually ranges from 0.2-0.5g/l and remains 
stable from birth
204
. Several physiological states have been shown to influence the 
serum level of VDBP including prolonged fasting, pregnancy, and high oestrogen 
states
206-207
. In addition, recent studies have demonstrated an inverse association 
between serum VDBP concentration and liver-related diseases such as liver cirrhosis, 
acute liver failure, and hepatocellular carcinoma
208-210
.  
2.1.2 Retinol-binding protein 
Vitamin A has a number of biological roles including vision, maintenance of 
differentiated epithelia, mucus secretion, and growth
211
. The majority of vitamin A is 
stored in the liver and is usually transported by RBP in the systemic circulation as 
retinol (lipid alcohol form of vitamin A)
211-212
. RBP is a 21KDa molecule that 
consists of 182 amino acids arranged in a single polypeptide chain with three 
disulphide bonds
213-214
. It is produced by the liver and excreted by the kidneys and 
the plasma level of RBP typically ranges between 40-50 µg/ml
213-214
. However, a 
number of studies have shown that the systemic levels of RBP can be influenced by 
various diseases including malnutrition, liver diseases, and chronic renal diseases
215-
220
.  
2.1.3 Fibronectin 
Fibronectin is a multi-domain glycoprotein with a molecular weight of 
approximately 440kDa, which usually exists as a dimer composed of two identical 
monomers 
221-223
. FINC has been shown to bind to a variety of biologically important 
molecules including a number of clotting-related molecules (such as heparin, 
collagen, and fibrin) and in addition, FINC is capable of binding to cell surfaces 
through integrins
223
. Fibronectin can be sub-classified into two broad categories: 
plasma fibronectin and cellular fibronectin. Hepatocytes are the main source of 
circulating plasma fibronectin, which has been reported to be in a closed and non-
active state. In contrast, the active form of FINC (cellular fibronectin) is produced by 
multiple cell types (e.g. fibroblasts, epithelial cells, and macrophages) and is 
typically found in its insoluble form as a part of the extracellular matrix
222-223
.  
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2.2 Study Aims 
The aims of the current chapter: 
1. To validate the difference in the serum levles of VDBP, RBP-4, and FINC 
between PDAC and Controls observed in the original iTRAQ experiment 
performed by Seonaid Murray (Division of Surgery and Oncology, UOL) 
2. To determine the diagnostic potential of VDBP, RBP-4, and FINC for pancreatic 
cancer 
3. To determine the expression of VDBP and RBP-4 in pre-diagnostic serum 
samples 
4. To determine the expression of VDBP, RBP-4, and FINC in pancreatic cancer 
cell-lines 
2.3 Materials and Methods 
2.3.1 Study design 
The expression of VDBP, RBP-4, and FINC in pancreatic cancer and control 
subjects was examined in three phases (Figure 2.2). Each phase involved western 
blotting followed by relative quantification of the blots through densitometry 
analysis. In Phase-I, the levels of VDBP, RBP-4, and FINC in the pooled iTRAQ 
samples (section 2.3.2.1) were validated using the individual samples. In Phase-II, 
the expressions of VDBP, RBP-4, and FINC were assessed using an independent 
sample set consisting of 60 samples from the LPCD (section 2.3.2.1). In addition, the 
diagnostic potential of these proteins as individual and combination markers for 
early-staged pancreatic cancer were determined. Protein markers, which were 
differentially expressed in Phase-II were further assessed for their potential as a 
screening marker using the UKCTOCS pre-diagnostic serum samples (Phase-III, 
2.3.2.2). Western blot analyses in the current study were performed in triplicate to 
maximise the accuracy of the results. 
Supplementary to this experiment, western blot analyses were performed to 
determine whether VDBP, RBP-4, and FINC are expressed in five pancreatic cancer 
cell lines, one hepatocellular carcinoma cell line and one human embryonic kidney 
cell line (section 2.3.3).  
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Figure 2.2- Study design for Chapter 3 of the current thesis. The current study consists of 
three phases and each phase involves western blot analysis of a unique sample set. In Phase-
I, the expression of VDBP, RBP-4, and FINC were validated using 5 samples from of the 
following disease groups: node-negative earlier-staged PDAC (EC), node-positive later-
staged PDAC (LC), chronic pancreatitis (CP), and healthy volunteers (HC). Phase-II of the 
study aimed to validate the results in the original iTRAQ experiment and Phase-I by using 60 
samples from individuals with PDAC, CP, HC, and disease controls (DC). Phase-III aimed 
to determine the value of significant markers (VDBP and RBP-4) in screening for pancreatic 
cancer using samples from the UKCTOCS database. 
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2.3.2 Patients and samples 
Approval for the current study was obtained from the relevant research ethics 
committee including the multicentre research ethics committee (MREC) for the use 
of the serum samples from the Liverpool Pancreatic Cancer Database and the Central 
Office of Research Ethics Committee (COREC) for the use of UKCTOCS samples. 
Informed consent was obtained from all individuals involved.  
2.3.2.1 Phase I and II Liverpool pancreatic cancer database (LPCD) 
Pre-operative serum samples were prospectively collected at the Royal Liverpool 
University Hospital from patients with resectable PDAC, chronic pancreatitis, benign 
biliary obstruction, and healthy volunteers between 1996 and 2010. Serum samples 
were collected in Sarstedt Monovette tubes (Sarstedt Ltd, Leicester, UK) and allowed 
to clot at 4°C for 15 minutes. The serum fraction was acquired by centrifugation at 
800-x g for 10 minutes and was then aliquoted into cryotubes (Nunc GmbH & co 
KG., Thermo Fisher Scientific, Langenselbold, Germany). All samples were stored at 
minus 80°C until further use.  
Phase-I patient demographical data (iTRAQ) 
Demographical data of the twenty individuals involved in Phase-I of the current 
study is presented in Table 2.1. There were sixteen males, 3 females, and one 
individual whose gender was not recorded. The median ages for patients with node 
negative earlier-stage PDAC (EC), node-positive later-stage PDAC (LC), and CP 
were 66, 71, and 63, respectively. There were four individuals with a confirmed 
history of diabetes in the cancer groups (EC and LC) and none in the control groups. 
However, some demographical data were not available due to privacy and 
confidentiality reasons. 
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Phase II patient demographical data (LPCD) 
Demographical data of the 60 individuals involved in Phase-II of the current study is 
presented in Table 2.2. Thirty-two male and twenty-eight female participants were 
involved in the current Phase, of which, 20 had PDAC and 10 had CP, 20 had biliary 
obstruction (DC), and 10 were HC. The median ages were 69, 51, 64, and 36 years 
for the PDAC, CP, DC, and HC groups, respectively. Again, some demographical 
data were not available due to privacy and confidentiality reasons. 
Table 2.2- Summary of patient Demographics in Phase-II (Liverpool database) 
Parameters 
Disease Groups 
PDAC (n=20) CP (n=10) DC (n=20) HC (n=10) 
Age (median/year) 69 51 64 36 
Gender 
  Male/Female (n) 
 
10/10 
 
2/8 
 
15/5 
 
5/5 
Median CA19-9 (range)  307 (10-10061) 12 (7-50) 21 (0-1402) 6 (2-12) 
History of Diabetes (n) 
  Yes/No (n) 
  Unknown 
 
4/15 
1 
 
0/9 
1 
 
2/16 
2 
 
-/- 
10 
Abbreviations: Chronic pancreatitis (CP); Node positive later-staged pancreatic cancer (LC); Node negative 
earlier-staged pancreatic cancer (EC); Healthy volunteers (HC). 
 
  
Table 2.1- Summary of patient Demographics in Phase-I (iTRAQ) 
Parameters 
Disease Groups 
CP (n=5) LC (n=5) EC (n=5) HC (n=5) 
Age (median/year) 63 71 66 >50 
Gender 
  Male/Female (n) 
  Not recorded 
 
4/0 
1 
 
2/3 
0 
 
5/0 
0 
 
5/0 
0 
History of Diabetes (n) 
  Yes/No (n) 
  Unknown 
 
0/4 
1 
 
1/3 
1 
 
3/0 
2 
 
-/- 
5 
Abbreviations: Chronic pancreatitis (CP); Node positive later-staged pancreatic cancer (LC); Node negative 
earlier-staged pancreatic cancer (EC); Healthy volunteers (HC). 
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2.3.2.2 Pre-diagnostic serum samples- UKCTOCS 
The UK collaborative trial of ovarian cancer screening (UKCTOCS) is a multicentre 
trial involving 13 regional centres aimed to establish the impact of ovarian cancer 
screening on ovarian cancer mortality by comparing disease mortality in the screened 
and control groups
224
. Serum samples were prospectively collected from 50,000 
postmenopausal women aged 50-74 with no past medical history of malignant 
disease or familial predisposition to ovarian cancer in the screened group
224
. 
Participants in this group were sub-classified into low, intermediate and high risk for 
the development of ovarian cancer according to their serum CA-125 levels and were 
followed up prospectively at regular intervals: annually for low risk, 3-monthly for 
intermediate risk, and referral for further investigations for participants with elevated 
CA-125
224
. During each follow-up session, a serum sample was collected and the 
development of malignancies was recorded. Serum samples were collected in 
Greiner gel tubes (Greiner Bio-One 455071, Stonehouse, UK) and transported 
overnight at ambient temperature to the central laboratory where samples were 
processed within 56 hours of venepuncture (otherwise discarded)
224
. Separation of 
the serum layer was achieved by centrifugation at 4,000 rpm for 10 minutes. Excess 
serum was aliquoted into 500µl straws, which were then heat-sealed and stored in 
liquid nitrogen until transfer to a cryonic biorepository
224
.  
At the University of Liverpool, we collaborated with the biomarker group at the 
University College London to obtain over 300 pre-diagnostic (up to 6 years pre-
diagnosis) serum samples from UKCTOCS participants who developed pancreatic 
cancer within the trial period accompanied by an equal number of healthy control 
samples matched for time before sample processing and storage time.  
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Phase III patient demographics (UKCTOCS) 
One-hundred and twenty serum samples from the UK Collaborative Trial of Ovarian 
Cancer Screening (UKCTOCS) were analysed in Phase III (Table 2.3). Sixty pre-
diagnostic serum samples from post-menopausal women who developed pancreatic 
cancer during the course of the UKCTOCS trial (pre-pancreatic cancer, PPC) and 
sixty-paired healthy control samples (HC) matched for gender, storage, and 
processing time were used in this Phase. Samples were stratified into six time-
categories according to the duration between sample collection and diagnosis: 0-0.5, 
0.5-1, 1-2, 2-3, 3-4, and over 4 years. Each time group therefore, consists of 10 PPC 
samples and 10 matched HC samples. 
 
2.3.3 Cancer cell lines, cell culture and lysate preparation 
2.3.3.1 Cell lines and cell culture 
Five human pancreatic ductal adenocarcinoma cell lines (PANC-1, ASPC-1, BXPC-
3, CFPAC-1, and FAMPAC), one hepatocellular carcinoma cell line (HEPG-2), and 
one human embryonic kidney cell line (HEK) were were screened for mycoplasma 
contamination before cell culturing commenced. All cell lines except HEPG-2 were 
cultured in T-75 flasks at 37°C and 5% CO2 in 20 ml of RPMI 1640 media 
supplemented with 10% foetal calf serum, 2mM glutamine, 100U/ml penicillin, and 
100U/ml streptomycin (Sigma, Poole, UK). For culture of HEPG-2 cell lines 
Dulbecco‟s Modified Eagle Medium supplemented with 10% foetal calf serum, 2mM 
glutamine, 100U/ml penicillin, and 100U/ml streptomycin (Sigma, Poole, UK) was 
used instead of RPMI. When confluent, cancer cells were detached from the flask 
using 2ml trypsin (sigma, Poole, UK). Once fully detached, 8ml of culture media was 
added to the flask and the culture was split in the following ratio: 1ml for further 
culture, 9ml for cell lysate preparation. 
Table 2.3- Summary of demographics for UKCTOCS samples stratified by time-category 
Parameters 
Time Category/ year 
0-0.5 0.5-1 1-2 2-3 3-4 4+ 
HC PPC HC PPC HC PPC HC PPC HC PPC HC PPC 
Number (n) 10 10 10 10 10 10 10 10 10 10 10 10 
Age/ years             
    Median 61 65 62 70 60 61 61 61 58 61 61 65 
    Range 52-75 57-78 53-72 57-73 53-72 53-72 51-73 52-71 52-71 57-75 51-72 52-73 
Delay in sample processing/ hr              
    Median 22 22 20 21 23 23 24 24 23 23 20 20 
    Range 19-25 20-26 19-24 19-24 19-46 20-46 18-25 18-25 21-43 21-44 4-26 2-22 
Abbreviations: Healthy control (HC); pre-pancreatic cancer (PPC) 
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2.3.3.2 Lysate preparation 
Cells collected from culture splitting were centrifuged for 5 minutes at 1,200 rpm. 
The resulting pellet was washed three times in PBS solution and lysed using 100µl of 
lysis buffer (0.15 M NaCl, 5mM EDTA, 10mM Tris-Cl pH 7.4, 1% Triton X-100, 
and protease inhibitor cocktail; all from Sigma-Aldrich) at 4°C for 10 minutes then 
sonicated. The protein concentration of the lysate was then determined using the 
Bradford Assay. The lysate was then stored at minus 80°C until required. 
 
2.3.3.3 Measuring lysate protein concentration- Bradford Assay 
The Bradford reagent assay (Bio-Rad, Hemel Hempstead, UK) was employed to 
determine the protein concentration of cancer cell lysates. The Bradford reagent 
contains a dye (brilliant blue G), which forms a complex with the proteins in the 
reconstituted samples resulting in a shift in the absorption wavelength of the dye 
from 465 to 595 nm. Therefore, the amount of absorption is directly proportional to 
the protein concentration in the solution. 
Briefly, six reference standards ranging from 1 µg/µl to 10 µg/µl were constituted 
using bovine serum albumin (Sigma Aldrich, Gillingham, UK). Then 2 µl of 
standard or sample were added to 798µl of MilliQ water in a 1.5ml Eppendorf 
microfuge tube followed by 200µl of Bradford Reagent (Bio-Rad, Hemel Hempstead, 
UK). The mixture was incubated at room temperature for 10 minutes then analysed 
by spectrophotometry at a wavelength of 595nm. The protein concentration of each 
sample was calculated using a linear equation constructed from the reference 
standards, which converts Bradford assay values to protein concentration (µg/µl). 
Finally, the volume of lysate required for 15µg of protein was calculated for each 
lysate.  
2.3.4 Western Blot Analysis 
2.3.4.1 SDS-polyacrylamide gel preparation 
The composition of SDS-polyacrylamide gel required for the analysis of VDBP, 
RBP-4, and FINC are 12%, 15%, and 6%, respectively. The running gel solution was 
prepared according to Table 2.4, and immediately poured into a gel cast (BioRad, 
Hemel Hempstead, UK) and allowed to set. A stacking gel solution was added to the 
cast followed by a 10-well or 15-well comb and allowed to set.  
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Table 2.4- Recipe for 10 ml of Resolving Gels and 4ml of Stacking Gel for SDS-PAGE 
Components required /ml 
Gel Density 
6% (FINC) 12% (VDBP) 15% (RBP-4) 5% (Stacking) 
H20 5.3 3.3 2.3 2.7 
30% acrylamide mix 2.0 4.0 5.0 0.67 
1.5M Tris (pH 8.8) 2.5 2.5 2.5 0.5 
10% SDS 0.1 0.1 0.1 0.04 
10% ammonium persulphate 0.1 0.1 0.1 0.04 
TEMED 0.01 0.006 0.005 0.005 
Abbreviations: Sodium dodecyl sulphate (SDS); Polyacrylamide Gel Electrophoresis (PAGE); fibronectin 
(FINC); retinol-binding protein 4 (RBP-4); vitamin D-binding protein (VDBP); Tetramethylethylenediamine 
(TEMED) 
 
2.3.4.2 Sample preparation 
Four micro-litres of diluted serum samples/standards (Table 2.5) or 10µg of cell 
lysate were denatured and ionised by adding 3µl of 5x reducing sample buffer 
(300mM Tris pH 6.8, 50% Glycerol, 10% SDS, 0.05% Bromophenol blue, 5% 
Dithiothreitol [DTT]) and made up to a final volume of 10µl using 1x reducing 
sample buffer in a 0.5ml Eppendorf microfuge tube. The mixture was heated at 95°C 
for 15 minutes then cooled on ice for 3 minutes. Finally, the mixture was flash spun 
at 13,000g to bring down condensation prior to gel loading. 
Table 2.5- Preparation of samples and standards for western blot 
Analyte Protein Dilution Sample Volume (µl) 
Standard volume (µl) 
Std 1 Std 2 Std 3 
VDBP 1:100 4 2 4* 6 
RBP-4 1:10 4 2 4* 6 
FINC 1:10 4 4 6 10* 
*The volume of serum standard was used in the densitometry analysis of serum samples 
 
2.3.4.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Prior to performing polyacrylamide gel electrophoresis, the 
wells were flushed with running buffer to remove any un-
polymerised polyacrylamide. Five micro-litres of PageRuler™ 
Pre-stained Protein Ladder (Fermentas, York, UK; Figure 2.3) 
was loaded into the first well and 10µl of prepared 
standard/samples were loaded to each subsequent well. 
Electrophoresis was performed using the Mini-PROTEAN 
Tetra Electrophoresis System (Bio-Rad, Hemel Hempstead, 
UK) set at 25-50mA constant (depending on the number of 
gels) until the dye front completely left the gel (approximately 
1-1.5 hour).  
Figure 2.3-  
Pre-stained protein 
ladder used in western 
blot analysis 
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Proteins in the gel were transferred onto a nitrocellulose membrane using the Mini-
Transblot pack (Bio-Rad, Hemel Hempstead, UK) set at 110V (constant voltage) for 
1 hour. The membrane was incubated at room temperature with 20ml of 5% milk 
diluted in phosphate buffer solution with 1% Tween-20 (5% milk-PBST solution) for 
2 hours followed by incubation with the appropriate concentration of primary 
antibody diluted in 5% milk-PBST solution for 16 hours at 4°C (Table 2.6). The 
membrane was then washed six times at 10-minute intervals (1 hour) with PBST 
followed by incubation with the appropriate secondary antibody-HRP diluted in 5% 
milk-PBST for 1 hour. After a further six washes at 10-minute intervals, the 
membrane was incubated with Enhanced Chemiluminescence (ECL) substrate 
(Western Lightning®  Plus, PerkinElmer, Cambridge, UK) for 4 minutes followed by 
chemiluminescence detection by x-ray films (Fisher Scientific, Leicestershire, UK) 
or the Kodak digital imaging machine. For subsequent western blotting of β-Actin in 
protein lysates, the membrane was incubated at 60°C for 30 minutes in stripping 
buffer, rinsed with PBST, and then incubated with primary β-Actin antibody 
(1:10,000 dilution) for 16 hours. Washes, secondary antibody incubation, and 
detection were carried out as described above. Each gel was repeated twice to obtain 
three sets of results per gel, per antibody.  
 
  
2.3.5 Relative quantification of western blots 
The Kodak digital imaging machine and Kodak molecular imaging software 
(Carestream molecular Imaging, Woodbridge, USA) were used to analyse the 
Western Blot images. The relative quantity of protein in each band was assessed 
using densitometry analysis. To define the profiles a rectangular box was defined 
arbitrarily with the same width as the widest band on the film and longer than the 
Table 2.6- Summary of sample preparation, primary antibody, and secondary antibody information 
Analyte 
MW 
(kDA) 
Primary anti-analyte antibody Secondary anti-primary antibody-HRP 
Company Dilution Description Company Dilution Description 
VDBP 53 Abcam 1:30,000 Rabbit Monoclonal Dako 1:3,000 
Polyclonal Goat Ant-
rabbit Ig/HRP 
RBP-4 25 Santa Cruz 1:5,000 Mouse Monoclonal Dako 1:3,000 
Polyclonal Goat Ant-
mouse Ig/HRP 
FINC 
 
220 Santa Cruz 1:20,000 Mouse Monoclonal Dako 1:3,000 
Polyclonal Goat Ant-
mouse Ig/HRP 
Beta-
Actin 
42 Sigma-Aldrich 1:10,000 Mouse Monoclonal Dako 1:3,000 
Polyclonal Goat Ant-
mouse Ig/HRP 
Abbreviations: vitamin D-binding protein (VDBP); retinol-binding protein (RBP-4); fibronectin (FINC); 
Immunoglobulin (Ig); expected molecular weight (MW) Note: 5% Milk in Phosphate Buffer Solution with 1%-
Tween 20 used as blocking solution; 
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largest band. This same box was used to measure all bands in the image, resulting in 
a mean intensity value for all bands. To account for gel-to-gel variation relative 
intensities for each sample were calculated by dividing sample mean intensity by the 
internal control mean intensity. 
2.3.6 Statistical Analysis 
2.3.6.1 General statistics, univariate, and multivariate analyses 
All continuous data (e.g. Age, serum analyte levels) were classified as non-
parametric data and were summarised using median and range. The Kruskal-Wallis 
test was used to determine whether there is a significant difference in non-parametric 
distribution between multiple (>2) groups (e.g. age versus PDAC, CP, HC, and DC). 
For univariate analysis, the Wilcoxon‟s test was used to assess any difference in the 
distribution of a non-parametric variable (e.g. age) between two groups and the 
Fisher‟s Exact test was used to assess the difference between two categorical 
variables (e.g. gender versus PDAC/Control). Variables that were significant on 
univariate analysis were further tested using multivariate analysis to identify any 
independent variables. For univariate and multivariate analyses, a p-value of <0.05 
was considered statistically significant.  
 
In Hierarchical Cluster Analysis, data from each variable was first standardised by 
mean and standard deviation to give a value between -1 and 1. The standardised 
values were then analysed by Ward‟s minimal variance method and represented 
graphically in a heat map.  
Data from the current study were also graphically represented using box plots, 
mosaic plots, logistic plots, and receiver-operator characteristic (ROC) curves. 
 
2.3.6.2 Correlation analysis 
The correlation between age and the relative serum concentration of VDBP, RBP-4, 
and FINC were assessed using Kendall Tau () multivariate correlation analysis for 
non-parametric tied data. The Kendall  coefficient ranges from -1 to 0 to 1 where a  
coefficient of -1 or 1 represents a perfect negative or positive correlation, 
respectively, and a coefficient of 0 indicates that there is no correlation. The 
associated p-value represents how confident the test is that the actual value would 
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be more negative or more positive than then calculated value. In the current study, 
a Kendall Tau coefficient of >0.5 was regarded as significant. 
 
2.3.6.3 Diagnostic potential of biomarkers for PDAC  
The diagnostic accuracies of biomarkers were assessed using ROC Area Under 
Curve (AUC) and a ROC-AUC of >0.70 was considered statistically significant. In 
sections 2.4.2.6 to 2.4.2.10, the accuracies of VDBP, RBP-4, and FINC for 
diagnosing PDAC were independently assessed against the each of the following 
groups: HC, CP, DC, and all controls (HC, CP, and DC together). Additionally for 
each group, the diagnostic accuracy of the three proteins as a single combined 
marker of pancreatic cancer was assessed.  
The Multinomial Logistic Regression (M-LR) model was used to combine candidate 
markers into a single marker by generating a disease-predicting algorithm, which 
estimates the probability of PDAC based on the relative serum concentrations of 
VDBP, RBP-4, and FINC. The estimated probability of PDAC ranges from 0-1 
where an estimated PDAC probability value of 0 indicates a likely control sample 
whereas a value closer to 1 indicates a likely pancreatic cancer sample.  
2.3.6.4 Software for statistical analyses 
All statistical analyses were performed using JMP version 8.02 (SAS, 
Buckinghamshire, UK). In addition, Microsoft Excel 2007 (Microsoft Limited, 
Berkshire, UK), was used to graphically represent the data.  
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2.4 Results 
2.4.1 Phase I- Validation of iTRAQ results by Western Blotting 
The aim of Phase I is to validate the serum expression of VDBP, RBP-4, and FINC 
in individual samples used by the original iTRAQ experiment (which consisted of 
pooled samples from 5 patients per disease group) by Western Blotting. An example 
of Western Blot image for VDBP, RBP-4, and FINC is shown in Figure 2.4 and the 
expected molecular weight of each protein can be found in Table 2.6. Results from 
densitometry analyses were expressed as a ratio relative to the intensity of the control 
reference band. The relative intensities (RI) of FINC, RBP-4, and VDBP for each 
disease group in the original iTRAQ experiment were comparable to the Western 
Blot results (Figure 2.5A-F). Furthermore, the RIs of all three proteins were 
decreased in the cancer groups (EC and LC) compared to the control groups (CP and 
HC). In particular, the pattern of FINC expression in the western blot analysis is 
almost identical to the original iTRAQ results. The box plots in Figure 2.6 confirm 
this pattern and therefore suggest that the results were not due to the effects of 
outliers. However, results from Phase-I were not sufficiently powered to show any 
significance on further statistical analysis (Figure 2.6). Therefore, all three proteins 
were analysed in Phase-II of the current study, which involves a larger sample set 
from the Liverpool Pancreatic Cancer Database.  
Figure 2.4- Western blotting (WB) of original 
iTRAQ samples. [A] WB image of iTRAQ result 
for Vitamin D-Binding Protein (VDBP). Serum 
sample results were standardised to 4µl of Sigma 
control serum (Std).Samples were diluted 1:100 
[B] WB image for Retinol-Binding Protein 4 
(RBP-4). Serum sample results were standardised 
to 4µl Std. Samples diluted to 1:10 [C] WB image 
of Fibronectin (FINC). Serum sample results were 
standardised to 10µl Std, Samples diluted to 1:10.  
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Figure 2.5 (Above)- [A-F]Bar charts 
showing the mean relative intensity of the 
chronic pancreatitis (CP, n=5), lymph node 
positive later-staged pancreatic cancer (LC, 
n=5), lymph node negative earlier-staged 
pancreatic cancer (EC, n=5), and healthy 
volunteers (HC, n=5) in the original iTRAQ 
experiment (A,C, and E; consists of pooled 
samples from the 5 patients in each disease 
group) and in Phase I (B,D, and F, samples 
were analysed individually by Western 
Blotting ).  
Figure 2.6 (left)- Box plots showing the 
relative intensities of VDBP, RBP, and FINC 
in each disease group. Relative intensities 
were obtained following densitometry scan of 
Western Blot images then comparing the 
density of each sample with an internal 
control on the same gel. 
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2.4.2 Phase II- Further Validation by Western Blot (Liverpool samples) 
2.4.2.1 Patient demographics and clinical characteristics 
The aim of Phase II is to further verify the serum expression of VDBP, RBP-4, and 
FINC in a larger sample set consisting of 20 PDAC, 10 CP, 20 DC, and 10 HC 
individuals (Table 2.7). As expected, the serum level of CA19-9 in the PDAC group 
is significantly higher than the control group (Wilcoxon‟s Test, p=0.0003; Table 2.7). 
Furthermore, a significant difference in age between the PDAC group and the 
Control group was observed (69 years versus 53 years; Wilcoxon‟s Test, p=0.0018; 
Figure 2.7). However, we did not find any statistical difference in gender between 
the two groups (Fisher‟s Exact Test, P>0.05). In view of the fact that the current 
study involves a relatively small sample size and that there is a large number of 
missing data for diabetes especially in the HC group, the correlation between PDAC 
and diabetes cannot be fully elucidated.  
Table 2.7- Summary of patient Demographics in Phase-II (Liverpool database) 
Parameters 
Disease Groups 
P-value 
PDAC (n=20) CP (n=10) DC (n=20) HC (n=10) 
Age (median/year) 69 51 64 36 0.0018 
Gender 
  Male/Female (n) 
 
10/10 
 
2/8 
 
15/5 
 
5/5 
 
N.S. 
Median CA19-9 (range)  307 (10-10061) 12 (7-50) 21 (0-1402) 6 (2-12) 0.0003 
History of Diabetes (n) 
  Yes/No (n) 
  Unknown 
 
4/15 
1 
 
0/9 
1 
 
2/16 
2 
 
-/- 
10 
N.S. 
Abbreviations: Chronic pancreatitis (CP); Node positive later-staged pancreatic cancer (LC); Node negative 
earlier-staged pancreatic cancer (EC); Healthy volunteers (HC). 
 
  
Figure 2.7- [A] Comparison of age between patients with pancreatic cancer (PDAC) and control 
patients (inc. healthy volunteers and chronic pancreatitis; Wilcoxon’s Test, p=0.0018)); [B] 
Comparison of serum CA19-9 levels between the PDAC and control groups (Wilcoxon’s Test, 
p=0.0003) 
P=0.0003 
 
p=0.0018 
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2.4.2.2 Western Blot images for VDBP, RBP-4, and FINC 
Examples of Phase II Western Blot images are shown in Figure 2.8. All gels were 
analysed by Western Blot in triplicates.   
Figure 2.8- Examples of Phase II Western Blot (WB) images. [A] WB of PDAC, CP, and HC samples 
for VDBP, [B] WB of DC samples for VDBP. [C] WB of PDAC, CP, and HC samples for RBP-4. [D] 
WB of DC samples for RBP-4. [E] WB of PDAC, CP, and HC samples for FINC. [F] WB of DC 
samples for FINC.  
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2.4.2.3 The serum level of VDBP in PDAC and Controls 
The serum level of VDBP was significantly reduced in patients with pancreatic 
cancer compared to individuals with chronic pancreatitis and healthy volunteers 
(Wilcoxon‟s Test, p=0.004 and p=0.006, respectively; Figure 2.9A-B; Table 2.8). 
However, the expression of VDBP was similar between individuals with PDAC and 
biliary obstruction (DC) (Wilcoxon‟s Test, p=0.465; Figure 2.9B). Further analyses 
stratified patients into PDAC and non-cancer groups (Figure 2.9C). Statistical 
analysis by Wilcoxon‟s Test showed that there was significant difference in the 
serum level of VDBP between the PDAC group and the combined HC and CP group 
(p<0.001). However, when the DC group was added to the combined control group 
(i.e. PDAC against HC, CP, and DC) this significance is lost (Wilcoxon‟s, p=0.113). 
This may be explained by the apparently low relative intensity of VDBP in both the 
PDAC and DC groups Figure 2.9A.  
Table 2.8- Relative quantification of serum VDBP by densitometry analysis 
VDBP 
Chronic Pancreatitis Disease control Healthy Control Pancreatic Cancer 
Median (Range)  Median (Range)  Median (Range)  Median (Range)  
Relative intensity* 1.350 (1.128-1.922)  1.066 (0.894-1.274)  1.338 (1.156-1.520)  1.066 (0.892-1.562)  
Note: *relative intensity calculated from densitometry results: sample mean region of interest (ROI ) intensity 
divided by the standard reference mean ROI Intensity  
 
 
  
Figure 2.9- [A] Box plots showing the relative intensity 
of VDBP in individuals with chronic pancreatitis (CP, 
n=10), disease controls (DC, n=20), healthy volunteers 
(HC, n=10), and pancreatic cancer (PDAC, n=20) 
Kruskal Wallis’s Test showed significant difference 
between the groups (p<0.001). [B] Univariate analyses 
represented graphically. The relative intensity of VDBP 
in PDAC was individually compared to HC, CP, and 
DC. [C]Box plots showing that the p-value is 
significantly decreased when the DC group is added to 
the combined control group (HC+CP). 
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2.4.2.4 The serum levels of RBP-4 in PDAC and Controls 
Results from the Kruskal Wallis Test showed that there was a statistically significant 
decrease in the serum level of RBP-4 between the disease groups (p=0.043; Table 
2.9; Figure 2.10A). On univariate analysis, the expression of RBP-4 was 
significantly decreased in the PDAC group compared to the HC and the CP groups 
but not the DC group (Wilcoxon‟s Test, p=0.011, p=0.031, p=0.176; Figure 2.10B). 
Further analysis stratified the groups into PDAC and control groups (Figure 2.10C). 
Results suggest that there was a significant difference in serum level of RBP-4 
between PDAC and the combined HC/CP control group (Wilcoxon‟s Test, p=0.004)). 
This significance was maintained even when DC was added to the combined control 
group (Wilcoxon‟s Test, p=0.014). 
Table 2.9- Relative quantification of serum RBP-4 by densitometry analysis 
RBP-4 
Chronic Pancreatitis Disease control Healthy Control Pancreatic Cancer 
Median (Range)  Median (Range)  Median (Range)  Median (Range)  
Relative intensity* 1.260 (0.996-1.387) 1.177 (0.857-1.446) 1.240 (1.076-1.646) 1.066 (0.666-1.410) 
Note: *relative intensity calculated from densitometry results: sample mean region of interest (ROI ) intensity 
divided by the standard reference mean ROI Intensity  
 
  
Figure 2.10- [A] Box plots showing the relative intensity 
of RBP-4 in individuals with chronic pancreatitis (CP, 
n=10), disease controls (DC, n=20), healthy volunteers 
(HC, n=10), and pancreatic cancer (PDAC, n=20) 
Kruskal Wallis’s Test showed significant difference 
between the groups (p=0.043). [B] Univariate analyses 
represented graphically. The relative intensity of RBP-4 
in PDAC was individually compared to HC, CP, and DC. 
[C] Box plots showing that the difference in FINC 
relative intensity remains significant even when the DC 
group is added to the combined control group (HC+CP). 
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2.4.2.5 The serum level of FINC in PDAC and Controls 
General analysis by Kruskal Wallis Test showed that the there is insignificant 
difference in serum FINC level between the disease groups (p=0.146; Figure 2.11A; 
Table 2.10). However, on univariate analysis, the expression of FINC was 
significantly decreased in the PDAC group compared to the HC and the CP groups 
but not the DC group (Wilcoxon‟s Test, p=0.031, p=0.035, p=0.176; Figure 2.11B). 
Further analysis stratified the groups into PDAC and control groups (Figure 2.11C). 
Again, there seemed to be a significant difference in serum level of FINC between 
PDAC and the combined control group (HC+CP; Wilcoxon‟s Test, p=0.009). This 
significance was maintained when DC was added to the combined control group 
(Wilcoxon‟s Test, p=0.012). 
Table 2.10- Relative quantification of serum FINC by densitometry analysis 
FINC Chronic Pancreatitis Disease control Healthy Control Pancreatic Cancer 
Median (Range)  Median (Range)  Median (Range)  Median (Range)  
Relative intensity* 1.989 (1.224-2.428) 2.018 (0.918-2.999) 1.941 (1.707-2.170) 1.754 (0.919-2.125) 
Note: *relative intensity calculated from densitometry results: sample mean region of interest (ROI ) intensity 
divided by the standard reference mean ROI Intensity  
 
  
Figure 2.11- [A] Box plots showing the relative 
intensity of FINC in individuals with chronic 
pancreatitis (CP, n=10), disease controls (DC, n=20), 
healthy volunteers (HC, n=10), and pancreatic cancer 
(PDAC, n=20) The difference in FINC relative intensity  
was not statistically significant (p=0.146). [B] 
Univariate analyses represented graphically. The 
relative intensity of FINC in PDAC was individually 
compared to HC, CP, and DC. [C] Box plots showing 
that the difference in FINC relative intensity remains 
significant even when the DC group is added to the 
combined control group (HC+CP). 
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2.4.2.6 Accuracy of candidate markers for the diagnosis of PDAC versus HC 
Results from the diagnostic accuracy analyses for PDAC against healthy controls are 
summarised in Table 2.11. On univariate analysis, VDBP, RBP-4, and FINC were 
significant discriminators of PDAC against HC (Wilcoxon‟s test, all p<0.05). 
However, this significance was not maintained on multivariate analysis i.e. the three 
markers were not independent to each other. Nevertheless, results from ROC analysis 
showed that VDBP, RBP-4, and FINC were all relatively accurate at discriminating 
between PDAC against HC with ROC-AUCs of 0.82, 0.80, and 0.75 respectively. In 
particular, VDBP achieved a relatively high sensitivity (0.75) and specificity (1.00) 
at the optimal cut-off of 1.15 (Figure 2.12). A preliminary analysis was performed to 
assess the impact of combining the three markers on the accuracy for the diagnosis of 
PDAC against HC. Interestingly, the diagnostic accuracy was increased to 0.89 when 
the three markers were combined by the M-LR model with relative sensitivity and 
specificity of 0.85 and 0.90 at a cut-off of 0.70 (Figure 2.12). Although results from 
this analysis would require verification in an independent sample set. 
Table 2.11- The diagnostic accuracy of VDBP, RBP-4, and FINC for PDAC against HC 
Biomarker 
 Pancreatic Cancer versus Healthy Control 
Univariate Multivariate ROC-AUC C/O Sensitivity Specificity 
VDBP 0.006 0.05 0.815 1.15 0.75 1.00 
RBP-4 0.011 0.09 0.790 1.13 0.75 0.80 
FINC 0.031 0.16 0.745 1.68 0.45 1.00 
Combined - - 0.890 0.70 0.85 0.90 
Abbreviations: Vitamin D-Binding Protein (VDBP); Retinol-Binding Protein 4 (RBP-4); Fibronectin (FINC); 
M-LR combined marker consisting of VDBP, RBP-4, and FINC (Combined); Receiver Operator Characteristics 
Area Under the curve (ROC-AUC); Cut-off for the reported sensitivity and specificity (C/O) 
 
  
Figure 2.12- Logistic Plots 
showing the diagnostic 
accuracy of [A] VDBP ,[B] 
RBP-4, and [C] FINC as 
individual markers of PDAC 
against HC. [D] Logistic 
plot showing the diagnostic 
accuracy when all three 
proteins were combined. 
Individuals with PDAC are 
coloured Blue HC in red. 
The optimal cut-off value 
(C/O) was determined by 
ROC and is shown on the 
logistic plots as a solid 
black line. Although results 
from this preliminary 
analysis was encouraging, 
further analysis would be 
required to verify the 
accuracy of the M-LR model 
56 
 
2.4.2.7 Accuracy of candidate markers for the diagnosis of PDAC against CP 
Results from the diagnostic accuracy analyses for PDAC against chronic pancreatitis 
are summarised in Table 2.12. On univariate analysis, VDBP, RBP-4, and FINC 
were significant discriminators of pancreatic cancer against chronic pancreatitis 
(Wilcoxon‟s test, all p<0.05). Furthermore, this significance was maintained on 
multivariate analysis i.e. the three markers were independent markers of pancreatic 
cancer against CP. In addition, results from ROC analysis showed that VDBP, RBP-
4, and FINC were all relatively accurate at discriminating between PDAC against CP 
with ROC-AUCs of 0.83, 0.75, and 0.74 respectively. Again, VDBP appeared to be 
the best individual maker with a relatively high sensitivity (0.75) and specificity 
(0.90) at the optimal cut-off of 1.15 (Figure 2.13). Similar to the HC results, the 
accuracy of combining all three markers for the diagnosis of PDAC against CP was 
assessed (Figure 2.13). Results showed that there is a dramatic increase in the 
diagnostic accuracy with relative sensitivity and specificity of 0.85 and 1.00 at a cut-
off of 0.70. Again, despite these encouraging results, further validation on an 
independent samples set would be necessary. 
Table 2.12- The diagnostic accuracy of VDBP, RBP-4, and FINC for PDAC against CP 
Biomarker 
 Pancreatic Cancer versus Chronic Pancreatitis 
Univariate Multivariate ROC-AUC C/O Sensitivity Specificity 
VDBP 0.004 0.002 0.825 1.15 0.75 0.90 
RBP-4 0.031 0.03 0.745 1.13 0.75 0.80 
FINC 0.035 0.029 0.740 1.72 0.50 0.90 
Combined - - 0.920 0.70 0.85 1.00 
Abbreviations: Vitamin D-Binding Protein (VDBP); Retinol-Binding Protein 4 (RBP-4); Fibronectin (FINC); 
M-LR combined marker consisting of VDBP, RBP-4, and FINC (Combined); Receiver Operator Characteristics 
Area Under the curve (ROC-AUC); Cut-off for the reported sensitivity and specificity (C/O) 
 
  
Figure 2.13- Logistic Plots showing the diagnostic accuracy of [A] VDBP ,[B] RBP-4, and [C] FINC as 
individual markers of PDAC against chronic pancreatitis. [D] Logistic plot showing the diagnostic accuracy 
when all three proteins were combined. Individuals with PDAC are coloured Blue and chronic pancreatitis are in 
red. The optimal cut-off value (C/O) was determined by ROC and is shown on the logistic plots as a solid black 
line.   
57 
 
2.4.2.8 Accuracy of candidate markers for the diagnosis of PDAC against DC 
Results from the diagnostic accuracy analyses for PDAC against disease controls are 
summarised in Table 2.12. On univariate analysis, VDBP, RBP-4, and FINC were 
not significant discriminators of pancreatic cancer against individuals with biliary 
obstruction (DC) (Wilcoxon‟s test, all p>0.05). Subsequently, no multivariate 
analysis was performed. Furthermore, results from ROC analysis showed that VDBP, 
RBP-4, and FINC were not sufficiently accurate at discriminating between PDAC 
against DC with ROC-AUCs of 0.57, 0.63, and 0.63 respectively. Moreover, the 
diagnostic accuracy was not significant (AUC 0.74) when the three markers were 
combined by multinomial logistic regression (M-LR) with relative sensitivity and 
specificity of 0.55 and 0.90 at a cut-off of 0.62 (Figure 2.14).  
Table 2.13- The diagnostic accuracy of VDBP, RBP-4, and FINC for PDAC against DC 
Biomarker 
 Pancreatic Cancer versus Disease Control 
Univariate Multivariate ROC-AUC C/O Sensitivity Specificity 
VDBP 0.465 - 0.568 1.36 0.25 1.00 
RBP-4 0.176 - 0.625 1.13 0.75 0.55 
FINC 0.176 - 0.625 2.20 1.00 0.45 
Combined - - 0.743 0.62 0.55 0.90 
Abbreviations: Vitamin D-Binding Protein (VDBP); Retinol-Binding Protein 4 (RBP-4); Fibronectin (FINC); 
M-LR combined marker consisting of VDBP, RBP-4, and FINC (Combined); Receiver Operator Characteristics 
Area Under the curve (ROC-AUC); Cut-off for the reported sensitivity and specificity (C/O) 
 
  
Figure 2.14 Logistic Plots showing the diagnostic accuracy of [A] VDBP ,[B] RBP-4, and [C] FINC as 
individual markers of PDAC against disease control. [D] Logistic plot showing the diagnostic accuracy when all 
three proteins were combined. Individuals with PDAC are coloured Blue and disease controls are in red. The 
optimal cut-off value (C/O) was determined by ROC and is shown on the logistic plots as a solid black line.   
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2.4.2.9 Diagnostic accuracy of PDAC against all controls 
Results from the diagnostic accuracy analyses for PDAC against all controls are 
summarised in Table 2.14. On univariate analysis, only RBP-4, and FINC were 
significant discriminators of pancreatic cancer against chronic pancreatitis 
(Wilcoxon‟s test, p<0.05). Furthermore, results from multivariate analysis indicate 
that only RBP-4 was an independent discriminator of pancreatic cancer against 
control subjects. Results from ROC analysis showed that VDBP, RBP-4, and FINC 
were insufficiently accurate at discriminating between PDAC against controls 
subjects with ROC-AUCs of 0.626, 0.696, and 0683, respectively. Similar to 
previous results, the diagnostic accuracy was increased when all three markers were 
combined by M-LR modelling with ROC-AUC of 0.756 and relative sensitivity and 
specificity of 0.70 and 0.80 at a cut-off of 0.36 (Figure 2.15), although this result 
would required verification with an independent sample set. 
Table 2.14- The diagnostic accuracy of VDBP, RBP-4, and FINC for PDAC against all controls 
Biomarker 
 Pancreatic Cancer versus all controls 
Univariate Multivariate ROC-AUC C/O Sensitivity Specificity 
VDBP 0.113 - 0.626 1.069 0.55 0.75 
RBP-4 0.014 0.006 0.696 1.130 0.75 0.67 
FINC 0.021 0.067 0.683 1.853 0.70 0.65 
Combined - - 0.756 0.36 0.70 0.80 
Abbreviations: Vitamin D-Binding Protein (VDBP); Retinol-Binding Protein 4 (RBP-4); Fibronectin (FINC); 
M-LR combined marker consisting of VDBP, RBP-4, and FINC (Combined); Receiver Operator Characteristics 
Area Under the curve (ROC-AUC); Cut-off for the reported sensitivity and specificity (C/O) 
 
  
Figure 2.15 Logistic Plots showing the diagnostic accuracy of [A] VDBP ,[B] RBP-4, and [C] FINC as 
individual markers of PDAC against all control subjects. [D] Logistic plot showing the diagnostic accuracy 
when all three proteins were combined. Individuals with PDAC are coloured Blue and controls are in red. The 
optimal cut-off value (C/O) was determined by ROC and is shown on the logistic plots as a solid black line.   
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2.4.2.10 Accuracy of candidate markers for the diagnosis of PDAC against HC 
and CP combined 
In view of the fact that existing literature on novel biomarkers invariably compared 
PDAC against HC and CP control subgroups only and to facilitate the comparison 
between the current and previous biomarker studies, a separate analysis was 
performed to determine the overall performance of the three markers in absence of 
the DC group (see Table 2.15). Results from this analysis indicated that VDBP, 
RBP-4, and FINC were all independent markers of PDAC against the combination of 
HC and CP (Figure 2.17 and Figure 2.16). Furthermore, ROC analysis demonstrated 
that the markers have a relatively high accuracy for discriminating between PDAC 
against HC and CP with ROC-AUCs of 0.82, 0.77, and 0.74. Finally, results from the 
combination of the markers by M-LR were encouraging with ROC-AUC of 0.91 and 
relative sensitivity and specificity of 0.85 and 0.95, respectively, at the optimal cut-
off of 0.59 (Figure 2.17). However, similar to previous analyses, results from this 
analysis would require verification with an independent sample set 
Table 2.15- The diagnostic accuracy of VDBP, RBP-4, and FINC for PDAC against HC and CP 
Biomarker 
 Pancreatic Cancer versus healthy control and chronic pancreatitis 
Univariate Multivariate ROC-AUC C/O Sensitivity Specificity 
VDBP <0.001 0.002 0.820 1.15 0.75 0.95 
RBP-4 0.004 0.015 0.768 1.13 0.75 0.80 
FINC 0.009 0.028 0.741 1.70 0.45 0.95 
Combined - - 0.908 0.59 0.85 0.95 
Abbreviations: Vitamin D-Binding Protein (VDBP); Retinol-Binding Protein 4 (RBP-4); Fibronectin (FINC); 
M-LR combined marker consisting of VDBP, RBP-4, and FINC (Combined); Receiver Operator Characteristics 
Area Under the curve (ROC-AUC); Cut-off for the reported sensitivity and specificity (C/O) 
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Figure 2.16- Heat maps showing the clustering of patients according to the cancer status. [A] Clustering in 
absence of the DC subgroup resulted in two defined clusters. Cluster 1 (Blue) consists of PDAC samples only 
whereas cluster 2 (Red) consists of mainly HC and CP samples. 
[B] Clustering of all PDAC and control samples. Although the heat map pattern is similar to [A], Clustering of 
patients became much less define when the disease control group is added to the analysis (marked). 
 
 
 
  
Figure 2.17 Logistic Plots showing the diagnostic accuracy of [A] VDBP ,[B] RBP-4, and [C] FINC as 
individual markers of PDAC against the combined HC and CP group. [D] Logistic plot showing the diagnostic 
accuracy when all three proteins were combined. Individuals with PDAC are coloured Blue and HC/CP are in 
red. The optimal cut-off value (C/O) was determined by ROC and is shown on the logistic plots as a solid black 
line.   
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2.4.2.11 Correlation between age and candidate protein markers 
Univariate analysis of demographical data in section 2.4.2.1 showed that individuals 
in the PDAC group were older compared to individuals in the control subgroups. 
This is supported by the pattern shown in Figure 2.18. Therefore, the correlations 
between age and the relative serum concentrations of the VDBP, RBP-4, and FINC 
in PDAC patients and controls were independently assessed using the Kendall Tau 
non-parametric correlation analysis. Results indicated that there was minimal 
correlation (Kendall <0.5) between age, individual protein markers, and the M-LR 
disease-predicting model (Table 2.16; see section 2.3.6.2 for a description of the 
Kendall Tau test and the interpretation of its results). 
 
 
 
 
 
 
 
 
 
  
Table 2.16- Correlation between Age, individual protein markers, and disease-predicting formulae 
 Controls PDAC 
Parameters Kendall τ Prob>|τ| Kendall τ Prob>|τ| 
Vitamin D-Binding Protein -0.32 <0.01 0.27 0.10 
Retinol-Binding Protein 0.06 0.58 0.00 1.00 
Fibronectin <-0.01 0.94 -0.11 0.52 
M-LR algorithm 0.03 0.77 0.00 1.00 
Abbreviations: Multinomial Logistic Regression (M-LR); Artificial neural network (NN) 
Note: Kendall Tau () coefficients ranges from -1 (perfect negative correlation) to 0 (no correlation) to +1 
(perfect positive correlation); Prob>|| represents the probability that the actual correlation coefficient 
() would be greater than the calculated coefficient. 
Figure 2.18- Two-way clustering of Age, vitamin D-binding protein (VDBP), Retinol-Binding 
Protein 4 (RBP-4), and Fibronectin (FINC). Whilst the heat map pattern suggests that VDBP, 
RBP-4, and FINC may be decreased in older individuals, this is likely to be attributable to the fact 
that individuals in the PDAC groups are older than individuals in the control group. 
Standardised relative intensity on western blot densitometry analysis (RI)  
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2.4.3Phase III- Validation with pre-diagnostic samples (UKCTOCS) 
2.4.3.1Characteristics of the UKCTOCS samples 
Pre-Pancreatic cancer (PPC) samples were stratified into six time-categories 
according to the duration between sample collection and diagnosis: 0-0.5, 0.5-1, 1-2, 
2-3, 3-4, and over 4 years). Each time group therefore, consists of 10 PPC samples 
and 10 matched HC samples. There were no significant difference in age, gender (all 
females), or delay in sample processing between the PPC and HC group.  
 
Table 2.17- UCKTOCKS samples characteristics 
Time category 
 (years) 
Age/ years 
Collection to processing 
Time (hours)  
Collection to diagnosis 
Time (Months) 
Median (range) p Median (range) p Median (range) 
0 yr - 0.5yr 
         HC, n=10 64 (52-75) 
N.S. 
22 (19-25) 
N.S. 
- 
    PPC, n=10 65 (57-78) 22 (20-26) 2.1 (1.3-5.5) 
0.5yr – 1yr 
 
 
 
 
     HC, n=10 62 (53-72) 
N.S. 
20 (19-24) 
N.S. 
- 
    PPC, n=10 70 (57-73) 21 (19-24) 9.5 (6.3-11.0) 
1yr – 2yr 
 
 
 
 
     HC, n=10 60 (53-72) 
N.S. 
23 (19-46) 
N.S. 
- 
    PPC, n=10 61 (53-72) 23 (20-46) 17.4 (12.7-22.7) 
2yr – 3yr 
 
 
 
 
     HC, n=10 61 (51-73) 
N.S. 
24 (18-25) 
N.S. 
- 
    PPC, n=10 61 (52-71) 24 (18-25) 28.2 (24.6-34.3) 
3yr – 4yr 
 
 
 
 
     HC, n=10 58 (52-71) 
N.S. 
23 (21-43) 
N.S. 
- 
    PPC, n=10 61 (57-75) 23 (21-44) 39.3 (36.6-47.9) 
4+ years 
 
 
 
 
     HC, n=10 61 (51-72) 
N.S. 
20 (4-26) 
N.S. 
- 
    PPC, n=10 65 (52-73) 20 (2-22) 60.6 (52.1-80.6) 
Abbreviations: N.S. Not significant (Wilcoxon’s Test p>0.05); Healthy Control (HC); pre-diagnosis pancreatic 
cancer samples (PPC) 
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2.4.3.2 Example of Western Blot images for VDBP and RBP-4 
Examples from the Western Blot analyses of UKCTOCS samples for VDBP and 
RBP-4 are shown in Figure 2.19.  
  
Figure 2.19- Western Blot images of VDBP and RBP-4 for UKCTOCS Samples [A]Western Blot 
of UKCTOCS Gel 11 for VDBP; [B] Western Blot of UKCTOCS Gel 15 for VDBP; [C] Western 
Blot of UKCTOCS Gel 11 for RBP-4; [D] Western Blot of UKCTOCS Gel 15 for RBP-4. Each gel 
consists of 5 PPC samples each from a different time-category and 5 matching controls and was 
analysed in triplicate.  
Abbreviations: Pre-Pancreatic Cancer (PPC); Healthy Controls (HC); Molecular Weight Band 
(MWB)  
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2.4.3.3 Selection of markers for validation in Phase III 
Due to a limitation in the availability of the UKCTOCS samples, it was decided that 
only RBP-4 and VDBP would be validated in Phase III. This is because RBP-4 was 
the only significant biomarker on multivariate analysis when comparing PDAC 
against control samples (HC, CP, and DC) in Phase-II of the current study. 
Furthermore, VDBP was also analysed since it was the best discriminator of PDAC 
against HC and CP. In addition, the protein requirement for the relative 
quantification of VDBP was a tenth compared to either RBP-4 or FINC.  
 
2.4.3.4 The level of VDBP in pre-diagnosis samples compared to Controls 
Univariate analysis by Wilcoxon‟s Test indicated that there is no significant 
difference in the serum level of VDBP in pre-diagnostic pancreatic cancer samples 
compared to the matched controls across most time categories (Figure 2.20 and 
Table 2.18). However, in the 2-3 years category, there is a significant decrease in the 
serum level of VDBP in control subjects compared to PPC. The reason for this 
difference is unclear but likely to be co-incidental. 
 
 
 
 
 
 
 
 
 
 
Figure 2.20- Box Plots showing the level of VDBP between pre-diagnosis pancreatic cancer (PPC) 
and healthy controls (HC) across the six time categories. Univariate analysis by Wilcoxon’s Test 
showed no significance expect for the 2-3 yr category where VDBP in HC is lower than PPC. 
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Table 2.18- Relative quantification of serum VDBP in UKCTOCS samples by densitometry analysis 
VDBP 
Time Categories (years before diagnosis)/ median (range) 
0-0.5 0.5-1 1-2 2-3 3-4 4+ 
Control 
PPC 
1.03 (0.75-1.31) 
0.95 (0.81-1.40) 
1.07 (0.79-1.28) 
1.09 (0.82-1.38) 
1.06 (0.79-1.16) 
1.06 (0.75-1.31) 
0.95 (0.88-1.04) 
1.12 (0.93-1.25) 
1.02 (0.93-1.10) 
1.10 (0.88-1.32) 
1.03 (0.78-1.32) 
1.04 (0.86-1.38) 
Note: *relative intensity calculated from densitometry results: sample mean region of interest (ROI ) intensity 
divided by the standard reference mean ROI Intensity  
 
2.4.3.5 Change in the relative serum level of VDBP through time 
Subsequent analyses aimed to identify any trends in the serum level of VDBP 
through time. There were three individuals in the PPC group with data from at least 
four different time categories: PPC patients 10, 12, and 20. Interestingly, PPC patient 
10 showed a progressive decrease in relative serum level of VDBP closer to 
diagnosis; however, this pattern was not maintained in the other two individuals with 
PPC (Figure 2.21). Therefore, whilst the relative serum level of VDBP may not a 
good predictor of pancreatic cancer development in all patients, a gradual decline in 
VDBP over time may be observed in certain individuals and may be an indication of 
pancreatic malignancy. 
 
  
Figure 2.21- scatter plots showing the change 
in relative serum level of VDBP across 
different time categories. PPC patient 10 
showed a progressively decreasing serum 
level of VDBP closer to diagnosis. However, 
this trend was not followed in patient 12 and 
20. 
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2.4.3.6 The level of RBP-4 in pre-diagnosis samples compared to Controls 
There appears to be a trend towards lower serum expression of RBP-4 in the PPDC 
group. However, univariate analysis by Wilcoxon‟s Test yielded insignificant results. 
Furthermore,the serum level of RBP-4 between the PPC and HC groups across the 
other time categories also yielded insignificant results (Wilcoxon‟s Test) p>0.05; 
Figure 2.22 and Table 2.19). 
  
Table 2.19- Relative quantification of serum RBP-4 in UKCTOCS samples by densitometry analysis 
RBP-4 
Time Categories (years before diagnosis)/ median (range) 
0-0.5 0.5-1 1-2 2-3 3-4 4+ 
Control 
PPC 
1.18 (0.94-2.00) 
1.07 (0.82-1.84) 
1.27 (0.99-1.76) 
1.18 (0.86-1.56) 
1.21 (1.05-1.47) 
1.22 (0.93-1.49) 
1.18 (0.98-1.33) 
0.86 (1.24-1.43) 
1.25 (1.11-1.64) 
1.33 (1.03-1.62) 
1.17 (0.93-1.91) 
1.23 (0.93-1.58) 
Note: *relative intensity calculated from densitometry results: sample mean region of interest (ROI ) intensity 
divided by the standard reference mean ROI Intensity  
  
Figure 2.22- Box Plots comparing the serum level of RBP-4 between healthy controls (HC) and pre-
diagnosis pancreatic cancer (PPC) patients. Univariate analyses indicated that there is no 
significant difference between the two groups in any of the time groups. 
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2.4.3.7 Change in the relative serum level of RBP-4 through time 
Subsequent analyses aimed to identify any trends in the serum level of RBP-4 
through time. There were three individuals in the PPC group with data from at least 
four different time categories: PPC patients 10, 12, and 20. Similar to VDBP, the 
serum level of RBP-4 in PPC patient 10 seemed to be decreasing closer to diagnosis. 
However, there was a sudden drop in RBP-4 level at 2-3 year pre-diagnosis. Once 
again, this pattern was not maintained in the other three individuals with PPC. 
Clearly, the relative serum level of RBP-4 is also not a good predictor of the 
development of pancreatic cancer (Figure 2.23).  
 
  
Figure 2.23- Scatter plots showing the serum 
level of RBP-4 through time. The serum level of 
RBP-4 seems to follow a progressively 
decreasing pattern closer to diagnosis. 
However, there is an unexplained drop in RBP-
4 level at 2-3 years pre-diagnosis. This patter is 
not seen in the other two PPC patients. 
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2.4.4 Expression of VDBP, RBP-4, and FINC in cell lines 
2.4.4.1 Quantification of cell lysate 
The protein concentrations of cell lysates were quantified by Bradford Assay. Linear 
modelling of the reference standards generated a linear equation with a R
2
 value of 
0.998 therefore indicating that the linear equation fits the data almost perfectly. The 
concentration of each lysate was calculated using this linear equation and the volume 
of lysate required for 10µg of protein was calculated for each lysate. 
Table 2.20- Protein quantification of cell lysate by Bradford Assay 
Cell-line Av. Bradford Concentration µg/µl Volume (µl)/ 10 µg 
HEPG-2 1.08 6.74 1.48 
HEK 0.65 2.01 4.97 
BXPC-3 0.67 2.20 4.54 
ASPC 1.20 8.08 1.24 
PANC-1 1.02 6.09 1.64 
CFPAK 0.94 5.18 1.93 
FAMPAC 0.76 3.26 3.06 
Note: Protein Concentration= 0.5*(Bradford assay reading-0.4642)/ 0.0457;  
Reference standard curve R2= 0.9976 
 
 
  
Figure 2.24- Standard Reference Curve for the Bradford protein quantification assay. To 
calculate the protein concentration of cell lysate, the linear equation for the line of best fit was 
rearranged for x: x=(y-0.4642)/0.0457. Since 2µl of lysate was used in the protein, the 
calculated result was then divided by 2 to give the concentration in µg/µl.  
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2.4.4.2 Expression of VDBP, RBP-4 and FINC in cancer cell lines 
Western blot analysis of the two non-cancer cell lines HEPG-2 (hepatocellular cancer) 
and HEK (human embryonic kidney) and five pancreatic cancer cell lines BXPC-3, 
ASPC, PANC-1, CFPAK, and FAMPAC showed that VDBP, RBP-4, and FINC 
were present in an undetectable quantity in these cell lines (Figure 2.25). 
  
Figure 2.25- Images from Western Blot (WB) of 1 hepatocellular carcinoma cell line (HEPG-2), one human 
embryonic kidney cell line (HEK), and five pancreatic adenocarcinoma cell line (BXPC-3, ASPC, PANC-1, 
CFPAK, and FAMPAC) for VDBP, RBP-4, and FINC. [A] WB results indicate that VDBP is expressed in serum 
standards (Std) but cannot be detected in cell lines. [B]Beta-actin of VDBP blot. [C] RBP-4 is expressed in 
serum standards but cannot be detected in cell lines. [D]Beta-actin of RBP-4 blot. [E] FINC is expressed in 
serum standards but cannot be detected in cell lines. [F] Beta-actin of FINC blot. 
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2.5 Discussion 
Recent advances in protein identification techniques have enabled researchers to 
mine the serum proteome in greater depth. Indeed, the advent of protein detection 
techniques such as iTRAQ/MS and protein microarray has opened up a new 
dimension in biomarker research. These new techniques have proven to be as reliable, 
accurate, and sensitive for the discovery of less abundant and smaller proteins 
compared to traditional methods such as spot identification for 2D polyacrylamide 
gel electrophoresis
128
. In particular, the mass spectrometry analysis performed by 
Murray et al. from this department has identified over 300 proteins with over 95% 
identification confidence including many novel proteins, which have never been 
associated with pancreatic cancer by previous studies.  
2.5.1 VDBP, RBP-4, and FINC for the diagnosis of pancreatic cancer 
The current study sought to verify the serum concentrations of three protein markers 
(VDBP, RBP-4, and FINC) identified by the iTRAQ experiment mentioned above. I 
observed that in concordance with the original iTRAQ results, western blot analyses 
of these proteins demonstrated a general decrease in relative serum concentrations of 
all three proteins in individuals with pancreatic cancer compared to controls (Phase I, 
section 2.4.1). Furthermore, I found that in agreement with existing literature
225
, 
validation with the LPCD independent sample set indicated that the presence of 
biliary obstruction has a negative impact on the diagnostic accuracies of all three 
markers (Phase II, sections 2.4.2.6 to 2.4.2.10). This finding once again emphasised 
the importance of recognising the potential confounding effects of benign 
pancreaticobiliary diseases (e.g. biliary obstruction) in the discovery of serum 
proteomic biomarker for pancreatic cancer. Nonetheless, preliminary results from 
sections 2.4.2.6Error! Reference source not found., 2.4.2.7, and 2.4.2.10 suggest 
that VDBP, RBP-4, and FINC are accurate diagnostic markers of PDAC against 
individuals with CP or HC. In addition, we report that the use of the M-LR model to 
combine all three markers dramatically improved the diagnostic accuracy for PDAC 
in the absence of DC. However, further validation with an independent validation 
sample set would be necessary to assess the integrity of the individual and combined 
markers.  
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2.5.2 VDBP and RBP-4 as screening modalities for pancreatic cancer 
Pancreatic cancer is a disease of late presentation where the majority of individuals 
with PDAC have metastatic, inoperable disease at diagnosis
54-55
. As such, much 
effort has been put into the search for a marker, which can detect the presence of 
early-stage PDAC with the ultimate aim of implementing a nation-wide screening 
programme for pancreatic cancer. Such implementation would facilitate the early 
detection of PDAC in otherwise asymptomatic individuals thereby increasing the 
chance of resectable disease, which in turn, would improve the prognosis for these 
patients.  
Results from the current study thus far were based on the use of serum samples from 
patients with confirmed resectable (therefore by mostly early-stage) PDAC. Whilst 
biomarkers discovered and verified in this way can be concluded to be good 
indicators of early-stage PDAC, their potential as a screening modality remain 
untested. Phase-III of the current study sought to address this issue by using samples 
from the UKCTOCS trial, which consisted of serum samples taken from up to 6 
years before the confirmed diagnosis of PDAC. Results from this analysis indicated 
that neither VDBP nor RBP-4 was sufficiently accurate as single markers of PDAC 
in the pre-diagnosis setting.  
There were several limitations to this study. In particular, a relatively small number 
of samples were analysed in the first validation set meaning that the current study 
should be regarded as a pilot screen of candidate markers aimed at assessing their 
potential utility as markers of pancreatic cancer and further validation with a larger 
independent sample set would be required to confirm our findings. Furthermore, the 
use of Western Blotting for the quantitative protein analysis has its own inherent 
limitations, such as the need to compare values across different blots.  
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2.5.3 The roles of VDBP, RPB-4, and FINC in pancreatic cancer 
The exact roles of VDBP, RPB-4, and FINC in pancreatic cancer and the reason 
behind their apparent decrease in the serum of individuals with PDAC are not clear. 
However, there are a number of hypotheses, which may explain the inverse 
relationship between the serum concentrations of the three proteins and the presence 
of PDAC. One explanation could simply be that patients with PDAC are generally 
under-nourished (e.g. due to anorexia or impaired absorption), which subsequently 
result in a decreased production of these proteins
21
. Furthermore, the fact that the 5-
year survival rate of resectable pancreatic cancer is <25% due to cancer recurrence 
and metastasis
88
 suggest that most patients with resectable PDAC may have an 
underlying micro-metastasis undetectable by conventional diagnostic procedures at 
the time of surgery. Therefore, specifically for the two hepatocyte-secreted proteins, 
VDBP and RBP-4, another possible explanation for the decrease in serum VDBP and 
RBP-4 could be that the production of both proteins is impaired in the presence of 
pancreatic liver metastasis.  
2.5.3.1Vitamin D-Binding protein and cancer 
There is a current lack of evidence associating VDBP specifically with pancreatic 
cancer. However, increasing evidence has suggested that VDBP may be associated 
with several types of cancers through its metabolite, DBP-MAF
226-229
. In particular, 
an in vivo study by Kisker et al. demonstrated that BxPC-3, a pancreatic cancer cell 
line, is capable of converting VDBP to DBP-MAF and in addition, the systemic 
administration of DBP-MAF (4ng/kg) has significant antiproliferative and 
antiangiogenic effects on immune-compromised mice implanted with BxPC-3
227
. 
The authors however, did not discuss the apparent contradiction in the ability of a 
cancer cell line to convert DBP into an anti-tumour factor. One possible explanation 
is that pancreatic cancer is characterised by an unusually hypoxic condition and as 
such, very limited amount of systemic DBP is converted into DBP-MAF and 
subsequently does not have a noticeable effect on the tumour. Another possible 
explanation is that VDBP may be readily converted to DBP-MAF and that this 
stimulates tumour-associated macrophages in the tumour microenvironment to 
promote growth and proliferation.  
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2.5.3.2 Retinol-Binding protein and cancer 
The association between retinol-binding proteins (RBP) and pancreatic cancer was 
first described in 1984 by Fabris et al.
212
. The authors observed that the serum 
concentration of RBP is significantly lower in patients with chronic pancreatitis and 
pancreatic cancer compared to healthy subjects
212
. Furthermore, this association was 
also observed by later studies in a number of other epithelial cancers and benign 
diseases such as malnutrition and liver cirrhosis 
220, 230-232
. Although the findings 
originally reported by Fabis et al.
212
 was not fully recapitulated by this study, as I 
found that the levels of RBP-4 were down regulated in PDAC compared to HC but 
not in CP compared to HC, this difference may be accountable by the fact that the 
current study analysed a specific member of the RBP family (RBP-4) rather than 
RBP in general. 
Interestingly, recent studies have focused on the role of RBP in type II diabetes and 
insulin resistance where the authors described an inverse association between the 
serum concentration of RBP-4 and insulin sensitivity 
233-237
. This association may be 
of biological relevance to the poor glycaemic control in pancreatic cancer. 
Particularly in patients with tumour-induced dysfunction of pancreatic endocrine 
cells where there is an increased insulin resistance, a higher sensitivity to insulin 
would be desirable, which would correlate to decrease in circulating RBP. Therefore, 
combining the two observations given above, we propose that as a part of a complex 
compensatory mechanism for the decreased insulin secretion in PDAC, hepatocyte 
may inhibit the production of RBP-4 to increase the sensitivity of the liver to insulin. 
2.5.3.3 Fibronectin and cancer 
Fibronectin is an essential component of the extracellular matrix (ECM). It has been 
associated with tissue fibrosis and several types of cancer through its role in 
controlling cellular proliferation, differentiation, and organization of tissue 
architecture
147, 154, 185, 238-239
. In particular, several studies have demonstrated that 
there is extensive remodelling of the ECM in pancreatic cancer by fibroblasts and 
pancreatic stellate cells (PSCs), which may induce a permissive microenvironment 
for the transition of cancer cells from dormancy to growth
147, 152-154, 185, 238-240
. 
Furthermore, the release of angiogenic factors from the remodelled ECM may trigger 
the angiogenic switch thereby promoting tumour growth and metastasis
198
. Recently, 
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evidence indicated that pancreatic cancer-associated fibrosis might be partially 
attributable to elevated levels of TGF-β, which alters the ECM composition by 
promoting collagen and fibronectin gene transcription, production, and secretion in 
PSCs
185, 238, 241-242
. Therefore, it is conceivable that the decrease in the serum 
concentration of FINC may be due to an excess consumption of circulating FINC as 
the result of extensive remodelling of the tumour microenvironment by tumour-
associated cells such as PSCs.  
Finally, the finding that all three proteins were down regulated in individuals with 
benign biliary obstruction may provide some indication as to why they are observed 
to be down regulated in PDAC. Over 70% of patients with PDAC have biliary 
obstruction at presentation
21
. Such obstructions are frequently associated with the 
impairment in liver function, which may account for the decrease in the three 
proteins observed in PDAC. 
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Chapter 3 
The Diagnostic Potential of CCGFs 
for Pancreatic Cancer 
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3.1 Introduction 
The role of cytokines, chemokines, and growth factors (CCGFs) in pancreatic 
inflammatory diseases (e.g. acute and chronic pancreatitis) has been reported by 
many studies
138-144
. Although there is a current lack of evidence directly associating 
CCGFs with pancreatic cancer, recently, evidence from clinical and experimental 
studies have demonstrated that CCGFs play a pivotal role in mediating cancer-related 
inflammation
144-150
, which in turn is an essential component for the formation, 
propagation, survival, and metastasis of several other types of cancers
143, 151-154
. In 
2000, Hanahan et al.
45
 proposed in their review that there are six hallmarks of cancer, 
of these, five hallmarks were mediated by CCGFs including self-sufficiency in 
growth signals, insensitivity to anti-growth signals, limitless replicative potential, 
sustained angiogenesis, and evading apoptosis. Recent studies have now associated 
the sixth hallmark (tissue invasion and metastasis) with CCGFs by demonstrating 
their role in stimulating tumour-associated macrophages to promote the remodelling 
of the extracellular matrix in the tumour microenvironment
187, 198
. More importantly, 
results from a recent review by Colotta et al.
150
 would suggest that cytokine mediated 
cancer-related inflammation should be regarded as the seventh hallmark of cancer.  
Therefore, based on the evidence above, we postulate that CCGFs should also be 
heavily involved in pancreatic cancer and that certain CCGFs would be differentially 
expressed only in cancer-related inflammation and not benign inflammatory 
conditions. To test this hypothesis, we utilise a relatively new multiplex assay, the 
LUMINEX cytokines assay, to quantify and compare the presence of CCGFs in 
serum samples from four distinct disease groups: pancreatic cancer, chronic 
pancreatitis, biliary obstruction, and healthy controls. The multiplex cytokines assay 
combines several existing technologies including microsphere, flow cytometry, 
conventional ELISA, digital, traditional chemistry, digital signal processing, and dual 
laser detection to quantify the serum concentrations of 27 different CCGFs 
simultaneously in a single sample. Furthermore, we will use the resulting data was 
used to assess the diagnostic potential of CCGFs as individual markers of resectable 
PDAC. In addition, we will present a statistical method for the selection of 
independent biomarkers amongst a large number of potential biomarkers and two 
independent methods, which can be employed to combine the selected markers in to 
a single diagnostic marker panel for PDAC. 
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3.2 Study Aims 
The aims of the current chapter include: 
 To determine the serum expression of 27 CCGFs in resectable PDAC and 
Control subjects. 
 To determine the diagnostic potential of CCGFs for resectable pancreatic cancer 
 To compare the diagnostic potential of novel CCGF markers against CA19-9 
 To determine the effects of combining candidate CCGF markers on the 
diagnostic accuracy for pancreatic cancer 
 To validate the disease-predicting algorithms generated in aim (4) using an 
independent validation sample set. 
 
3.3 Materials and Methods 
3.3.1 Patients and Samples- The Liverpool Pancreatic Cancer 
Database 
One-hundred and eighty pre-operative serum samples were prospectively collected at 
the Royal Liverpool University Hospital from patients with resectable PDAC (n=90), 
CP (n=30), obstructive jaundice (DC, n=30), and healthy volunteers (HC, n=30) 
between 1996 and 2010; Table 3.1). Serum samples were collected in Sarstedt 
Monovette tubes (Sarstedt Ltd, Leicester, UK) and allowed to clot at room 
temperature for 15 minutes. The serum fraction was acquired by centrifugation at 
800x g for 10 minutes, which was then aliquoted into cryotubes (Nunc GmbH & Co 
KG., Thermo Fisher Scientific, Langenselbold, Germany). All samples were stored at 
minus 80°C until analysis. 
Of the 90 individuals in the control group, 44 were female and 46 were male and of 
the 90 individuals with PDAC, 42 were female and 48 were male. Although there 
was a significant difference in age between the PDAC group and the individual 
control subgroups groups (CP, DC, and HC), there was no significant difference 
when the PDAC group was analysed against the overall Control group (Wilcoxon‟s 
Test, P=0.073; Table 3.1). Furthermore, analysis of available demographical data 
showed that there was no significant difference in gender, histories of smoking, 
diabetes, or pancreatitis in the PDAC group compared to the controls (Fisher‟s Exact, 
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p>0.05). In addition, comparison of the serum bilirubin levels indicated that 
individuals in the PDAC and DC groups have a significantly higher serum 
concentration of bilirubin compared to the CP group. Furthermore, the serum CA19-
9 levels in the PDAC group is significantly higher compared to all control subgroups 
(Wilcoxon‟s Test, p<0.001; Table 3.1). It should be noted that some demographical 
data could not be obtained due to privacy and confidentiality reasons. 
In subsequent analyses, samples within each disease group were randomised into the 
Discovery Phase and the Validation Phase in a 2 to 1 ratio (see sections 3.3.1.1, 
3.3.1.2, and 3.3.2 for details). 
Table 3.1- Demographical and clinical characteristics of individuals involved in this study 
Characteristics 
Disease groups Cancer status 
CP DC HC PDAC p (K-W) Control PDAC p (W) 
Count, n 30 30 30 90 - 90 90 - 
Age 
        
    Median 60 72.5 56.4 66.5 
<0.001 
62 66.5 
N.S. 
    Range 50-78 24-86 37-77 36-81 24-86 36-81 
Gender, n 
        
    Female/male 14/16 15/15 15/15 42/48 N.S. 44/46 42/48 N.S. 
Smoking 
        
    Yes 19/6 20/7 -/- 51/22 
N.S. 
39/13 51/22 
N.S. 
    Unknown 5 3 30 17 38 17 
Diabetes 
        
    Yes 7/18 4/23 -/- 14/59 
N.S. 
11/41 14/59 
N.S. 
    Unknown 5 3 30 17 38 17 
Alcohol 
consumption         
    Yes 16/8 17/10 -/- 55/18 
N.S. 
33/18 55/18 
N.S. 
    Unknown 6 3 30 17 39 17 
Pancreatitis 
        
    Yes 30/0 3/0 -/- 4/43 
-/- 
33/0 4/43 
-/- 
    Unknown 0 27 30 43 57 43 
Bilirubin 
        
    Median 6 34 -/- 46.5 
<0.001 
15 46.5 
<0.001 
    Range 1-261 6-643 -/- 5-448 1-643 5-448 
CA19-9 
        
    Median 21.5 24.5 4.5 656.5 
<0.001 
13.4 188.1 
<0.001 
    Range 0-331 0-1402 0-18 0-42094 0-1402 0-42094 
Abbreviations: chronic pancreatitis (CP); disease controls (DC); healthy controls (HC); pancreatic cancer (PDAC); 
Kruskal Wallis’s test *p (K-W)+; Wilcoxon’s Test *p (W)]; p-value <0.05 (N.S.); data unavailable (-/-)  
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3.3.1.1 Discovery Phase patient demographics and sample characteristics 
One-hundred and twenty samples including sixty individuals with PDAC and twenty 
individuals from each of the three control subgroups (CP, DC, and HC) were 
randomly chosen and analysed in Discovery Phase (Table 3.2). Although a 
significant difference in age was observed between HC and other disease subgroups, 
there were no significant difference in age, gender, histories of smoking, diabetes and 
alcohol consumption between the PDAC group and the combined Control group. As 
expected, the serum levels of bilirubin and CA19-9 were significantly higher in the 
PDAC group compared to the overall control group. 
Table 3.2- Demographical and clinical characteristics of individuals in the Discovery Phase 
Characteristics 
Disease groups Cancer status 
CP DC HC PDAC p (K-W) Control PDAC p (W) 
Count, n 20 20 20 60 - 60 60 - 
Age 
        
    Median 60 74 56 67 
0.002 
62 67 
N.S. 
    Range 50-78 45-86 37-77 36-81 37-86 36-81 
Gender, n 
        
    Female/male 8/12 11/9 10/10 31/29 N.S. 29/31 31/29 N.S. 
Smoking 
        
    Yes/No 12/4 13/5 -/- 34/15 
N.S. 
25/9 34/15 
N.S. 
    Unknown 4 2 20 11 26 11 
Diabetes 
        
    Yes/ No 5/11 4/14 -/- 12/28 
N.S. 
9/25 12/28 
N.S. 
    Unknown 4 2 20 10 26 10 
Alcohol 
consumption         
    Yes/ No 10/5 12/6 -/- 34/15 
N.S. 
22/11 34/15 
N.S. 
    Unknown 5 2 20 11 27 11 
Pancreatitis 
        
    Yes/ No 20/0 1/0 -/- 3/24 
-/- 
21/0 3/24 
-/- 
    Unknown 0 19 20 23 39 23 
Bilirubin 
        
    Median 8 30 -/- 38 
<0.001 
14 38 
<0.0028 
    Range 4-58 6-585 -/- 5-379 4-585 5-379 
CA19-9 
        
    Median 21 44 5 293 
<0.001 
15 293 
<0.001 
    Range 0-188 4-1402 0-18 0-42094 0-1402 0-42094 
Abbreviations: chronic pancreatitis (CP); disease controls (DC); healthy controls (HC); pancreatic cancer (PDAC); 
Kruskal Wallis’s test *p (K-W)+; Wilcoxon’s Test *p (W)]; p-value <0.05 (N.S.); data unavailable (-/-)  
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3.3.1.2 Validation Phase patient demographics and sample characteristics 
The Validation Phase utilized sixty independent samples for the validation of the two 
disease-predicting algorithms generated in the Discovery Phase (Table 3.3). The 
sample set includes thirty individuals with PDAC and ten individuals from each of 
the control sub-groups (CP, DC, and HC). Again, whilst a significant difference in 
age was observed between the HC and the other disease groups, there were no 
statistical difference in age, gender, histories of smoking, diabetes, and alcohol 
consumption between individuals with PDAC and the combined Control group. 
Similar to the Discovery Phase, there was a significant increase in serum 
concentration of bilirubin and CA19-9 in individuals with PDAC compared to the 
Controls group. 
Table 3.3- Demographical and clinical characteristics of individuals in the Discovery Phase 
Characteristics 
Disease groups Cancer status 
CP DC HC PDAC p (K-W) Control PDAC p (W) 
Count, n 10 10 10 30 - 30 30 - 
Age 
        
    Median 60 73 57 66 
0.029 
61 66 
N.S. 
    Range 52-77 24-84 44-71 45-77 24-84 45-77 
Gender, n 
        
    Female/male 6/4 4/6 5/5 11/19 N.S. 15/15 11/19 N.S. 
Smoking 
        
    Yes/No 7/2 7/2 -/- 17/7 
N.S. 
14/4 17/7 
N.S. 
    Unknown 1 1 10 6 2 6 
Diabetes 
        
    Yes/No 2/7 0/9 -/- 2/1 
N.S. 
2/16 2/1 
N.S. 
    Unknown 1 1 10 7 12 7 
Alcohol 
consumption         
    Yes/No 6/3 5/4 -/- 21/3 
N.S. 
11/7 21/3 
N.S. 
    Unknown 1 1 10 6 12 6 
Pancreatitis 
        
    Yes/No 10/0 1/0 -/- 1/17 
-/- 
11/0 1/17 
-/- 
    Unknown 0 9 10 12 19 12 
Bilirubin 
        
    Median 6 51 -/- 52 
0.005 
22 52 
<0.0028 
    Range 1-261 6-643 -/- 11-448 1-643 11-448 
CA19-9 
        
    Median 24 22 4 125 
<0.001 
12 125 
<0.001 
    Range 5-331 0-265 0-15 5-2749 0-331 5-2749 
Abbreviations: chronic pancreatitis (CP); disease controls (DC); healthy controls (HC); pancreatic cancer (PDAC); 
Kruskal Wallis’s test *p (K-W)+; Wilcoxon’s Test *p (W)]; p-value <0.05 (N.S.); data unavailable (-/-)  
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3.3.2 Study design 
Approval for the current study was obtained from the relevant research ethics 
committee including the multicentre research ethics committee (MREC) for the use 
of the serum samples from the Liverpool Pancreatic Cancer Database (LPCD). 
Informed consent was obtained from all individuals involved.  
The serum concentrations of CCGFs in one hundred and eighty serum samples were 
quantified using the BioRad Pro 27-Plex Human Cytokines Assay. Basic analyses 
(including median, univariate, multivariate, and ROC analyses) were performed to 
determine the serum expression and diagnostic accuracies of each CCGF for PDAC 
against the following disease groups: HC, CP, DC, and all controls. Subsequent 
analyses were designed to evaluate the impact of combining several CCGF markers 
into a single combined marker on the diagnostic accuracy for PDAC. This was 
achieved by dividing the study into a Discovery Phase and a Validation Phase 
(Figure 3.1).  
In the Discovery Phase, CCGF data from 120 randomly selected serum samples were 
analysed by stepwise regression model to select candidate markers for combination 
by two independent modelling methods (multinomial logistic regression model [M-
LR] and artificial neural network model [NN]) to generate two independent disease-
predicting algorithms. The accuracies of the disease-predicting algorithms for DPAC 
were represented by ROC-AUC. In the Validation Phase, the two disease-predicting 
algorithms were directly applied to the CCGF data from the sixty remaining samples 
and their diagnostic accuracies assessed by ROC. 
A separate analysis was performed to compare the diagnostic accuracy of the current 
biomarker standard, CA19-9, against those of the individual and combined CCGF 
markers. This was achieved by completing the quantification of serum CA19-9 using 
a CA19-9 ELISA assay and by statistical comparison using ROC-AUCs, sensitivities, 
and specificities. Furthermore, the effects of including CA19-9 as the fifth marker in 
the generation of the disease-predicting algorithms on the diagnostic accuracy in the 
Discovery and Validation Phases will be determined. Finally, the impact of each 
candidate biomarker on the M-LR CCGF algorithm and the M-LR CCGF-CA19-9 
algorithm will be evaluated by comparing the diagnostic accuracies of the algorithms 
when each of the four CCGFs was independently removed (section 3.4.5).  
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Figure 3.1- Study design. 180 serum samples from the Liverpool Pancreatic Cancer 
database were quantified for 27 serum CCGFs in this study, of these, 90 were PDAC, 90 
were non-cancer: 30 CP, 30 DC, and 30 HC. A basic analysis was performed to 
determine the serum expression and diagnostic accuracy of CCGFs for pancreatic 
cancer against all control groups using univariate, multivariate, and ROC analyses. The 
study is then divided into 2 Phases. In the Discovery Phase, CCGF data from 120 serum 
samples was used to select potential CCGF markers for combination by stepwise 
regression. A disease predicting algorithm was then generated using two independent 
modelling methods (multinomial logistic regression [M-L] and artificial neural network 
[NN] models). Finally, the diagnostic accuracies of the two models were determined 
using ROC. The Validation Phase aimed to validate the diagnostic accuracies of CCGFs 
as individual markers of PDAC and to validate the Discovery Phase disease-predicting 
algorithms using an independent sample set consisting of 60 serum samples. Results 
were then compared to CA19-9 in a separate section. 
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3.3.3 Quantification of Cytokines, Chemokines, and Growth Factors 
A panel of 27 CCGFs were simultaneously quantified by the BioPlex Pro 27-Plex 
Human Cytokines Assay kit (BioRad Laboratories Inc, California, USA). The 
CCGFs analysed were Platelet-Derived Growth Factor (PDGF), Interleukin (IL)1, 
IL-1 receptor alpha (IL-1R, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, 
IL-13, IL-15, IL-17, Eotaxin, Basic Fibroblast Growth Factor (FGF-b), Granulocyte 
Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating 
Factor (GM-CSF), Interferon Gamma (IFN-), Monocyte Chemotactic Protein-1 
(MCP-1), Macrophage Inflammatory Protein 1-alpha (MIP-1, Macrophage 
Inflammatory Protein 1-beta (MIP-1, Interferon Gamma Inducible Protein-10 (IP-
10), Vascular Endothelial Growth Factor (VEGF), Tumour Necrosis Factor-alpha 
(TNF-), and Regulated Upon Activation Normal T-Cell Expressed And Secreted 
Protein (RANTES). This BioPlex Pro 27-Plex Human Cytokines Assay kit provides 
a mixture of 27 magnetic micro-bead populations pre-coated with antibodies specific 
to a corresponding CCGF. Each bead population is internally dyed with a mixture of 
red and infrared dye, which produces a unique signature that can be identified by the 
dual laser technology in the Luminex-200 system. Serum samples were analysed in 
duplicate using a standardised assay protocol:  
3.3.3.1 Sample and Standard Preparation  
All samples and standards were thawed and kept on ice until ready to use. 30µl of 
each serum sample was diluted by a factor of four using 90µl of sample diluent. 
Premixed lyophilized standard was reconstituted in 500µL of sample diluent, 
vortexed for 3 seconds then incubated on ice for 30 minutes. 128µl of reconstituted 
standard was added to 72µl of standard diluent in a 1.5ml Eppendorf microfuge tube 
followed by seven 1/4 serial dilutions to generate eight standard references. 200µl of 
standard diluent was aliquoted for use as a “Blank” sample (Figure 3.2).  
  
Figure 3.2- (image from BioPlex Pro Cytokines Assay manual). Serial dilutions of reconstituted lyophilized 
standards. 128 µl of Reconstituted standard was added to 72µl of standard diluent followed by seven 1/4 
serial dilutions to generate 8 standard references. 150µl of standard diluent was used for blank sample. 
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3.3.3.2 Coupled magnetic beads, detection antibody, and Streptavidin-PE 
preparation 
Coupled magnetic beads (10x) were centrifuged for 30 seconds and then re-
suspended using a pipette. 575µl of coupled beads (10x) were diluted to 1x 
concentration using 5175µl of assay buffer. Reconstituted coupled beads were kept 
on ice and protected from light until ready for use. 
The detection antibody was prepared when the magnetic coupled beads were 
incubated with standard/sample. Detection antibody (10x) was centrifuged for 30 
seconds before 300µl of detection antibody (10x) was diluted with 2700µl of 
detection antibody diluent into 1x concentration. The diluted serum detection 
antibody was protected from light until ready for use. 
The Streptavidin-PE was prepared when the magnetic coupled beads were incubated 
with detection antibody. Streptavidin-PE (100x) was centrifuged for 30 seconds 
before 60µl of Streptavidin-PE (100x) was diluted with 5940µ l of assay buffer into 
1x concentration. The diluted Streptavidin-PE (1x) was protected from light until 
ready for use. 
3.3.3.3 Assay Procedure 
The 96-well multiplex plate was pre-wet with 100µl of assay buffer. The buffer was 
removed by vacuum manifold and the bottom of the plate was dried using a clean 
paper towel. The coupled beads (1x) were vortexed for 30 seconds and 50µl was 
aliquoted into each of well. The plate was washed (and vacuum emptied) twice with 
100µl of wash buffer. 40µl of prepared standards, blank, or serum samples were 
vortexed for 3 seconds before being added to each well, and incubated at room 
temperature on a shaker (900rpm) for 30 minutes. The plate was washed (and 
vacuum emptied) three-times with 100µl of wash buffer. 25µl of 1x detection 
antibody (for preparation see section 3.3.3.2) was vortexed for 3 seconds before 
being added to each well and incubated on a shaker (900rpm) at room temperature 
for 30 minutes. The plate was washed (and vacuum emptied) three-times with 100µ l 
of wash buffer. 50µl of Streptavidin-PE (1x) was vortexed for 3 seconds before being 
added to each well and incubated on a shaker (900rpm) at room temperature for 10 
minutes. The plate was washed (and vacuum emptied) three-times with 100µl of 
wash buffer. 125µl of assay buffer was added to each well and shaken (900rpm) for 
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30 seconds at room temperature before detection by the LUMINEX-200 systems 
(Luminex Co, Austin, USA).  
The LUMINEX-200 was calibrated per experiment and the Bio-Plex Manager 
Software Version 5.0 was used covert assay data to serum concentration in pg/ml.  
3.3.4 Quantification of serum CA19-9 by ELISA 
The serum concentration of CA19-9 in 141 serum samples has been previously 
measured, either at diagnosis or in the department by Dr Sarah Tonack. The current 
study quantified the remaining 39 samples using a CA19-9 ELISA kit (Alpha 
Diagnostics).  
A 96-well streptavidin-coated ELISA plate was pre-wet with 200µl of wash buffer. 
Then 25µl of standards (provided by the kit) and sample were aliquoted into the 
appropriate wells in duplicate followed by 100µl of biotinylated anti-CA19-9 
antibody. After the mixture was allowed to incubate at room temperature for 60 
minutes, the content was discarded and the wells were washed five times manually 
using 200µl of wash buffer per well. 100µl of anti-CA19-9-HRP conjugate was then 
added to each well. The content was mixed and allowed to incubate at room 
temperature for a further 60 minutes. Once completed, the wells were washed 
manually five times using 200µl of wash buffer and incubated with 100µl of 
chromogenic HRP substrate solution for 30 minutes at room temperature. This will 
cause a varying degree of colour shift from clear to blue, which is directly 
proportional to the concentration of CA19-9. After incubation, the reaction was 
stopped by adding 50µl of stop solution to all wells and mixed gently for 3-10 
seconds. The stop solution changes the colour of the solution from blue to yellow and 
the intensity of yellow is again proportional to the serum concentration of CA19-9. 
Finally, an ELISA reader was used to quantify the colour intensity at a wavelength of 
450nm. 
The ELISA readings were exported to Microsoft Excel for further analysis. A linear 
equation was generated using the ELISA readings of the standard references with 
known concentrations of CA19-9. This equation was then used to convert ELISA 
readings from the samples into estimated serum CA19-9 concentrations. 
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3.3.5 Statistical Analysis 
3.3.5.1 General statistics, univariate, and multivariate analyses 
All continuous data (e.g. Age, serum analyte levels) were classified as non-
parametric data and were summarised using median and inter-quartile range (IQR). 
The Kruskal-Wallis test was used to determine whether there is a significant 
difference in non-parametric distribution between multiple (>2) groups (e.g. age 
versus PDAC, CP, HC, and DC). For univariate analysis, the Wilcoxon‟s test was 
used to assess any difference in the distribution of a non-parametric variable (e.g. age) 
between two groups and the Fisher‟s Exact test was used to assess the difference 
between two categorical variables (e.g. gender versus PDAC/Control). Variables that 
were significant on univariate analysis were further tested using multivariate analysis 
to identify any independent variables. For univariate and multivariate analyses, a p-
value of <0.05 was considered statistically significant.  
 
In Hierarchical Cluster Analysis, data from each variable was first standardised by 
mean and standard deviation to give a value between -1 and 1. The standardised 
values were then analysed by Ward‟s minimal variance method and represented 
graphically in a heat map.  
Data from the current study were also graphically represented using box plots, 
mosaic plots, logistic plots, and receiver-operator characteristic (ROC) curves. 
 
3.3.5.2 Correlation analysis 
The correlation between age and the relative serum concentration of CCGFs were 
assessed using Kendall Tau () multivariate correlation analysis for non-parametric 
tied data. The Kendall  coefficient ranges from -1 to 0 to 1 where a  coefficient of -
1 or 1 represents a perfect negative or positive correlation, respectively, and a 
coefficient of 0 indicates that there is no correlation. The associated p-value 
represents how confident the test is that the actual value would be more negative or 
more positive than then calculated value. In the current study, a Kendall Tau 
coefficient of >0.5 was regarded as significant. 
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3.3.5.3 Diagnostic accuracies of CCGFs for PDAC  
The Receiver-Operator Characteristic (ROC) Area Under Curve (AUC) was used to 
assess the diagnostic accuracies of the markers. A ROC-AUC of >0.70 was 
considered statistically significant. An optimal cut-off value was obtained from the 
ROC analysis and the relative sensitivity and specificity at the optimal cut-off was 
reported.  
3.3.5.4 Selection of candidate markers 
Cytokine markers, which showed significance on univariate analyses were analysed 
in the Discovery Phase using the Stepwise Regression model with parameters of 
<0.05 for entering and >0.05 for leaving the model. Briefly, at each step, the 
cytokine marker with the lowest Wald/Score p-value that is also <0.05 is entered into 
the model. The Wald/Score p-values for each cytokine marker were then recalculated 
and a marker will leave the model if it has a p-value of >0.05. This process is iterated 
until no further cytokine marker can enter or leave the model.  
3.3.5.5 Generating disease-predicting mathematical algorithms: M-LR and NN 
The four most significant cytokine markers selected by the stepwise regression 
model were used to generate two independent disease-predicting algorithms using 
two separate modelling methods: Multinomial Logistic Regression (M-LR) model 
and Artificial Neural Network (NN) model. Both models are designed to estimate the 
probability of PDAC using the serum concentration of selected CCGF markers. The 
resulting probability value ranges from zero to one where an estimated probability 
value close to zero indicates that the sample is likely to be a non-cancer sample 
whereas a probability value closer to one suggests a pancreatic cancer sample. 
Briefly, the M-LR model combines the markers using a simple logistic function with 
the appropriate coefficients. This function was then transformed mathematically into 
a value ranging from zero to one. The artificial neural network model utilizes 
multiple complex logistic functions. The input data (i.e. serum concentrations from 
selected CCGFs) were randomly entered into a pre-defined number of „hidden nodes‟. 
At each hidden node, a logistic function was generated. The logistic functions from 
all the nodes were then combined into a single logistic function and transformed into 
a probability value, which ranges from zero to one.  
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3.3.5.6 Diagnostic accuracies of the models 
The optimal cut-off values for the estimated probability of pancreatic cancer 
generated by the models were determined by ROC. A sample with an estimated 
probability above the cut-off value was classified as pancreatic cancer and a 
probability value below the cut-off was classified as control. The sensitivity and 
specificity of the predicted classifications were the then calculated and the results 
were graphically represented as mosaic plots. 
            
                        
                                                  
 
             
                       
                                                 
 
 
3.3.5.7 Software for statistical analyses 
All statistical analyses were performed using JMP version 8.02 (SAS, 
Buckinghamshire, UK). In addition, Microsoft Excel 2007 (Microsoft Limited, 
Berkshire, UK) was used to graphically represent the data. 
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3.4 Results 
3.4.1 Basic analysis- CCGFs as individual markers of PDAC 
3.4.1.1 Diagnostic accuracy of individual CCGFs for PDAC against HC 
Results from the basic analysis of the twenty-seven CCGFs and CA19-9 serum 
concentration data obtained using the 180 serum samples are summarised in Table 
3.4. Fourteen CCGFs and CA19-9 were observed to have a significantly different 
serum concentration between the PDAC group and the HC control subgroup, 
(Univariate by Wilcoxon‟s Test, p<0.05). In addition to CA19-9, eleven CCGFs 
were identified as up regulated in PDAC compared to HC including PDGF, IL-4, IL-
6, IL-8, IL-9, IL-10, IL-17, IFN-, IP-10, MIP-1 and VEGF. Furthermore, three 
CCGFs were down regulated in PDAC compared to HC including IL-1, IL-5, and 
IL-13.  
Subsequent analyses assessed the diagnostic accuracies of the twenty-seven CCGFs 
and CA19-9 for differentiating between PDAC and HC. Results from ROC analysis 
showed that seven CCGFs and CA19-9 had a ROC-AUC of >0.7 and are therefore 
good discriminators between the two disease groups. In particular, IP-10, IFN-, and 
CA19-9 were highly accurate markers of PDAC with ROC-AUCs of 0.90, 0.91, and 
0.95, respectively (Table 3.4).  
We report that whilst IFN-achieved a sensitivity of 0.89 and a specificity of 0.87 at 
the optimal cut off value of 65.44 pg/ml, CA19-9 remained the most accurate single 
marker of PDAC against HC with a sensitivity of 0.92 and a specificity of 0.97 at a 
cut-off of 16 U/ml (Figure 3.3) 
                                                                                                                                                                                                                                                                             
  
Figure 3.3- Logistic Plot showing the diagnostic accuracies of IFN-g (left) and CA19-9 (right) for 
PDAC against HC. Optimal cut-off as determined by ROC (C/O). Individuals with PDAC are 
coloured Blue and individuals in the HC group are in Red. 
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Table 3.4- Diagnostic potential of CCGFs and CA19-9 for PDAC against HC 
A
n
al
yt
e 
Quartile (pg/ml) 
Univariate 
(p) 
Reg. 
Diagnostic accuracy 
Healthy Control PDAC 
25th  Median 75th  25th  Median 75th  AUC C/O Sens. Spec. 
PDGF 9037.4 12048.2 16887.7 12415.5 15557.1 20338.0 0.013 Up 0.65 12463.50 0.76 0.53 
IL-1 1.1 1.5 1.9 0.0 0.0 0.0 <0.001 Down 0.19 2.41 0.14 0.97 
IL-1R 40.2 76.5 108.1 32.1 70.8 160.3 0.687 - 0.53 112.74 0.36 0.80 
IL-2 0.0 0.0 0.0 0.0 0.0 0.0 0.313 - 0.52 2.78 0.03 1.00 
IL-4 1.3 1.7 2.0 1.5 3.4 6.2 <0.001 Up 0.74 2.40 0.62 0.97 
IL-5 1.3 1.5 1.9 0.0 0.0 0.0 <0.001 Down 0.19 3.91 0.13 0.97 
IL-6 1.9 3.3 5.4 2.6 9.5 21.0 <0.001 Up 0.72 7.72 0.71 0.93 
IL-7 2.7 4.4 5.7 0.0 9.5 24.6 0.094 - 0.60 8.62 0.54 0.97 
IL-8 6.8 8.3 10.7 10.7 23.6 40.3 <0.001 Up 0.77 16.18 0.64 1.00 
IL-9 0.0 0.0 0.0 0.0 0.0 11.2 0.007 Up 0.65 1.34 0.46 0.87 
IL-10 0.0 0.0 0.0 0.0 2.4 18.7 <0.001 Up 0.77 0.86 0.59 0.97 
IL-12 5.0 11.1 18.5 0.0 13.2 38.4 0.946 - 0.50 22.92 0.39 0.87 
IL-13 0.0 0.2 2.7 0.0 0.0 0.0 0.004 Down 0.35 5.66 0.12 0.97 
IL-15 0.0 0.0 0.0 0.0 0.0 0.0 0.091 - 0.54 0.40 0.09 1.00 
IL-17 0.0 0.0 0.0 0.0 0.0 136.9 <0.001 Up 0.72 32.27 0.44 1.00 
Eotaxin 74.1 109.0 166.8 0.0 106.8 187.6 0.394 - 0.55 0.00 0.38 1.00 
FGF Basic 0.0 0.0 0.0 0.0 0.0 0.0 0.237 - 0.53 11.08 0.09 1.00 
G-CSF 0.0 0.0 3.4 0.0 0.0 1.7 0.415 - 0.46 22.82 0.07 1.00 
GM-CSF 0.0 0.0 0.0 0.0 0.0 1.8 0.328 - 0.55 0.53 0.30 0.80 
IFN- 38.2 47.4 59.6 90.3 153.1 247.5 <0.001 Up 0.91 65.44 0.89 0.87 
IP-10 320.6 448.1 700.6 880.2 1368.9 2298.6 <0.001 Up 0.90 749.31 0.84 0.80 
MCP-1 18.4 31.6 47.1 8.5 40.3 64.7 0.799 - 0.52 45.81 0.40 0.77 
MIP-1 0.0 0.0 0.0 0.0 0.0 0.0 0.313 - 0.52 17.15 0.03 1.00 
MIP-1 59.8 83.4 127.9 83.0 111.4 161.3 0.002 Up 0.69 68.57 0.91 0.40 
RANTES 6638.6 7709.4 9163.9 6059.4 7421.9 9591.6 0.451 - 0.55 6539.75 0.40 0.79 
TNF- 0.0 0.0 0.0 0.0 0.0 0.0 0.301 - 0.53 30.45 0.08 1.00 
VEGF 16.8 52.5 108.1 35.2 167.2 307.0 0.002 Up 0.69 153.80 0.54 0.90 
CA19-9 2.0 4.5 9.3 49.0 188.1 656.5 <0.001 Up 0.95 16.40 0.92 0.97 
Note: Sensitivity (Sens.); Specificity (Spec.); Wilcoxon’s Test p-value (Univariate, (P)); Inter-quartile range= 
25th to 75th quartile; Receiver-Operator Characteristic Area Under Curve (AUC); Optimal Cut-off as 
determined by ROC (C/O); Regulation in PDAC (Reg.)  
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3.4.1.2 Diagnostic accuracy of individual CCGFs for PDAC against CP 
Results from the basic analysis of the twenty-seven CCGFs and CA19-9 serum 
concentration data obtained using the 180 serum samples are summarised in Table 
3.5. Thirteen CCGFs and CA19-9 were observed to have a significantly different 
serum concentration between the PDAC group and the CP control subgroup, 
(Univariate by Wilcoxon‟s Test, p<0.05). In addition to CA19-9, seven CCGFs were 
identified as up regulated in PDAC compared to CP including IL-4, IL-8, IL-10, IL-
17, IFN-, IP-10, and VEGF. Furthermore, six CCGFs were down regulated in 
PDAC compared to CP including IL-1, IL-1R, IL-5, IL-13, G-CSF, and Eotaxin.  
Subsequent analyses assessed the diagnostic accuracies of the twenty-seven CCGFs 
and CA19-9 for differentiating between PDAC and CP. Results from ROC analysis 
showed that four CCGFs and CA19-9 had a ROC-AUC of >0.7 and are therefore 
good discriminators between the two disease groups. In particular, IL-1, IFN-, and 
CA19-9 achieved a relatively high accuracy for diagnosing PDAC with ROC-AUCs 
of 0.83, 0.83, and 0.84, respectively. Furthermore, we report that IL-1 and IFN-
achieved similar sensitivity (0.77 and 0.76, respectively) and specificities (1.00 and 
0.90) at optimal cut-off values of 0.00 pg/ml and 90.73 pg/ml compared to CA19-9 
(sensitivity, 0.78; specificity; 0.83 at cut-off of 45.8 U/ml; Figure 3.4). 
  
Figure 3.4- Logistic Plot showing the diagnostic 
accuracies of [A] IL-1b, [B] IFN-g, and [C] CA19-
9 for PDAC against CP. Optimal cut-off as 
determined by ROC (C/O). Individuals with PDAC 
are coloured Blue and individuals in the CP group 
are in Red. 
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Table 3.5- Diagnostic potential of CCGFs and CA19-9 for PDAC against CP 
A
n
al
yt
e 
Quartile (pg/ml) 
Univariate 
(p) 
Reg. 
Diagnostic accuracy 
Chronic Pancreatitis PDAC 
25
th
 Median 75
th
 25
th
 Median 75
th
 
AUC C/O Sens. Spec. 
PDGF 7996.0 13657.4 22684.7 12415.5 15557.1 20338.0 0.163 - 0.59 8989.14 0.93 0.33 
IL-1 1.6 1.9 2.2 0.0 0.0 0.0 <0.001 Down 0.83 0.00 0.77 1.00 
IL-1R 87.3 111.7 204.6 32.1 70.8 160.3 0.026 Down 0.36 221.72 0.18 0.87 
IL-2 0.0 0.0 0.0 0.0 0.0 0.0 0.313 - 0.52 2.78 0.03 1.00 
IL-4 1.4 1.8 2.2 1.5 3.4 6.2 0.003 Up 0.68 2.40 0.62 0.87 
IL-5 1.7 2.1 2.9 0.0 0.0 0.0 <0.001 Down 0.17 6.11 0.08 1.00 
IL-6 5.1 8.5 17.8 2.6 9.5 21.0 0.879 - 0.51 7.72 0.71 0.47 
IL-7 4.4 5.8 8.2 0.0 9.5 24.6 0.309 - 0.56 14.07 0.47 0.97 
IL-8 12.3 15.6 21.1 10.7 23.6 40.3 0.039 Up 0.63 29.46 0.40 0.97 
IL-9 0.0 0.0 18.9 0.0 0.0 11.2 0.717 - 0.49 16.86 0.80 0.27 
IL-10 0.0 0.0 1.7 0.0 2.4 18.7 0.004 Up 0.67 1.93 0.54 0.87 
IL-12 3.1 12.0 24.2 0.0 13.2 38.4 0.729 - 0.48 20.97 0.42 0.73 
IL-13 0.2 1.9 3.9 0.0 0.0 0.0 <0.001 Down 0.26 9.59 0.09 1.00 
IL-15 0.0 0.0 0.0 0.0 0.0 0.0 0.091 - 0.54 0.40 0.09 1.00 
IL-17 0.0 0.0 0.0 0.0 0.0 136.9 <0.001 Up 0.70 32.27 0.44 1.00 
Eotaxin 106.2 132.6 205.7 0.0 106.8 187.6 0.045 Down 0.62 0.00 0.38 0.97 
FGF Basic 0.0 0.0 0.0 0.0 0.0 0.0 0.637 - 0.48 123.88 0.03 1.00 
G-CSF 0.0 1.0 10.1 0.0 0.0 1.7 0.010 Down 0.65 7.28 0.88 0.43 
GM-CSF 0.0 0.0 2.9 0.0 0.0 1.8 0.994 - 0.50 21.32 0.08 0.97 
IFN- 35.8 52.3 73.9 90.3 153.1 247.5 <0.001 Up 0.83 90.73 0.76 0.90 
IP-10 401.5 588.0 1053.8 880.2 1368.9 2298.6 <0.001 Up 0.81 797.21 0.83 0.67 
MCP-1 27.5 50.3 101.2 8.5 40.3 64.7 0.061 - 0.61 9.99 0.27 1.00 
MIP-1 0.0 0.0 0.0 0.0 0.0 0.0 0.977 - 0.50 17.15 0.03 1.00 
MIP-1 65.0 136.0 188.2 83.0 111.4 161.3 0.585 - 0.53 161.65 0.77 0.47 
RANTES 6159.9 8188.9 8883.9 6059.4 7421.9 9591.6 0.752 - 0.54 10996.50 0.18 0.90 
TNF- 0.0 0.0 0.0 0.0 0.0 0.0 0.530 - 0.48 326.57 0.04 1.00 
VEGF 17.3 58.2 145.8 35.2 167.2 307.0 0.007 Up 0.66 164.89 0.51 0.83 
CA19-9 10.3 21.5 42.5 54.8 225.0 721.5 <0.001 Up 0.84 45.80 0.78 0.83 
Note: Sensitivity (Sens.); Specificity (Spec.); Wilcoxon’s Test p-value (Univariate, (P)); Inter-quartile range= 25th 
to 75th quartile; Receiver-Operator Characteristic Area Under Curve (AUC); Optimal Cut-off as determined by 
ROC (C/O); Regulation in PDAC (Reg.) 
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3.4.1.3 Diagnostic accuracy of individual CCGFs for PDAC against biliary 
obstruction (DC) 
Results from the basic analysis of the twenty-seven CCGFs and CA19-9 serum 
concentration data obtained using the 180 serum samples are summarised in Table 
3.6. Thirteen CCGFs and CA19-9 were observed to have a significantly different 
serum concentration between the PDAC group and the DC (biliary obstruction) 
control subgroup, (Univariate by Wilcoxon‟s Test, p<0.05). In addition to CA19-9, 
seven CCGFs were identified as up regulated in PDAC compared to DC including 
PDGF, IL-4, IL-10, IL-17, IFN-, IP-10, and VEGF. Furthermore, six CCGFs were 
down regulated in PDAC compared to DC including IL-1, IL-1R, IL-5, IL-13, G-
CSF, MCP-1, and IL-13.  
Subsequent analyses assessed the diagnostic accuracies of the twenty-seven CCGFs 
and CA19-9 for differentiating between PDAC and DC. In additional to CA19-9m 
results from ROC analysis showed that four CCGFs had a ROC-AUC of >0.7 
including IL-17, PDGF, IFN-, and IP-10, which indicated that they are good 
discriminators of PDAC against biliary obstruction. In particular, IFN-achieved a 
much higher accuracy for diagnosing PDAC against DC (ROC-AUC, 0.86 and 0.75, 
respectively). Furthermore, we report that IFN-is the most accurate diagnostic 
marker for PDAC against DC with a sensitivity of 0.74 and a specificity of 0.87 at a 
cut-off of 92.51 pg/ml whereas CA19-9 only achieved a sensitivity of 0.87 and a 
specificity of 0.57 at an optimal cut-off of 33U/ml (See Figure 3.5). 
  
Figure 3.5- Logistic Plot showing the diagnostic accuracies of IFN-g (left) and CA19-9 (right) 
for PDAC against DC. Optimal cut-off as determined by ROC (C/O). Individuals with PDAC are 
coloured Blue and individuals in the HC group are in Red. 
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Table 3.6- Diagnostic potential of CCGFs and CA19-9 for PDAC against DC 
A
n
al
yt
e 
Quartile (pg/ml) Univariate 
Reg. 
Diagnostic accuracy 
Disease Control PDAC (p) 
25th Median 75th 25th Median 75th 
 
AUC C/O Sens. Spec. 
PDGF 2397.6 7893.3 16658.8 12415.5 15557.1 20338.0 <0.001 Up 0.76 9198.56 0.91 0.60 
IL-1 1.2 1.8 2.2 0.0 0.0 0.0 <0.001 Down 0.18 5.67 0.08 1.00 
IL-1R 80.7 147.5 242.4 32.1 70.8 160.3 0.007 Down 0.66 104.02 0.63 0.70 
IL-2 0.0 0.0 0.0 0.0 0.0 0.0 0.992 - 0.50 10.55 0.99 0.03 
IL-4 0.5 1.5 2.1 1.5 3.4 6.2 <0.001 Up 0.70 2.40 0.62 0.90 
IL-5 0.7 1.8 2.6 0.0 0.0 0.0 <0.001 Down 0.19 4.97 0.10 1.00 
IL-6 6.8 11.4 17.2 2.6 9.5 21.0 0.543 - 0.46 56.59 0.13 0.97 
IL-7 1.1 5.7 9.8 0.0 9.5 24.6 0.228 - 0.57 13.56 0.48 0.90 
IL-8 13.0 19.4 29.2 10.7 23.6 40.3 0.606 - 0.53 24.64 0.48 0.70 
IL-9 0.0 11.6 25.4 0.0 0.0 11.2 0.051 - 0.62 11.10 0.76 0.53 
IL-10 0.0 0.3 1.9 0.0 2.4 18.7 0.008 Up 0.66 6.22 0.41 0.97 
IL-12 3.4 13.4 27.2 0.0 13.2 38.4 0.975 - 0.50 37.86 0.27 0.97 
IL-13 0.2 2.5 4.0 0.0 0.0 0.0 <0.001 Down 0.26 15.83 0.07 1.00 
IL-15 0.0 0.0 0.0 0.0 0.0 0.0 0.091 - 0.54 0.40 0.09 1.00 
IL-17 0.0 0.0 0.0 0.0 0.0 136.9 <0.001 Up 0.72 4.59 0.47 0.97 
Eotaxin 64.1 132.3 158.6 0.0 106.8 187.6 0.350 - 0.45 169.60 0.30 0.83 
FGF 
Basic 
0.0 0.0 0.0 0.0 0.0 0.0 0.237 - 0.53 11.08 0.09 1.00 
G-CSF 0.0 3.3 9.1 0.0 0.0 1.7 0.006 Down 0.64 2.42 0.80 0.50 
GM-CSF 0.0 0.0 7.1 0.0 0.0 1.8 0.111 - 0.42 116.61 0.03 1.00 
IFN- 26.9 47.6 79.4 90.3 153.1 247.5 <0.001 Up 0.86 92.51 0.74 0.87 
IP-10 461.1 571.1 951.1 880.2 1368.9 2298.6 <0.001 Up 0.79 733.62 0.86 0.63 
MCP-1 28.7 56.0 99.7 8.5 40.3 64.7 0.014 Down 0.65 12.80 0.28 1.00 
MIP-1 0.0 0.0 0.0 0.0 0.0 0.0 0.313 - 0.52 17.15 0.03 1.00 
MIP-1 73.6 107.4 158.9 83.0 111.4 161.3 0.544 - 0.54 80.88 0.81 0.37 
RANTES 4648.6 6196.6 8911.7 6059.4 7421.9 9591.6 0.063 - 0.39 17980.18 0.96 0.13 
TNF- 0.0 0.0 0.0 0.0 0.0 0.0 0.093 - 0.54 2.68 0.09 1.00 
VEGF 14.0 49.3 111.6 35.2 167.2 307.0 <0.001 Up 0.70 197.16 0.48 0.93 
CA19-9 8.5 24.5 128.6 49.0 188.1 656.5 <0.001 Up 0.75 33.00 0.87 0.57 
Note: Sensitivity (Sens.); Specificity (Spec.); Wilcoxon’s Test p-value (Univariate, (P)); Inter-quartile range= 25th 
to 75th quartile; Receiver-Operator Characteristic Area Under Curve (AUC); Optimal Cut-off as determined by 
ROC (C/O); Regulation in PDAC (Reg.) 
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3.4.1.4 Diagnostic accuracy of individual CCGFs for PDAC against all Controls 
Results from the basic analysis of the twenty-seven CCGFs and CA19-9 serum 
concentration data obtained using the 180 serum samples are summarised in Table 
3.7. Fourteen CCGFs and CA19-9 were observed to have a significantly different 
serum concentration between the PDAC group and the overall control group, 
(Univariate by Wilcoxon‟s Test, p<0.05). In addition to CA19-9, nine CCGFs were 
identified as up regulated in PDAC compared to CP including PDGF, IL-4, IL-8, IL-
10, IL-17, IL-15, IFN-, IP-10, and VEGF. Furthermore, four CCGFs were down 
regulated in PDAC compared to Controls including IL-1, IL-5, IL-13, and G-CSF.  
Subsequent analyses assessed the diagnostic accuracies of the twenty-seven CCGFs 
and CA19-9 for differentiating between PDAC and Controls. Results from ROC 
analysis showed that four CCGFs and CA19-9 had a ROC-AUC of >0.7 and are 
therefore good discriminators between the two disease groups. In particular, IFN-, 
and CA19-9 achieved a relatively high accuracy for diagnosing PDAC with ROC-
AUCs of 0.87 and 0.85, respectively. Furthermore, we report that IFN- and CA19-9 
have comparable diagnostic accuracy at their optimal cut-off values for PDAC 
against Control subjects with sensitivities of 0.77 and 0.87 and specificities of 0.89 
and 0.73, respectively (Figure 3.6). 
A multivariate analysis was performed on CCGFs, which were significant on 
univariate analysis to identify independent discriminators of PDAC amongst control 
subjects. Results indicate that IL-4, IL-17, G-CSF, and IL-10 were independently 
significant as diagnostic markers of PDAC (Table 3.7).  
 
  
Figure 3.6- Logistic Plot showing the diagnostic accuracies of IFN-g (left) and CA19-9 (right) 
for PDAC against all controls. Optimal cut-off as determined by ROC (C/O). Individuals with 
PDAC are coloured Blue and individuals in the HC group are in Red. 
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Table 3.7- Diagnostic potential of CCGFs and CA19-9 for PDAC against all Controls 
A
n
a
ly
te
 Quartile (pg/ml) 
Uni 
(p)  
Multi 
(p) 
Reg. 
Diagnostic accuracy 
Disease Control PDAC 
25
th
 Median 75
th
 25
th
 Median 75
th
 AUC C/O Sens. Spec. 
PDGF 6767.2 11958.9 17565.9 12415.5 15557.1 20338.0 <0.001 0.294 Up 0.67 9198.56 0.91 0.40 
IL-1 1.3 1.7 2.2 0.0 0.0 0.0 <0.001 0.902 Down 0.18 5.67 0.08 0.98 
IL-1R 60.7 106.0 190.6 32.1 70.8 160.3 0.034 0.862 Down 0.41 316.37 0.12 0.91 
IL-2 0.0 0.0 0.0 0.0 0.0 0.0 0.316 - - 0.51 2.78 0.03 0.99 
IL-4 1.2 1.7 2.0 1.5 3.4 6.2 <0.001 <0.001 Up 0.73 2.40 0.62 0.91 
IL-5 1.3 1.8 2.6 0.0 0.0 0.0 <0.001 0.338 Down 0.18 4.69 0.12 0.96 
IL-6 3.8 6.3 13.6 2.6 9.5 21.0 0.143 - - 0.56 7.72 0.71 0.58 
IL-7 3.3 5.2 8.0 0.0 9.5 24.6 0.068 - - 0.58 13.56 0.48 0.93 
IL-8 8.8 13.6 20.2 10.7 23.6 40.3 0.001 0.756 Up 0.64 23.30 0.52 0.82 
IL-9 0.0 0.0 17.0 0.0 0.0 11.2 0.639 - - 0.52 2.47 0.44 0.62 
IL-10 0.0 0.0 0.7 0.0 2.4 18.7 <0.001 0.033 Up 0.70 1.93 0.54 0.87 
IL-12 3.5 11.7 21.8 0.0 13.2 38.4 0.885 - - 0.49 20.71 0.43 0.74 
IL-13 0.0 1.2 3.8 0.0 0.0 0.0 <0.001 0.481 Down 0.29 5.66 0.12 0.94 
IL-15 0.0 0.0 0.0 0.0 0.0 0.0 0.004 1.00 Up 0.54 0.40 0.09 1.00 
IL-17 0.0 0.0 0.0 0.0 0.0 136.9 <0.001 <0.001 Up 0.71 36.76 0.43 1.00 
Eotaxin 82.2 123.2 180.0 0.0 106.8 187.6 0.076 - - 0.58 0.00 0.38 0.99 
FGF Basic 0.0 0.0 0.0 0.0 0.0 0.0 0.387 - - 0.52 11.08 0.09 0.97 
G-CSF 0.0 0.9 8.5 0.0 0.0 1.7 0.004 <0.001 Down 0.38 103.72 0.03 1.00 
GM-CSF 0.0 0.0 3.0 0.0 0.0 1.8 0.736 - - 0.49 99.65 0.04 0.99 
IFN- 36.8 48.1 71.4 90.3 153.1 247.5 <0.001 0.605 Up 0.87 88.95 0.77 0.89 
IP-10 399.8 533.4 890.8 880.2 1368.9 2298.6 <0.001 0.059 Up 0.83 797.21 0.83 0.70 
MCP-1 24.5 44.5 93.6 8.5 40.3 64.7 0.054 - - 0.58 9.99 0.27 0.99 
MIP-1 0.0 0.0 0.0 0.0 0.0 0.0 0.305 - - 0.51 17.15 0.03 1.00 
MIP-1 68.4 104.1 164.4 83.0 111.4 161.3 0.128 - - 0.57 81.26 0.80 0.39 
RANTES 5911.6 7498.2 9013.1 6059.4 7421.9 9591.6 0.688 - - 0.48 7272.12 0.49 0.55 
TNF- 0.0 0.0 0.0 0.0 0.0 0.0 0.359 - - 0.52 30.45 0.08 0.98 
VEGF 17.3 51.0 113.3 35.2 167.2 307.0 <0.001 0.120 Up 0.68 156.68 0.53 0.86 
CA19-9 4.8 13.4 41.5 49.0 188.1 656.5 <0.001 - Up 0.85 33.00 0.87 0.73 
Note: Sensitivity (Sens.); Specificity (Spec.); Univariate analysis by Wilcoxon’s Test p-value (Uni 
(P));Multivariate by Logistic Regression p-value (Multi (P)) Inter-quartile range= 25th to 75th quartile; Receiver-
Operator Characteristic Area Under Curve (AUC); Optimal Cut-off as determined by ROC (C/O); Regulation in 
PDAC (Reg.) 
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3.4.1.5 Correlation studies to determine the relationship between CCGFs 
The fourteen CCGFs, which were significant on univariate analysis, were analysed 
for non-parametric correlation. The correlation between CCGFs were analysed 
independently for the Control group (HC, CP, and DC) and the PDAC group.  
Five pairs of CCGFs were found to have a significantly positive correlation (Kendall 
 Test, >0.5 and p<0.05) in both the control group and the PDAC group. In 
particular, results from Table 3.8 and Table 3.9 suggest that regardless of the disease 
status, there seemed to be a positive correlation between the serum concentrations of 
IL-1 and IL-5 as well as between IL-4 and IFN-. It is also interesting to note that in 
general, the strength of the correlations appeared to be stronger in PDAC patients 
(Kendall Tau coefficient >0.7) compared to controls (Kendall Tau coefficient <0.65).  
In addition to non-parametric correlation studies, the relationships between 
individual CCGFs were analysed by hierarchy clustering. Results from this analysis 
confirmed the findings from the non-parametric correlation studies. Indeed, the heat 
map in Figure 3.7 identified separate three groups of CCGFs with similar patterns of 
serum expression (especially in the PDAC patients): (a) IL-10 and IL-17; (b) IL-4 
and IFN-; (c) IL-1, IL-5, and IL-13.  
Table 3.8- The correlation between individual CCGFs in the Control Group 
CCGF 1 CCGF 2 Kendall τ Prob>|τ| Plot 
IL-5  IL-1  0.6323 <0.0001              ++++++++     
IFN- IL-4  0.6089 <0.0001              ++++++++     
IL-4  IL-1  0.5386 <0.0001              +++++++      
IL-4  PDGF  0.5133 <0.0001              ++++++       
G-CSF  IL-1  0.5049 <0.0001              ++++++       
Note: Kendall Tau (t) coefficient ranges from -1 to 1 where -1 and 1 represents a perfect negative (-) and positive 
(+) correlation , respectively and a Tau coefficient of 0 represents no correlation. + under Plot represents 
positive correlation 
 
Table 3.9- The correlation between individual CCGFs in the PDAC group 
CCGF 1 CCGF 2 Kendall τ Prob>|τ| Plot 
IL-13 IL-5  0.973 <0.0001 ++++++++++++ 
IL-13 IL-1  0.968 <0.0001 ++++++++++++ 
IL-5 IL-1  0.968 <0.0001 ++++++++++++ 
IFN- IL-4  0.721 <0.0001 +++++++++    
IL-17 IL-10 0.613 <0.0001 ++++++++ 
Note: Kendall Tau (t) coefficient ranges from -1 to 1 where -1 and 1 represents a perfect negative (-) and 
positive (+) correlation , respectively and a Tau coefficient of 0 represents no correlation. + under Plot 
represents positive correlation 
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In summary, results from initial analysis indicated that individual CCGFs were 
insufficiently accurate as standalone markers for resectable pancreatic cancer. 
However, IFN- has been shown to have a similar accuracy compared to the standard 
biomarker, CA19-9. Nevertheless, the aim of the Discovery Phase will be to 
determine the value of combining a panel of CCGF to improve the diagnostic 
accuracy of CCGFs as markers for pancreatic cancer. 
 
 
  
Figure 3.7- Two-Way Hierarchical clustering of the fourteen significant CCGFs and CA19-9. 
Individuals with resectable pancreatic cancer (PDAC) are displayed in blue and control patients in 
red. It can be seen from the heat map that the serum concentrations of IL-10 and IL-17 were similar, 
especially in individuals with PDAC. Similarly, IL-4 and IFN-g appeared to be increased in the same 
individuals with PDAC. In addition, it is also worth noting that the patterns of IL-1b, IL-5, and IL-13 
expression in the serum were almost identical to each other in individuals with PDAC.  
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3.4.2 Discovery Phase- Diagnostic potential of CCGFs in combination 
One hundred and twenty randomly selected samples were analysed in the Discovery 
Phase to identify candidate biomarkers, which can be combined as a single marker 
for the diagnosis of PDAC. 
3.4.2.1 Selection of CCGFs for combination 
The fourteen CCGFs, which were significant in section 3.4.1.4 were shortlisted for 
further selection by stepwise regression (see section 3.3.5.4). The selection process 
was completed in four steps, after which no further CCGF satisfied the criteria for 
entering or leaving the model (Table 3.10). Amongst the fourteen CCGF markers, 
four were identified as independently significant combined markers for 
discriminating PDAC against control subjects: IL-4, IL-17, G-CSF, and IP-10 (Table 
3.10). In view of the results from the previous section, which suggested that some 
CCGFs might share a common serum expression pattern, the stepwise regression 
model was repeated four times, each with one marker (IL-4, IL-17, G-CSF, or IP-10) 
excluded from the analysis. However, none of the alternative models was better than 
the original (Table 3.11).  
Cluster analysis was performed on the four CCGFs selected by the stepwise 
regression model (Candidate CCGFs) and a heat map was created to illustrate 
graphically the regulation of CCGFs in the serum of cancer and control subjects 
(Figure 3.8). It appeared from the heat map pattern that PDAC is associated with the 
up-regulation of IL-4, IL-17, or IP-10 whereas the up-regulation of G-CSF appeared 
to identify a group of control patients, some of whom have a high serum IL-4 
concentration. 
Table 3.10- CCGF markers selected by the stepwise regression model for combination 
Step Parameter Action Wald/Score p-value R
2 
1 Il-17 Entered < 0.0001 0.23 
2 IL-4 Entered < 0.0001 0.51 
3 G-CSF Entered < 0.0001 0.78 
4 IP-10 Entered    0.0003 0.86 
Note: The R2 value reflects how closely the data fits with the model 
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Table 3.11 -Alternative markers for combination 
Step Parameter Action Wald/Score p-value R2 
IL-17 excluded 
1 IP-10 Entered <0.001 0.18 
2 PDGF Entered <0.001 0.28 
3 VEGF Entered   0.012 0.32 
4 IL-4 Entered <0.001 0.46 
5 PDGF Removed   0.066 0.42 
6 IL-1 Entered <0.001 0.49 
7 G-CSF Entered <0.001 0.69 
8 IFN- Entered <0.001 0.76 
9 VEGF Removed   0.072 0.74 
10 IL-5 Entered <0.001 0.83 
11 IL-4 Removed   0.184 0.82 
IL-4 removed 
1 IL-17 Entered <0.001 0.23 
2 IFN- Entered <0.001 0.45 
3 G-CSF Entered <0.001 0.70 
4 IL-17 Removed <0.001 0.53 
G-CSF removed 
1 IL-17 Entered <0.001 0.23 
2 IL-4 Entered <0.001 0.51 
3 IL-1 Entered   0.018 0.55 
4 IP-10 Entered <0.001 0.62 
5 IFN- Entered   0.017 0.66 
6 IL-17 Removed <0.001 0.57 
IP-10 removed 
1 IL-17 Entered <0.001 0.23 
2 IL-4 Entered <0.001 0.51 
3 G-CSF Entered <0.001 0.78 
4 IL-8 Entered   0.004 0.83 
5 IL-5 Entered   0.011 0.87 
6 IL-1 Entered   0.139 0.88 
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3.4.2.2 Diagnostic accuracy of the combined CCGF marker 
Subsequent analyses combined the four candidate markers using two independent 
modelling methods: Multinomial logistic regression (M-LR) and Artificial Neural 
Network (NN). Each model generated a mathematical algorithm, which predicted the 
probability of PDAC based on the serum concentrations of IL-4, IL-17, G-CSF, and 
IP-10. The resulting probability values range from zero (likely control) to one (likely 
PDAC). The diagnostic accuracy of each model are summarised in Table 3.12 and 
graphically represented in Figure 3.9 and Figure 3.10.  
Results from the analysis of the diagnostic accuracy of the M-LR model were 
promising. In the Discovery Phase, the M-LR model achieved a very high diagnostic 
accuracy with ROC-AUCs of >0.99 for discriminating PDAC from the CP, DC, and 
HC control subgroups individually and as a combined Control group (Figure 3.9). 
Two PDAC patients were misdiagnosed as Control at the optimal cut-off value of 0.4 
(as determined by ROC) and one Control subject (from the CP subgroup) was 
misclassified as PDAC (Table 3.12). 
Results from the analysis of the diagnostic accuracy of the NN model were equally 
encouraging. In the Discovery Phase, the NN model again achieved a very high 
diagnostic accuracy with ROC-AUCs of 0.99 for discriminating PDAC from CP, DC, 
and HC control subgroups individually and as a combined Control group (Figure 
3.10). Only one Control subject (CP subject) was misdiagnosed as PDAC at the 
optimal cut-off value of 0.365 (as determined by ROC) and two individuals with 
PDAC were misclassified as Control (Table 3.12). 
Table 3.12- Diagnostic accuracy of the combined CCGF marker in the Discovery Phase 
Parameter 
Multinomial Logistic Regression 
 
Artificial Neural Network 
C/O AUC Sens. Spec. 
 
C/O AUC Sens. Spec. 
PDAC Vs CP 0.4 0.99 0.97 0.95 
 
0.365 0.99 0.97 0.95 
PDAC Vs DC 0.4 1.00 0.97 1.00 
 
0.365 1.00 0.97 1.00 
PDAC Vs HC 0.4 1.00 0.97 1.00 
 
0.365 1.00 0.97 1.00 
PDAC Vs Controls 0.4 0.99 0.97 0.98 
 
0.365 1.00 0.97 0.98 
Abbreviations: Cut-off value (C/O) for the relative Sensitivity (Sens.)and specificity (Spec.); Receiver Operatory 
Characteristics Area Under Curve (AUC); resectable pancreatic cancer (PDAC); chronic pancreatitis (CP); disease 
controls (DC, mainly obstructive jaundice); Healthy volunteers (HC) 
Note: The same algorithms (M-LR or NN) were used for each parameter.  
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Figure 3.9- Accuracy of the multinomial logistic 
regression algorithm (M-LR) for discriminating 
PDAC from control subjects. Individuals with 
PDAC were coloured blue and control subjects in 
red [A] Logistic plot of cancer status (y-axis) 
against the predicted probability of PDAC (x-axis). 
The optimal cut-off value (C/O) is 0.4 [B] A mosaic 
plot of actual diagnosis (y-axis) against predicted 
diagnosis (x-axis). [C] ROC curve of the sensitivity 
against 1-specificity of the M-LR model with an 
area under curve of 0.994.   
  
 
Figure 3.10 Accuracy of the Artificial Neural 
Network model (NN) for discriminating PDAC 
from control subjects. Individuals with PDAC 
were coloured blue and control subjects in red 
[A] Logistic plot of cancer status (y-axis) against 
the predicted probability of PDAC (x-axis). The 
optimal cut-off value (C/O) is 0.365 [B] A mosaic 
plot of actual diagnosis (y-axis) against predicted 
diagnosis (x-axis). [C] ROC curve of the 
sensitivity against 1-specificity of the NN model 
with an area under curve of 0.996.   
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3.4.3 Validation Phase- Validation of the disease-predicting algorithms 
3.4.3.1 The diagnostic accuracy of the prediction models in the Validation Phase 
Both algorithms generated in the Discovery Phase by the M-LR and the NN models 
were directly applied to the CCGF data from the sixty samples in the validation 
sample set. The resulting probability values were classified into PDAC if the 
probability was >0.4 and Control if the probability was ≤0.4. The results are 
summarized in Table 3.13, Error! Reference source not found. and Figure 3.11.  
Although the diagnostic accuracy of the M-LR combined CCGF algorithm was 
slightly reduced in the Validation Phase compared to the Discovery Phase, the M-LR 
model still performed very well with ROC-AUCs of >95% for discriminating PDAC 
from CP, DC, and HC control subgroups individually and as a combined Control 
group. Furthermore, we report that the M-LR model only misclassified two 
individuals in the PDAC group and no Control subjects were misclassified. 
Results from the validation of the NN combined CCGF algorithm were remarkable 
with ROC-AUCs of 1.00 discriminating PDAC from the CP, DC, and HC control 
subgroups as individually and as a combined Control group. Furthermore, all 
individuals in the validation sample set were correctly classified into their disease 
group at the Discovery Phase defined cut-off value of 0.4.  
 
Table 3.13- Diagnostic accuracy of the combined CCGF marker in the Validation Phase 
Parameter 
Multinomial Logistic Regression 
 
Artificial Neural Network 
C/O AUC Sens. Spec. 
 
C/O AUC Sens. Spec. 
PDAC Vs CP 0.4 0.97 0.93 1.00 
 
0.365 1.00 1.00 1.00 
PDAC Vs DC 0.4 0.95 0.93 1.00 
 
0.365 1.00 1.00 1.00 
PDAC Vs HC 0.4 0.95 0.93 1.00 
 
0.365 1.00 1.00 1.00 
PDAC Vs Controls 0.4 0.96 0.93 1.00 
 
0.365 1.00 1.00 1.00 
Abbreviations: Cut-off value (C/O) for the relative Sensitivity (Sens.)and specificity (Spec.); Receiver Operatory 
Characteristics Area Under Curve (AUC); resectable pancreatic cancer (PDAC); chronic pancreatitis (CP); disease 
controls (DC, mainly obstructive jaundice); Healthy volunteers (HC) 
Note: The same algorithms (M-LR or NN) were used for each parameter.  
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Figure 3.11- Accuracy of the Multinomial Logistic 
regression model (M-LR) in the Validation Phase. 
Individuals with PDAC were coloured blue and 
control subjects in red [A] Logistic plot of cancer 
status (y-axis) against the predicted probability of 
PDAC (x-axis). The optimal cut-off value (C/O) is 0.4 
[B] A mosaic plot of actual diagnosis (y-axis) against 
predicted diagnosis (x-axis). [C] ROC curve of the 
sensitivity against 1-specificity of the M-LR model 
with an area under curve of 0.957   
Figure 3.12 Accuracy of the Artificial Neural 
Network model (NN) in the validation phase. 
Individuals with PDAC were coloured blue and 
control subjects in red [A] Logistic plot of 
cancer status (y-axis) against the predicted 
probability of PDAC (x-axis). The optimal cut-
off value (C/O) is 0.365 [B] A mosaic plot of 
actual diagnosis (y-axis) against predicted 
diagnosis (x-axis). [C] ROC curve of the 
sensitivity against 1-specificity of the NN model 
with an area under curve of 1.00.   
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3.4.4 The diagnostic accuracy of CA19-9 compared to CCGFs 
3.4.4.1 Quantification of CA19-9 
The serum concentration of CA19-9 in the 180 individuals involved in the current 
study was determined by ELISA. Of these, 141 samples were previously quantified 
(section 3.3.4) and 39 samples were quantified in the current study using a 
commercially available CA19-9 ELISA kit. An image of the ELISA plate at 
quantification is shown in Figure 3.13. It can be seen in Figure 3.13 that many 
PDAC samples are clearly more yellow in colour compared to healthy controls 
(virtually all colourless) and the intense yellow colour in some DC and CP samples 
suggest these patients are likely to have a high serum expression of CA19-9.  
 
  
Figure 3.13- [Above] CA19-9 ELISA plate layout. Note that sample were analysed in duplicates. 
Wells 1A to 2D were pre-mixed standard references. PDAC samples were coloured in light blue, 
disease controls (BIL) in pink, chronic pancreatitis (CP) in grey and healthy volunteers in green. 
Sample X40-X42 were from the sample patient but at different dilutions. 
[Below] A photograph of the ELISA plate at plate reading. Note that the intensity of the yellow colour 
directly correlates to the concentration of CA19-9.  
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3.4.4.2 The diagnostic accuracy of CA19-9 compared to the NN-CCGF algorithm 
Univariate analysis showed that CA19-9 was significantly raised in pancreatic cancer 
compared all control groups (Wilcoxon’s Test, p<0.01; sections 3.4.1.1 to 3.4.1.4 ). 
Furthermore, it was the most accurate individual marker of PDAC against the HC 
and CP control subgroups. Therefore, subsequent analyses aimed to compare the 
diagnostic accuracy of CA19-9 with that of the M-LR and NN combined CCGF 
algorithms described in sections 3.4.2 and 3.4.3 (for ease of reading, the results for 
the NN combined CCGF algorithm from sections 3.4.2 is included in Table 3.14).  
In the Discovery Phase, CA19-9 was highly accurate for discriminating PDAC 
against HC with ROC-AUC of 0.94 with an optimal sensitivity and specificity of 
0.92 and 0.95, respectively (Table 3.14). However, CA19-9 was less accurate for 
discriminating PDAC from the CP and DC control subgroups with ROC-AUCs of 
0.86 and 0.73, respectively. Furthermore, on analysis of the diagnostic accuracy of 
CA19-9 for PDAC against all control subjects, ROC analysis yielded a ROC-AUC of 
0.85 and an optimal sensitivity and specificity of 0.73 and 0.90, respectively (Table 
3.14). Comparing the diagnostic accuracy of CA19-9 for the CP, DC, and HC control 
groups individually and as a combined Control group showed that CA19-9 alone was 
less accurate than either the M-LR or the NN combined CCGF algorithm. 
Similarly in the Validation Phase, CA19-9 was highly accurate at discriminating 
between PDAC and HC (ROC-AUC= 0.98) but performed less well against CP and 
DC (ROC-AUC 0.78 and 0.78, respectively; Table 3.14). Furthermore, the 
diagnostic accuracy of CA19-9 against all control groups yielded ROC-AUC of 0.85 
and a relative sensitivity of 0.5 and a relative specificity of 0.90 at the diagnostic 
phase cut-off value of 125U/ml. Again, comparison between the accuracies of CA19-
9 and the M-LR or NN combined CCGF algorithm in the Validation Phase showed 
that CA19-9 alone was a less accurate diagnostic marker of PDAC. 
Table 3.14- The diagnostic accuracies of CA19-9 and the CCGF Neural Network Algorithm 
Parameters 
 Carbohydrate Antigen 19-9  CCGF Neural Network Algorithm 
C/O 
Discovery Validation 
C/O 
Discovery Validation 
AUC Sens. Spec. AUC Sens. Spec. AUC Sens. Spec. AUC Sens. Spec. 
PDAC Vs 
CP 
45.0 0.86 0.78 0.90 0.78 0.73 0.70 0.365 0.99 0.97 0.95 1.00 1.00 1.00 
PDAC Vs 
DC 
125.0 0.73 0.73 0.75 0.78 0.50 0.80 0.365 1.00 0.97 1.00 1.00 1.00 1.00 
PDAC Vs 
HC 
16.0 0.94 0.92 0.95 0.98 0.93 1.00 0.365 1.00 0.97 1.00 1.00 1.00 1.00 
PDAC Vs 
Controls 
125.0 0.85 0.73 0.90 0.85 0.50 0.90 0.365 1.00 0.97 0.98 1.00 1.00 1.00 
Abbreviations: ROC area under curve (AUC); cut-off value (C/O); sensitivity (Sens.); Specificity (Spec.); Chronic pancreatitis 
(CP), Disease controls (DC), Healthy volunteers (HC), combined CP+DC+HC (Controls)  
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3.4.5 CA19-9 in combination with CCGFs 
The Discovery Phase was repeated with CA19-9 included in the selection process for 
candidate CCGFs. Interestingly, the same four CCGFs were selected in step 1-4 in 
the stepwise regression model. However, CA19-9 remained statistically significant 
after step 4 and therefore it was added to the combination in step 5 (Table 3.15). 
Two-way hierarchical clustering of CA19-9 with the four candidate markers showed 
a similar pattern compared to the same analysis in section 3.4.2.1, Figure 3.8. 
However, it was unclear from the heat map as to the exact contribution of CA19-9 in 
the diagnostic algorithm. 
Table 3.15- CCGF markers selected by the stepwise regression model for combination 
Step Parameter Action Wald/Score p-value R2 
1 IL-17 Entered < 0.0001 0.23 
2 IL-4 Entered < 0.0001 0.51 
3 G-CSF Entered < 0.0001 0.78 
4 IP-10 Entered    0.0003 0.86 
5 CA19-9 Entered    0.0048 0.90 
Abbreviations: Interleukin (IL); granulocyte colony stimulating factor (G-CSF); Interferon-gamma inducible 
protein 10 (IP-10), Carbohydrate Antigen 19-9 (CA19-9) 
Note: R2 ranges from 0-1 and directly correlates how closely the model fits the data 
  
Figure 3.14- Two-Way hierarchical analysis of CA19-9, IP-10, IL-4, G-CSF, and IL-17. Individuals 
with PDAC were coloured Blue and controls in Red. Results from the heat map showed a similar 
pattern to Figure 3.8 and the samples were broadly clustered into a PDAC dominated group and a 
Control dominated group. However, the exact contribution of CA19-9 in the prediction process could 
not be elucidated  from the heat map.  
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3.4.5.1 Discovery Phase- accuracy of the combined CCGF-CA19-9 marker 
Using the same sample randomisation as described in section 3.3.2, the CCGF-
CA19-9 combined algorithm achieved ROC-AUCs of 0.999 for both the M-LR and 
the NN models in the Discovery Phase. At the optimal cut-off of 0.38 (M-LR model) 
and 0.4 (NN model), the models yielded sensitivities of 1.00 and relative specificities 
of 0.98 (Table 3.16, Figure 3.15, Figure 3.16 ). The CCGF-CA19-9 model appeared 
to be slightly more robust than the CCGF combined algorithm as evident by the fact 
that it only misclassified one control subject as PDAC. Furthermore, the logistic plot 
of cancer status against the predicted probability of PDAC was better defined than 
the previous models i.e. most samples were either at the control end (probability= 0) 
or at the PDAC end (probability =1).  
Table 3.16- Diagnostic accuracy of the CCGF-CA19-9 marker in the Discovery Phase 
Parameter 
Multinomial Logistic Regression 
 
Artificial Neural Network 
C/O AUC Sens. Spec. 
 
C/O AUC Sens. Spec. 
PDAC Vs CP 0.38 1.00 1.00 0.95 
 
0.4 1.00 1.00 0.95 
PDAC Vs DC 0.38 1.00 1.00 1.00 
 
0.4 1.00 1.00 1.00 
PDAC Vs HC 0.38 1.00 1.00 1.00 
 
0.4 1.00 1.00 1.00 
PDAC Vs Controls 0.38 1.00 1.00 0.98 
 
0.4 1.00 1.00 0.98 
Abbreviations: Cut-off value (C/O) for the relative Sensitivity (Sens.)and specificity (Spec.); Receiver Operatory 
Characteristics Area Under Curve (AUC); resectable pancreatic cancer (PDAC); chronic pancreatitis (CP); disease 
controls (DC, mainly obstructive jaundice); Healthy volunteers (HC) 
Note: The same algorithms (M-LR or NN) were used for each parameter. AUCs rounded to 2dp 
  
Figure 3.15- Diagnostic accuracy of the Multinomial 
logistic CCGF-CA19-9 algorithm. Individuals with 
PDAC were coloured Blue and controls in Red. [A] At 
the optimal cut-off value of 0.38, the M-LR CCGF-
CA19-9 algorithm misclassified only one control 
patient (arrowed).    From the logistic plot, it can be 
seen that the majority of PDACs were lined up at 
probability of PDAC=1 and the majority of controls 
were lined up at probability of PDAC=0. [B] This 
mosaic plot showed that only one control was 
misclassified (arrowed). [C] ROC curve with ROC-
AUC of 0.999 
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Figure 3.16- Diagnostic accuracy of the Artificial 
Neural Network CCGF-CA19-9 algorithm. 
Individuals with PDAC were coloured Blue and 
controls in Red. [A] At the optimal cut-off value of 
0.48, the NN CCGF-CA19-9 algorithm misclassified 
the same control patient (arrowed).From the logistic 
plot, it can be seen that the majority of PDACs were 
lined up at probability of PDAC=1 and the majority 
of controls were lined up at probability of PDAC=0. 
[B] This mosaic plot showed that only one control 
was misclassified (arrowed). [C] ROC curve with 
ROC-AUC of 0.999 
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3.4.5.2 Validation Phase- validation of the CCGF-CA19-9 algorithms 
The combined CCGF-CA19-9 algorithms and their relative cut-off values were 
directly applied to an independent validation sample set consisting of 30 PDAC, 10 
CP, 10 DC, and 10 HC (section 3.3.1.2 for details regarding the samples).  
With the Discovery Phase cut-off of 0.38, the multinomial logistic CCGF-CA19-9 
algorithm achieved the same accuracy as the M-LR CCGFs algorithm described in 
section 3.4.2.2 with a ROC-AUC of 0.96 and relative sensitivity and specificity of 
0.93 and 1.00, respectively. Interestingly, the two misclassified individuals with 
pancreatic cancer in the CCGF-CA19-9 algorithm were the same as the two 
identified by the M-LR combined CCGF algorithm in section 3.4.3.1.  
Similarly, the NN CCGF-CA19-9 algorithm achieved the same accuracy as the NN 
combined CCGF algorithm described in section 3.4.3.1 with a ROC-AUC of 1.00 
and relative sensitivity and specificity of both 1.00.  
In view of the fact that only one individual with chronic pancreatitis was 
misclassified in both the Discovery and Validation Phase, it would seem that the 
addition of CA19-9 to the NN algorithm might slightly improve the diagnostic 
accuracy of the model. Interestingly, review of the misclassified patient‟s medical 
records revealed that this patient was initially suspected of pancreatic cancer but 
there were no signs of the primary tumour of metastasis on contrast enhanced CT and 
biopsy was negative.  
Table 3.17- Diagnostic accuracy of the CCGF-CA19-9 markers in the Validation Phase 
Parameter 
Multinomial Logistic Regression 
 
Artificial Neural Network 
C/O AUC Sens. Spec. 
 
C/O AUC Sens. Spec. 
PDAC Vs CP 0.38 0.96 0.93 1.00 
 
0.4 1.00 1.00 1.00 
PDAC Vs DC 0.38 0.95 0.93 1.00 
 
0.4 1.00 1.00 1.00 
PDAC Vs HC 0.38 0.95 0.93 1.00 
 
0.4 1.00 1.00 1.00 
PDAC Vs Controls 0.38 0.96 0.93 1.00 
 
0.4 1.00 1.00 1.00 
Abbreviations: Cut-off value (C/O) for the relative Sensitivity (Sens.)and specificity (Spec.); Receiver Operatory 
Characteristics Area Under Curve (AUC). Note: The same algorithms (M-LR or NN) were used for each parameter. 
AUCs rounded to 2dp 
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Figure 3.17- Diagnostic accuracy of the M-LR CCGF-
CA19-9 algorithm in the validation phase. Individuals 
with PDAC were coloured Blue and Controls in Red. 
[A] Logistic Plot showing that two patients with 
pancreatic cancer were misclassified as controls 
(arrowed). [B] This mosaic plot of actual cancer status 
(Blue for cancer; Red for controls) against the 
predicted cancer status (columns) showed that all 
controls were correctly classified but two PDACs were 
classified as control (arrowed). [C] ROC curve of the 
M-LR CCGF-CA19-9 algorithm with a ROC-AUC of 
0.96 
Figure 3.18- Diagnostic accuracy of the NN CCGF-CA19-
9 algorithm in the validation phase. Individuals with 
PDAC were coloured Blue and Controls in Red. [A] This 
logistic plot showed that all samples were classified 
correctly [B] This mosaic plot of actual cancer status 
(Blue for cancer; Red for controls) against the predicted 
cancer status (columns) showed that all controls and 
PDACs were correctly classified. [C] ROC curve of the NN 
CCGF-CA19-9 algorithm with a ROC-AUC of 1.00. 
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3.4.6 The impact of each biomarker on the M-LR diagnostic algorithm 
A separate analysis was performed to assess the contribution of each CCGF marker 
towards the diagnostic accuracy of the M-LR CCGF algorithm and M-LR CCGF-
CA19-9 algorithm for PDAC against all controls. This was achieved by assessing the 
diagnostic accuracies of the M-LR algorithms when each CCGF was independently 
removed. It should be noted that a new M-LR algorithm was generated upon the 
removal of each CCGF in order to maximise the diagnostic accuracy of the 
remaining markers.  
Results from the Discovery Phase suggest that the removal of IL-4, IL-17, G-CSF, 
IP-10, or CA19-9 from the M-LR algorithms will lead to a decrease in the diagnostic 
accuracy of the models (Table 3.18). However, the effect of removing one CCGF 
appeared to be well compensated by the remaining markers. In particular, the 
removal of IP-10 caused minimal decrease in the ROC-AUC in both the M-LR 
CCGF and the M-LR CCGF-CA19-9 algorithms (AUC, 0.994 versus 0.984 and 
0.999 versus 0.995, respectively; Table 3.18).  
Results from the Validation Phase are displayed in Table 3.19. When the M-LR 
CCGF algorithm generated in the Discovery Phase were directly applied to the 
Validation sample set, the impact of the removal of IL-17 was immediately obvious 
with a decrease in AUC from 0.940 to 0.814 on removal. Furthermore, there is a 
general decrease in the diagnostic accuracy in the Validation Phase compared to the 
Discovery Phase upon the removal of any CCGF. 
Table 3.18- Accuracy of the M-LR CCGF and CCGF-CA19-9 markers in the Discovery Phase 
Parameter  
(PDAC versus all controls) 
M-LR CCGF algorithm 
 
M-LR CCGF-CA19-9 algorithm 
C/O AUC Sens. Spec. 
 
C/O AUC Sens. Spec. 
Original Algorithm 0.400 0.994 0.97 0.98 
 
0.38 0.999 1.00 0.98 
Removal of IL-4 0.369 0.928 0.90 0.87 
 
0.38 0.931 0.88 0.88 
Removal of IL-17 0.380 0.940 0.90 0.90 
 
0.33 0.957 0.93 0.92 
Removal of G-CSF 0.460 0.958 0.88 0.93 
 
0.39 0.969 0.93 0.90 
Removal of IP-10 0.350 0.984 0.97 0.97 0.40 0.995 0.98 0.97 
 
Table 3.19- Accuracy of the M-LR CCGF and CCGF-CA19-9 markers in the Validation Phase 
Parameter  
(PDAC versus all controls) 
M-LR CCGF algorithm 
 
M-LR CCGF-CA19-9 algorithm 
C/O AUC Sens. Spec. 
 
C/O AUC Sens. Spec. 
Original Algorithm 0.400 0.957 0.93 1.00 
 
0.38 0.956 0.93 1.00 
Removal of IL-4 0.369 0.898 0.80 0.80 
 
0.38 0.956 0.93 1.00 
Removal of IL-17 0.380 0.814 0.77 0.83 
 
0.33 0.929 0.80 0.83 
Removal of G-CSF 0.460 0.989 0.87 0.97 
 
0.39 0.993 0.93 0.97 
Removal of IP-10 0.350 0.972 0.97 0.97 0.40 0.967 0.93 1.00 
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3.5 Impact of clinical-demographical factors on the 
accuracy of the disease-predicting models 
3.5.1 Impact of Patient Age on the serum levels of candidate CCGFs 
Analyses of demographical data in section 3.3.1 suggested that, as expected 
individuals with PDAC were generally older compared to individuals in the chronic 
pancreatitis or the healthy control subgroups. Although results shown no significant 
difference in age between the PDAC and the DC control sub-group, it is still 
important to identify any correlations between age, individual CCGFs, and the 
disease-predicting formulae.  
Correlation analyses of age against serum concentrations of IL-4, IL-17, G-CSF, and 
IP-10 yielded Kendall Tau correlation coefficients () of <0.3 (both control and 
PDAC group) suggesting that age is independent to the serum concentrations of the 
four candidate CCGFs (Table 3.20). Furthermore, correlation analysis of age and 
estimated probabilities generated from the prediction formulae yielded Kendal  
coefficients of <0.2, which indicate that there is minimal correlation between the two 
variables. A hierarchical clustering analysis was performed for age against each 
CCGF individually and graphically represented in Figure 3.19. Results showed that 
although individuals with PDAC tended to be older, the serum concentrations the 
four CCGFs were not influenced by age. 
Table 3.20- Correlation between Age, individual CCGFs, and disease-predicting formulae 
 Controls PDAC 
Parameters Kendall τ Prob>|τ| Kendall τ Prob>|τ| 
IL-4 -0.03 0.67 0.05 0.52 
IL-17 0.01 0.87 0.02 0.81 
G-CSF 0.13 0.11 -0.07 0.40 
IP-10 0.28 <0.01 0.15 0.05 
M-LR algorithm -0.08 0.27 0.15 0.04 
NN algorithm -0.18 0.01 0.04 0.63 
Abbreviations: Interleukin (IL); Granulocyte colony stimulating factor (G-CSF); Interferon-gamma inducible 
protein-10 (IP-10); Multinomial Logistic Regression (M-LR); Artificial neural network (NN) 
Note: Kendall Tau () coefficients ranges from -1 (perfect negative correlation) to 0 (no correlation) to +1 
(perfect positive correlation); Prob>|| represents the probability that the actual correlation coefficient () 
would be greater than the calculated coefficient. 
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3.5.2 Impact of diabetes on the serum levels of candidate CCGFs 
The correlation between the presence of diabetes (a frequently reported disease in 
PDAC), the serum levels of candidate CCGFs, and the estimated probability values 
generated by the disease-predicting formulae were investigated. Univariate analyses 
of the serum levels of candidate CCGF markers and the estimated probabilities 
generated by the disease-predicting formulae against available data on diabetes status 
yielded insignificant results (Wilcoxon‟s Test, p>0.05; Table 3.21). Furthermore, a 
final analysis was performed to determine the accuracy of the two disease-predicting 
formulae for discriminating between diabetics and non-diabetic (Figure 3.20). 
Results from this analysis showed that neither algorithms is accurate at discriminate 
between diabetics and non-diabetics (ROC<0.7). It should be noted however, that 
there is a substantial number of missing data (especially for HC subgroup), which 
may decrease the integrity of these results. 
Table 3.21- Correlation between Diabetes, individual CCGFs, and disease-predicting formulae 
Parameters Characteristic 
Univariate Analysis, p-value 
Controls PDAC All data 
IL-4 
Diabetes 
0.43 0.54 0.81 
IL-17 0.30 0.96 0.78 
G-CSF 0.92 0.93 0.98 
IP-10 0.17 0.46 0.23 
M-LR algorithm 0.08 0.70 0.86 
NN algorithm 0.85 0.65 0.72 
Abbreviations: Interleukin (IL); Granulocyte colony stimulating factor (G-CSF); Interferon-gamma inducible 
protein-10 (IP-10); Multinomial Logistic Regression (M-LR); Artificial neural network (NN) 
Note: Wilcoxon’s Test was used for the univariate analysis of non-parametric variables between two groups 
 
 
 
  
Figure 3.20- Accuracy of the disease-predicting algorithms at discriminating between individuals with and 
without diabetes. [A, C] Logistic plots showing the distribution of individuals with diabetes (blue) and without 
diabetes (red) against the probability of PDAC. [B, D] ROC-curves showing the accuracy of the algorithms for 
predicting the presence of diabetes.  ROC-AUC: multinomial logistic regression (M-LR) =0.51 and neural 
network (NN) =0.53  
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3.5.3 Impact of smoking on the serum levels of candidate CCGFs 
Univariate non-parametric analysis was performed to assess the impact of smoking 
on the serum concentrations of candidate CCGFs. Results indicated that smoking 
does not appear to influence the serum concentrations of IL-4, IL-17, or G-CSF. 
However, there seemed to be a statistically significant decrease in the serum levels of 
IP-10 in smokers and when all data were combined (Wilcoxon‟s Test, p=0.04 and 
p=0.01 respectively). However, further analysis using the probability values 
generated by the two algorithms yielded insignificant results on univariate and ROC 
analyses (Wilcoxon‟s Test, p≥0.05; ROC <0.7). Again, these results should be 
considered in view of the fact that there is a large number of missing data for 
smoking status, especially in the HC control subgroup. 
Table 3.22- Correlation between smoking, individual CCGFs, and disease-predicting formulae 
Parameters Characteristic 
Univariate Analysis, p-value 
Controls PDAC All data 
IL-4 
Sm
o
ki
n
g 
0.53 0.52 0.36 
IL-17 0.23 0.54 0.66 
G-CSF 0.37 0.49 0.24 
IP-10 0.06 0.04 (↓) 0.01 (↓ in PDAC) 
M-LR algorithm 0.53 0.05 0.09 
NN algorithm 0.15 0.49 0.61 
Abbreviations: Interleukin (IL); Granulocyte colony stimulating factor (G-CSF); Interferon-gamma inducible 
protein-10 (IP-10); Multinomial Logistic Regression (M-LR); Artificial neural network (NN) 
Note: Wilcoxon’s Test was used for the univariate analysis of non-parametric variables between two groups 
 
  
Figure 3.21- Accuracy of the disease-predicting algorithms at discriminating between smokers and 
non-smokers. [A, C] Logistic plots showing the distribution of smokers (blue) and non-smokers (red) 
against the probability of PDAC. [B, D] ROC-curves showing the accuracy of the algorithms for 
identifying smokers. ROC-AUC: multinomial logistic regression (M-LR) =0.58 and neural network 
(NN) =0.54  
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3.6 Discussion 
Despite evidence from a number of robust studies describing the intimate and 
complex relationships between inflammatory mediators, tumour microenvironment, 
tumour-associated macrophages, inflammation, and cancer in general
150, 187, 191, 196, 
243-246
, the exact roles of cytokines, chemokines, and growth factors (CCGFs) in 
pancreatic cancer continue to elude researchers. It is known that the growth, 
proliferation, and metastasis of cancer cells are governed by many different 
mechanisms and pathways
162, 167, 169, 196, 247
. However, the communication within and 
between these mechanisms and pathways are invariably dependent upon various 
stimulatory and inhibitory mediators, especially CCGFs
167, 169, 179, 248-249
. 
We hypothesized that the initiation and continuation of cellular growth, proliferation, 
and metastasis in pancreatic cancer would require the production and inhibition of a 
number of specific CCGFs. It follows therefore, that there should be a different 
serum CCGF profile between individuals with pancreatic cancer and individuals with 
benign pancreatic inflammatory diseases such as chronic pancreatitis and benign 
biliary obstruction. Results from the current study confirmed this as the 
concentrations of fourteen CCGFs were differentially observed in the serum of 
individuals with pancreatic cancer compared to individuals in the CP, DC, and HC 
control subgroups. 
Results from the Discovery Phase (section 3.4.2.1) showed two important findings. 
First, the serum concentrations of some CCGFs appeared to be directly correlated 
only in individuals with PDAC (e.g. IL-17 and IL-10), which could indicate that 
some CCGFs may be involved in a common signalling pathway in cancer. 
Alternatively, it may an artefact of the heterogeneity of the combined Control group 
where a correlation between CCGFs in one control subgroup may be masked by the  
absence of this correlation in the other two control subgroups. With in mind, a 
stepwise regression model was employed to select CCGFs that were independently 
expressed in PDAC compared to others. This led to the second important finding that 
no single CCGF was differentially observed in all individuals with pancreatic cancer 
compared to Controls (i.e. there is no perfect marker). Rather, we report that each of 
the four independent CCGFs appeared to be responsible for identifying a unique sub-
group of patients in the PDAC or Control groups, which may mean that there are 
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four distinctly different cytokine mediated processes in these individuals. We report 
that IL-4, IL-17, and IP-10 were responsible for identifying a subset of patients with 
PDAC where as G-CSF may play a role in identifying individuals with pancreatic 
inflammatory disease.  
3.6.1 CCGFs for the diagnosis of pancreatic cancer 
For the past few decades, researchers have sought to identify a good and useful 
biomarker for pancreatic cancer. Considering the current lack of success in finding 
an accurate standalone marker of PDAC and in view of the evidence suggesting that 
the growth, proliferation, survival, and metastasis of PDAC is likely to be influenced 
by several independent pathways and processes (section 1.2.3 and 1.4.2), one might 
be tempted to conclude that a “magic marker” for PDAC is extremely unlikely to 
exist. Indeed, results from section 3.4.1 would support this predicament. Despite 
observing that a relatively large number of CCGFs were differentially expressed in 
patients with PDAC compared to controls, only IFN- achieved a similar sensitivity 
and specificity to the widely used biomarker of PDAC, CA19-9, which means that, 
as expected
250
, CCGFs are not sufficiently accurate as individual markers of 
pancreatic cancer.  
In consideration of the above findings, the current study utilised two independent 
models to combine a carefully selected panel of CCGFs- the Multinomial Logistic 
Regression model and the Neural Network model. The diagnostic accuracies for 
these models were very encouraging with ROC-AUCs of ≥0.99 for discriminating 
between PDAC against control subjects. Furthermore, in view of the results from 
section 3.4.3.1 and those from the validation of the NN CCGF algorithm, which 
demonstrated a perfect classification for the independent validation sample set, we 
conclude that a combined CCGF marker consisting of IL-4, IL-17, G-CSF, and IP-10 
may be used as a potential diagnostic biomarker for PDAC.  
Finally, we report that the addition of CA19-9 into the combined CCGF algorithms 
may marginally improves the diagnostic accuracy of both combined CCGF 
algorithms (M-LR and NN). However, results in section 3.4.6 would suggest that 
CA19-9 should not be used in place of any of the four CCGFs 
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3.6.2 The roles of Il-4, IL-17, G-CSF, and IP-10 in PDAC and 
pancreatic inflammatory diseases 
3.6.2.1 Interleukin 4 
IL-4 is a cytokine that is responsible for the activation of a number of immune cells 
(e.g. B-lymphocytes) and plays an important role in promoting the proliferation of T-
lymphocytes
251
. In addition, studies have shown that IL-4 is involved in the 
differentiation of CD4+ T-cells into Type II T-Helper (Th2) cells
139, 252-254
.  
Interestingly, existing literature appears to suggest that IL-4 plays a paradoxical role 
in cancer
251
. Several studies have demonstrated that IL-4 exhibits anti-tumour 
properties by inducing anti-tumour immune response, indeed, the potential of IL-4 as 
an anti-tumour agent was demonstrated in a number of solid tumours including renal 
and colorectal cancers
255-259
, although results from later studies on the therapeutic 
potential of IL-4 were disappointing
260-262
. There is increasing contrary evidence 
indicating that IL-4 acts to protect tumour cells from apoptosis
251
. Concordant to the 
results from the current study, evidence from a number of clinical studies have 
demonstrated that the IL-4 is up regulated in patients with pancreatic cancer as well 
as other types of solid cancers including renal cell, lung, colon, and breast cancers
263
. 
Furthermore, a study by Onishi et al. reported that the IL-4 expression at the tumour 
site is associated with the stage and grade of renal cell carcinoma
264
.  
Despite these observations, the exact biological mechanisms by which IL-4 exert its 
tumour promoting ability in pancreatic cancer is undetermined. However, recent 
evidence from in vitro and in vivo studies have demonstrated that high levels of IL-4 
in the tumour microenvironment can cause the induction of cathepsin activity in 
tumour-associated macrophages and therefore may play an indirect role in promoting 
the remodelling of the tumour microenvironment and ultimately facilitating tumour 
growth, proliferation, and metastasis
265
.  
3.6.2.2 Interleukin 17 
IL-17 belongs to a relatively new subclass of cytokines and is predominantly but not 
exclusively produced by T-helper 17 (Th17) cells which are a newly designated 
subset of CD4+ T-cells
266
. Other immune cells known to secrete IL-17 include 
natural killer T cells, CD8+ T cells, and lymph tissue inducer cells
266
. The role of IL-
17 in malignant diseases is not completely characterised. However, studies have 
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reported that IL-17 plays a role in promoting carcinogenesis and tumour growth by 
facilitating angiogenesis and stimulating remodelling to the extracellular matrix
267-268
. 
Indeed, in vivo studies have demonstrated that, IL-17 can stimulate the production of 
VEGF, prostaglandin E1, and prostaglandin E2 in fibroblasts thereby enhancing 
tumour angiogenesis
267
. Furthermore, recent evidence indicated that IL-17 is 
associated with an increased MMP expression, which in turn facilitates angiogenesis 
through the destruction of the extracellular matrix
266
.  
The biology behind IL-17 induced angiogenesis in pancreatic cancer specifically has 
not been previously reported. However, recent studies have indicated that the 
production of IL-17 (and subsequent angiogenesis) may be regulated by the STAT3 
transcription factor
169
. It has been proposed that the activation of the STAT3 pathway 
by stimuli from cytokine receptors such as IL-6R and IL-10R promotes the gene 
transcription and subsequent production of a number of inflammatory cytokines, 
including IL-6, IL-10, and IL-17, which are responsible for promoting tumour 
survival, proliferation, and angiogenesis
169
. Furthermore, studies have indicated that 
many of these up regulated cytokines are also activators of the STAT3 pathway and 
therefore forming a positive feedback loop for their own production
169
. 
In view of the results from sections 3.4.1.5 and 3.4.2.1 demonstrating that IL-17 is 
an independent indicator of PDAC and that is expression is closely correlated to that 
of IL-10, it is likely that IL-17 may be involved as an activator and/or a downstream 
product of the STAT3 transcription factor pathway in certain individuals with 
pancreatic cancer. 
 
3.6.2.3 G-CSF 
G-CSF, also called CSF3 is one of four members of the colony-stimulating factor 
(CSF) family proteins
269
. Other members of the CSF family including macrophage 
colony stimulating factor (M-CSF), granulocyte macrophage colony stimulating 
factor (GM-CSF), and Multi colony stimulating factor (M-CSF)
269
. G-CSF is a 19.6 
kDa glycosylated protein consisting of 174 amino acid residues and is mainly 
produced by macrophages
270
.  
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The role of G-CSF in pancreatic cancer is unclear. However, studies have shown that 
in the acute inflammatory setting, G-CSF plays an essential role in promoting the 
proliferation of neutrophil colonies, inducing the differentiation of precursor cells to 
neutrophils, and stimulating the activity of mature neutrophils
269-270
. Indeed, results 
from section 3.4.1 showed that the serum concentration of G-CSF is elevated in 
certain individuals with CP and biliary obstruction compared to PDAC. We therefore 
propose that G-CSF is not an indicator of pancreatic cancer. Rather, it is an indicator 
of inflammatory diseases where an elevated G-CSF serum concentration reflects the 
increased neutrophil activity in benign inflammatory diseases.  
 
3.6.2.4 IP-10 
IP-10 is a dimerized 10kDa protein consisting of 98 amino acids, which is 
predominantly secreted by macrophages in response to interferon gamma
271
. IP-10 
belongs to the CXCL chemokine subfamily and is responsible for the recruitment of 
monocytes and T-lymphocytes to its site of production
271
.  
Whilst there is a current lack of evidence associating IP-10 with pancreatic cancer, 
existing literature indicates that IP-10 may play a dual role as an anti-tumour agent 
for cancer in general
272
. First, IP-10 is responsible for the chemotaxis of tumour 
infiltrating T-lymphocytes
273
, in particular NK T-cells, and secondly, studies have 
shown that IP-10 have a role in the prevention of angiogenesis
272, 274-275
. A study by 
Musha et al. demonstrated that Th1 cells along the invasive margin of colorectal 
cancer produce IFN-gamma, which stimulates cancer cells and macrophages to 
produce IP-10 and ultimately resulting in the infiltration of CXCR3 expressing T-
cells at the invasive margin
273
.  
In view of the pro-invasive and aggressive nature of pancreatic cancer and the 
observation in section 3.4.1 that a subset of individuals with PDAC exhibits a higher 
serum level of IP-10, it is possible that the increase in serum level of IP-10 may be 
the direct result of host immune response against PDAC along the invasive margin.  
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4.1 Final Discussion and Conclusions 
The diagnosis of pancreatic cancer is seldom straightforward as patients often present 
with non-specific, systemic symptoms such as pain, weight loss, and jaundice
55
. 
There are two major problems to the current system for the diagnosis of pancreatic 
cancer. The first problem is that most patients seek help from their doctors only when 
they have systemic symptoms (tip of the clinical iceberg). These systematic 
symptoms are often indications of advanced disease and therefore, it is not surprising 
that up to 80% of patients have metastatic disease on presentation. The second 
problem is that patients are referred for further investigation by CE-CT based on the 
vague systemic symptoms, which can also be present in many other benign diseases 
such as peptic ulcer, gall stone obstruction, and cholangitis to name but a few. 
Therefore, the use of an accurate diagnostic biomarker of pancreatic cancer can 
significantly reduce the number of patients with non-malignant diseases undergoing 
an unnecessary invasive and potentially harmful diagnostic procedure.  
In the past few decades, researchers have sought to identify proteomic biomarkers for 
the diagnosis of pancreatic cancer via a number of different approaches. In particular, 
researchers are increasingly interested in newer biomarker discovery techniques such 
as mass spectrometry and protein microarray, which can simultaneously identify 
multiple differentially expressed proteins in pancreatic cancer. However, the progress 
of biomarker research can often be impeded by the verification techniques such as 
western blotting, ELISA, and immunohistochemistry, which are only capable of 
verifying the expression of one protein per experiment. The invention of novel 
experimental methods, such as infrared detection of western blots and the 
development of multiplex assays, have partially addressed this issue. Nonetheless, 
these methods are invariably more expensive (per experiment) compared to 
traditional methods and in particular, the use of multiplexing assays is often limited 
by the availability, sensitivity, and specificity of the detection antibodies.  
Currently, Carbohydrate Antigen 19-9 (CA19-9) is the most widely used biomarker 
for PDAC. However, with reported sensitivities and specificities of 0.87 and 0.73 
from the current series, CA19-9 is neither adequately specific nor adequately 
sensitive as a diagnostic marker. Recent studies have proposed several novel 
standalone markers with high discriminatory power for PDAC and healthy subjects; 
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however, the diagnostic accuracy of the majority of these markers were either 
inferior to CA19-9 or performed poorly in distinguishing between PDAC and chronic 
pancreatitis 
100, 111, 276-283
.  
Considering the current lack of success in finding an accurate standalone marker of 
pancreatic cancer and in view of evidence suggesting that the growth, proliferation, 
survival, and metastasis of PDAC is likely to be influenced by a number of 
independent pathways, it is clear that a single standalone marker for pancreatic 
cancer is extremely unlikely to exist. Therefore, a possible solution would be to 
devise a mathematical algorithm, which would combine a panel of carefully selected 
markers each capable of identifying a unique signalling pathway or characteristic 
found in PDAC. Indeed, a number of studies have attempted to improve the 
diagnostic accuracy of existing and novel biomarkers for pancreatic cancer using 
various classification-modelling methods 
276, 284-286
. In particular, a recent study by 
Zhang et al. reported encouraging results using a panel of four salivary 
transcriptomic biomarkers (KRAS, MBD3L2, ACRV1, and DPM1) combined using 
multinomial logistic regression with reported sensitivity and specificity of 90% and 
95%, respectively, for discriminating between patients with PDAC against 
individuals with chronic pancreatitis and against healthy volunteers
286
.  
Nevertheless, despite the successes reported by studies combining multiple markers, 
their accuracies in the presence of pancreaticobiliary diseases other than chronic 
pancreatitis remain to be validated particularly in light of recent evidence from Yan 
et al.
225
 suggested that the diagnostic accuracy of novel markers might be 
significantly reduced when analysed against individuals with benign biliary 
obstruction.  
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4.1.1 Conclusions from the current study 
In chapters 2 and 3 of this thesis, the diagnostic accuracies of three iTRAQ-identified 
proteins and twenty-seven CCGFs as individual and combined markers of resectable 
pancreatic cancer were explored. Results from both chapters were encouraging.  
4.1.1.1 Validation of iTRAQ results 
In accordance with previous studies on the expression of VDBP and RBP-4 various 
types of cancers, results from chapter 2 indicate that the serum concentration of 
VDBP, RBP-4, and FINC were significantly decreased in pancreatic cancer 
compared to healthy controls and chronic pancreatitis
203, 212, 220, 231, 287
 (sections 
2.4.2.6, 2.4.2.7, and 2.4.2.10). Furthermore, the three proteins achieved a statistically 
significant accuracy for diagnosing PDAC against the HC and CP. However, in 
support of the study presented by Yan et al.
225
, the diagnostic accuracies of the 
markers were significantly decreased when faced with patients with biliary 
obstruction (section 2.4.2.8). Therefore, it can be concluded that whilst VDBP, RBP-
4, and FINC were relatively accurate at discriminating between PDAC against CP 
and HC, their diagnostic accuracy were far inferior to that of CA19-9 and therefore 
not sufficiently accurate to be used for the diagnosis of pancreatic cancer. In addition, 
results from the current study would suggest that biliary obstruction is a disease-
related confounding factor for the diagnostic accuracy of VDBP, RBP-4, and FINC.  
Subsequent analyses sought to improve the diagnostic accuracies by combining the 
markers into a single marker using the M-LR modelling method. Results were 
encouraging for PDAC against CP and HC with a reported sensitivity of 0.85 and a 
specificity of 0.95. However, the confounding effect of biliary obstruction was 
immediately obvious when all control subgroups were considered (sensitivity=0.70; 
specificity=0.80; section 2.4.2.10).  
Phase III of chapter 2 was designed to validate the iTRAQ results with a different 
sample set- the UKCTOCS pre-diagnostic serum samples. Western blotting results 
from this experiment indicated that in the 0-0.5 year pre-diagnosis category, there is 
a trend for decreased serum concentrations of VDBP and RBP-4 in the PDAC group 
compared to their matched controls. However, this tendency did not reach statistical 
significance due to the relatively small sample size (n=10 per group). Furthermore, 
that the serum concentrations of VDBP and RBP-4 in pre-pancreatic cancer patients 
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were comparable with the matched controls in the other time categories (section 
2.4.3). Interestingly, we noted that certain patients exhibited a gradual decrease in 
serum VDBP and RBP-4 nearer to diagnosis. However, the significance of this trend 
must be further analysed before any conclusions can be made.  
Although there are potential advantages for using the UKCTOCS pre-diagnostic 
serum samples for the discovery and validation of potential markers for the screening 
of PDAC, there are also a number of disadvantages. Firstly, these samples were from 
female participants only and therefore results derived from these samples would 
require validation in male subjects. Secondly, ~80% of all patients with pancreatic 
cancer have advanced disease on diagnosis therefore even though a serum sample 
may be labelled as pre-diagnostic, the individual may already be at an advanced of 
pancreatic cancer on sample collection, especially for samples collected in the 
weeks/months prior to diagnosis. This is particularly important because in the 
absence of data regarding the tumour staging for these patients, it would be difficult 
to determine whether an individual designated as pre-pancreatic cancer is likely to 
have already developed pancreatic cancer at the >1 year time-categories.  
4.1.1.2 Discovery and validation of CCGF markers 
In Chapter 3, we described the use of a multiplex cytokines assay to quantify the 
serum concentrations of 27 CCGFs. Furthermore, we assessed the diagnostic 
potential of these CCGFs as an individual and as a combined marker for pancreatic 
cancer. Results from the initial analysis identified fourteen differentially observed 
serum CCGFs in PDAC compared to the HC, CP, and DC control subgroups. In 
particular, IFN- was found to have a comparable diagnostic accuracy to the widely 
used pancreatic cancer biomarker, CA19-9 with sensitivities of 0.77 versus 0.87 and 
specificities of 0.89 and 0.73, respectively. Nevertheless, this level of accuracy is 
insufficient for the diagnosis of pancreatic cancer in a clinical setting.  
Subsequent analysis sought to improve the diagnostic accuracy of CCGFs by 
combining independent markers of PDAC (including IL-4, IL-17, G-CSF, and IP-10) 
using two separate modelling methods: M-LR and NN modelling methods. Results 
from the Discovery Phase were encouraging with reported sensitivities of 0.97 and 
specificities of 0.98. Furthermore, analysis of the diagnostic accuracies of the M-LR 
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CCGF and NN CCGF algorithms in the Validation Phase yielded remarkable results. 
In particular, the NN CCGF algorithm achieved a perfect diagnostic accuracy.  
Direct comparison between the diagnostic accuracy of the NN CCGF models against 
the existing biomarker for pancreatic cancer, CA19-9, in the Discovery Phase 
indicated that the NN CCGF model was the more accurate biomarker compared to 
CA19-9 with sensitivities of 0.97 versus 0.73 and specificities of 0.98 versus 0.90. 
This was reflected in the Validation Phase with sensitivities of 1.00 for the NN 
CCGF algorithm versus 0.50 for CA19-9 and specificities of 1.00 against 0.90, 
respectively.  
In a final analysis, the diagnostic potential of combining CA19-9 with IL-4, IL-17, 
G-CSF, and IP-10 was assessed. Results showed that the NN CCGF-CA19-9 marker 
performed better in the Discovery Phase than the NN CCGF marker with reported 
sensitivities of 1.00 versus 0.97 and specificities of 0.98 versus 0.98, respectively. In 
addition, the CCGF-CA19-9 marker also achieved perfect diagnostic accuracy in the 
Validation Phase.  
In view of the results presented in Chapter 3, we report that a combined marker 
CCGF marker consisting of IL-4, IL-17, G-CSF, and IP-10 may serve as an accurate 
diagnostic marker of pancreatic cancer. Furthermore, we conclude that the addition 
of CA19-9 may improve the sensitivity of the NN CCGF algorithm, which may be 
more desirable in the clinical setting.  
On a more technical note, we would like to emphasize that mathematical predication 
models combining multiple variables, such as the M-LR and the NN models, are 
susceptible to data overfitting. The reason for this is that whilst it would be entirely 
possible to include all 27 CCGFs in the prediction model and the resulting accuracy 
would likely to be extremely high, it would also mean that the model no long 
describes the structure of the data, rather, it would be fitting to individual points. 
Therefore, models with a large number of predictors tend not to generalise well. 
Chapter 3 was designed to account for this effect by the use of an independent 
validation sample set. However, based on the highly accurate predictive ability of the 
combined algorithms, we can conclude that there is minimal data overfitting present 
in our study. 
129 
 
4.1.2 General Limitations 
Although the results from the current study were promising, conclusions drawn from 
the current study have several limitations. For example, due to limitations in sample 
availability, the current study did not examine the serum CCGF profiles for other 
inflammatory diseases and other cancers and therefore there is doubt to whether the 
disease-predicting algorithm can be generalised for other benign and malignant non-
pancreatic diseases. Furthermore, as highlighted in a recent review article by Schrohl 
et al., pre-analytical parameters may have an impact on the protein concentrations of 
serum samples, such as the type of container used for serum collection, delays in 
sample processing, and repeated freeze-thaw cycles
288
. However, the impact of these 
parameters on the current study were minimise as serum samples were collected, 
processed, and stored according to a strict standard operations procedure at the 
Division of Surgery and Oncology, University of Liverpool. Despite this, the use of 
serum samples from the Liverpool Pancreatic Cancer database was not without 
disadvantages. In particular, PDAC serum samples were collected from individuals 
with resectable PDAC only and therefore it is unclear as to whether the disease-
predicting algorithms could be generalised to include individuals with metastatic 
pancreatic cancer.  
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4.1.2.1 Limitation of sample size 
The samples size of 180 was decided arbitrarily as there was no previous data, with 
which to base our sample size calculation on. However, in view of the results from 
the current study, we now estimate that the sample size that would be required to 
show a sensitivity of 0.9 and a specificity of 0.9 with 95% confidence (W) is 
approximately 280 patients
289
. 
Power calculation based on the lowest limit for sensitivity (SN) =0.9: 
                                         
           
  
 
              
             
     
 
            
     
   
 
        
   
                              
 
Similarly, power calculation based on the lowest limit for specificity (SP) =0.9: 
                                         
           
  
 
              
             
     
 
            
     
   
 
        
   
                              
Note “Z” is 1.96, which represents the standard deviation of the mean for 95% of sample population 
It is clear from the power calculation that the current thesis is significantly 
underpowered and that more samples for both the PDAC and control groups would 
be required to improve the strength of our study.  
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4.2 Future directions 
The current thesis has identified a number of potential biomarker for pancreatic 
cancer including VDBP, RBP-4, FINC, IL-4, IL-17, G-CSF, and IP-10. However, 
there is a current lack of literature directly associating these proteins to pancreatic 
cancer. Therefore, we propose that future studies should aim to determine the roles of 
these proteins in pancreatic cancer. 
In view of the limitations described in section 4.1.2, we propose that future studies 
should aim to increase the sample size of the study and to analysis the diagnostic 
accuracy of the disease-predicting algorithms against cancers of other origins and 
other inflammatory diseases. Furthermore, the impact of sample collection 
methodology, delays in sample processing, and repeated freeze-thaw on the serum 
concentrations of candidate biomarkers should be assessed.  
Moreover, the UKCTOCS samples (particularly samples within the 0-1 time 
category) should be quantified for serum CCGF and the resulting data used to 
validate the disease-predicting algorithms described in the current thesis and 
furthermore to identify potential pre-diagnostic CCGF markers for pancreatic cancer. 
Finally, considering that we now have CCGF data for ninety PDAC serum samples, 
it would be interesting to conduct a retrospective study with the aim of identifying a 
serum CCGF prognostic marker for pancreatic cancer. 
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